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ABSTRACT OF THE DISSERTATION
TRINUCLEOTIDE REPEAT INSTABILITY MODULATED BY DNA REPAIR
ENZYMES AND COFACTORS
by
Yaou Ren
Florida International University, 2018
Miami, Florida
Professor Yuan Liu, Major Professor
Trinucleotide repeat (TNR) instability including repeat expansions and repeat
deletions is the cause of more than 40 inherited incurable neurodegenerative diseases and
cancer. TNR instability is associated with DNA damage and base excision repair (BER).
In this dissertation research, we explored the mechanisms of BER-mediated TNR
instability via biochemical analysis of the BER protein activities, DNA structures,
protein-protein interaction, and protein-DNA interaction by reconstructing BER in vitro
using synthesized oligonucleotide TNR substrates and purified human proteins. First, we
evaluated a germline DNA polymerase β (pol β) polymorphic variant, pol βR137Q, in
leading TNR instability-mediated cancers or neurodegenerative diseases. We find that the
pol βR137Q has slightly weaker DNA synthesis activity compared to that of wild-type
(WT) pol β. Because of the similar abilities between pol βR137Q and WT pol β in
bypassing a template loop structure, both pol βR137Q and WT pol β induces similar
amount of repeat deletion. We conclude that the slightly weaker DNA synthesis activity
of pol βR137Q does not alter the TNR instability compared to that of WT pol β,
suggesting that the pol βR137Q carriers do not have an altered risk in developing TNR
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instability-mediated human diseases. We then investigated the role of DNA synthesis
activities of DNA polymerases in modulating TNR instability. We find that pol βY265C
and pol ν with very weak DNA synthesis activities predominantly promote TNR
deletions. We identify that the sequences of TNRs may also affect DNA synthesis and
alter the outcomes of TNR instability. By inhibiting the DNA synthesis activity of pol β
using a pol β inhibitor, we find that the outcome of TNR instability is shifted toward
repeat deletions. The results provide the direct evidence that DNA synthesis activity of
DNA polymerases can be utilized as a potential therapeutic target for treating TNR
expansion diseases. Finally, we explored the role of post-translational modification
(PTM) of proliferating cell nuclear antigen (PCNA) on TNR instability. We find that
ubiquitinated PCNA (ub-PCNA) stimulates Fanconi associated nuclease 1 (FAN1) 5’-3’
exonucleolytic activities directly on hairpin structures, coordinating flap endonuclease 1
(FEN1) in removing difficult secondary structures, thereby suppressing TNR expansions.
The results suggest a role of mono-ubiquitination of PCNA in maintaining TNR stability
by regulating nucleases switching. Our results suggest enzymatic activities of DNA
polymerases and nucleases and the regulation of the activities by PTM play important
roles in BER-mediated TNR instability. This research provides the molecular basis for
future development of new therapeutic strategies for prevention and treatment of TNRmediated neurodegenerative diseases.
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INTRODUCTION
A. DNA Damage and DNA Repair
Deoxyribonucleic acid (DNA) is a long chain of nucleotides that carry the genetic
information of all living organisms [15-17]. The integrity and stability of DNA in human
cells are of particular importance because it determines cell survival and determines
proper functioning, growth, and reproduction of cells [15-17]. However, the integrity of
the DNA molecule is often challenged by many assaults from endogenous and exiguous
sources [18-25]. In cells, DNA is not stable as it is prone to self-depurination:
spontaneous loss of purines Adenine (A) and Guanine (G) at neutral pH and
physiological temperature, resulting in an abasic or apurinic/apyrimidinic (AP) site [20,
26]. The AP site can further form single-strand DNA (ssDNA) breaks. Moreover, cellular
metabolic processes and other biochemical reactions can generate reactive oxygen
species (ROS) that damage DNA [25]. The ROS include superoxide (O2- ), hydroxyl
radicals (OH ), singlet oxygen (1O2), and hydrogen peroxide (H2O2) that can oxidize
DNA bases, causing ssDNA and double-strand DNA (dsDNA) breaks [25]. The ROS can
also indirectly attack DNA through oxidized polyunsaturated fatty acid residues of
phospholipidsor oxidized amino acid residue. The oxidized lipid or proteins attack DNA
molecules, resulting in lipid-DNA crosslinks and peptide-DNA crosslinks, respectively
[25]. On the other hand, endogenous agents such as X-ray and UV radiations, plant
toxins, environmental pollutants, and other chemicals can cause different types of DNA
lesions [18, 19, 21-24]. For example, both ionizing radiation and UV radiation (UV A
light) can damage DNA by generating free radicals, which oxidize DNA bases [23, 24].
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Meanwhile, ionizing radiation can also directly cause ssDNA and dsDNA breaks [24];
whereas, UV radiation (UV B light) can induce crosslinks between two adjacent thymines
or cytosines, generating pyrimidine dimers [23]. Exposure to the algal toxins, such as
okadaic acid from dinoflagellates, can also cause oxidated base lesions, DNA strand
breaks, and hydroxyl-deoxyguanine adducts [22]. Environmental pollutants, such as
bromate in drinking water, can induce 7,8-dihydro-8-oxoguanine (8-oxoG), an oxidized
base lesion [21]. Polycyclic aromatic hydrocarbon (PAH) in the photochemical smog (air
pollution) and tobacco smoke can cause bulky DNA adducts [18, 19].

Figure I.1 DNA damage and repair [10]
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To maintain the integrity of the DNA, the cells have evolved to respond precisely
to repair such DNA lesions via several different mechanisms (Figure I.1). Small
modifications of DNA bases, including oxidized bases, alkylated bases, and deaminated
bases, can be repaired through base excision repair (BER) [27, 28]. Aside from that, BER
can also repair AP lesions and ssDNA breaks [29]. However, to repair mismatched DNA
bases requires the mismatch repair (MMR), which also repairs small DNA loops (12
nucleotides or smaller), an error caused by misalignment during DNA synthesis [30-32].
Moreover, nucleotide excision repair (NER) repairs larger and more complex lesions,
including pyrimidine dimers and other bulky DNA adducts [23]. The dsDNA breaks can
be repaired either by homologous recombination (HR), which can faithfully restore the
genetic information [33], or non-homologous end joining (NHEJ), which can introduce
mutations [34]. However, not all the lesions can be repaired through one single repair
mechanism. For example, to repair a large DNA loop (26 nucleotides), it requires
coordination between the NER and the MMR [35]. To repair the interstrand crosslinks
(ICLs), it requires crosstalk between the Fanconi anemia (FA) DNA repair pathway and
the NER [36]. Occasionally, some lesions escape the repair; cells carry out the translesion
DNA synthesis (TL) to prevent catastrophic cellular events, such as replication forks
collapse and cell death [37].
The most frequently occurring DNA damage is the DNA-base lesion. For
example, the 8-oxoGs frequently occur in the cells: the naturally occurring 8-oxoGs in
vivo have an estimation of 0.53 and 4.01 per 106 in single cell because guanine is
particularly susceptible to oxidation because of its low-reduction potential [38-41].
Meanwhile, AP lesions are readily formed through self-depurination with an estimation
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of 10,000 AP lesions occurring in a 24-hour period [26]. Besides spontaneously occurring
8-oxoG and AP lesions, they can be easily induced by the insults from environmental
factors, such as UV radiation (UV A light), ionizing radiation, oxidative stress, industrial
pollutants, and plant toxins [23, 24, 38]. Accumulated 8-oxoG can be very mutagenic: it
tends to promote G to T and A to C substitution [42]. Meanwhile, accumulated AP lesions
can be both mutagenic and lethal [43, 44]. Apurinic/apyrimidinic lesions can induce -1
frame shift mutation, a mutation with a deletion of one nucleotide during DNA synthesis
[43]. Apurinic/apyrimidinic lesions can also potentially block DNA replication and
transcription [44], leading to cell death. However, all such lesions can be repaired by
BER [20, 38]. Base exicison repair is one of the most efficient DNA repair pathways in
both dividing and non-dividing cells [45]. In addition to repair 8-oxoG and AP lesions,
BER also specializes in repairing other small non-bulky base lesions, such as
misincorporated U and ssDNA breaks, which are also common lesions in the cells [20,
46]. Therefore, a highly efficient BER ensures the integrity and stability of the genome.

B. Mechanism of Base Excision Repair, Repair Enzymes, and Cofactors
Efficient BER is carried out by a plethora of BER enzymes that process and repair
the lesions in a coordinated manner [8, 27, 28]. Initial recognition and removal of base
lesions determine the success of BER. There are eleven DNA glycosylases that specialize
in recognition and the removal of different kinds of base lesions [3]. The uracil DNA
glycosylase 1 (UNG1), the uracil DNA glycosylase 2 (UNG2), and the single-strandspecific monofunctional uracil DNA glycosylase (SMUG1) specialize in removal of the
uracil lesions in the ssDNA and dsDNA [3]. The thymine DNA glycosylase (TDG) and
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the methyl-binding domain glycosylase 4 (MBD4) remove the thymine from G-T
mismatches [3]. The MutY homolog DNA glycosylase (MYH) removes adenosine (A)
opposite 8-oxoG or 2-hA opposite G; while the the 8-OxoG DNA glycosylase (OGG1)
removes the 8-oxoG [3]. The methylpurine glycosylase (MPG) removes the alkylated
purines like 3-meA, hypoxanthin, etc [3]. The endonuclease III-like (NTHL) 1, the
NTHL2, and the NTHL3 carry out excision on oxidized, ring-fragmented or saturated
pyrimidines, such as 5-hydroxyuracil (5-hU), thymine glycol (Tg), etc.[3].
The DNA glycosylases “scan” diligently on the DNA and search for the base
lesions [3, 47]. Once they identify a lesion, they flip the damaged base out from the DNA
helix and fit the modified base into their active site for further verification (FigureI.2) [3].
After verification, they carry out the nucleophilic attack on the N-glycosidic bond [3].
Removal of the base lesions leads to AP sites [48]. The AP sites from both glycosylase
cleavage and DNA damageare further processed by AP endonuclease 1 (APE1): APE1
exercises cleavage on phosphodiester bond at the 5’-side of AP site, and the cleavage
results in single strand DNA break with a 3’-hydroxyl group located at the upstream
strand and a 5’-deoxyribose phosphate (5’-dRP) group located at the downstream strand
[48].

Figure I.2 Removal of a base lesion by a DNA glycosylase [3]
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After APE1 cleavage, BER diverges into two sub-pathways: the short-patch (SP)
BER and the long-patch (LP) BER [8, 27, 28]. The SP-BER requires a native 5’-dRP
group, and it leads to a single-nucleotide replacement [8, 27, 28]. The LP-BER comes
into effect when the deoxyribose of the 5’-dRP is modified, and the LP-BER is a more
complicated repair pathway with the requirement of coordination of additional enzymes;
the repair leads to two or more nucleotides replacements [8, 27, 28]. The ability of
polymerase β (pol β), a bifunctional enzyme consists of a 31 kDa polymerase domain and
an 8 kDa deoxyribose phosphate (dRP) domain, in removing the deoxyribose of the 5’dRP group determines whether BER subjects to SP-BER or LP-BER [49].

Figure I.3 DNA polymerase β [12]

When the 5’-dRP is native, pol β removes the deoxyribose through β-elimination
with its dRP lyase domain [49]. The cleavage leaves a one-nucleotide gap with a 5’phosphate group [49]. The pol β further incorporates one nucleotide through its
polymerase domain, leaving a nick substrate [8, 27, 28]. The nick is then sealed by X-ray
cross-complementing group 1 (XRCC1)-DNA ligase IIIα (LIG IIIα) complex [8, 27, 28],
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leading to completion of SP-BER. The SP-BER results in one-nucleotide replacement
(Figure I.4). The ability of pol β in processing 5’-dRP quickly (at least 20-fold faster than
the polymerase gap filling) also contributes to the efficiency of SP-BER [50]. In contrast,
when the 5’-dRP group is modified, pol β cannot process the modified deoxyribose,
subjecting BER to LP-BER [8, 27, 28, 49]. Long-patch BER can be further divided into
two sub-pathways: Pol β/Flap endonuclease 1 (FEN1)-mediated LP-BER (“Hit and Run”
BER) and strand-displacement-mediated LP-BER (Figure I.4). During hit and run
pathway, pol β and FEN1 coordinate with high efficiency to repair the damage. The pol β
first incorporates one nucleotide, and then FEN1 removes one nucleotide that is
associated with the modified 5’-dRP at the downstream strand [51]. The cleavage by pol
β leaves another one nucleotide gap, and pol β continues to incorporate a second
nucleotide, which then leaves a nick substrate [51]. The ligase I (LIG I) comes and seals
the nick, completing the repair with two-nucleotide replacement [8]. The hit-and-run LP
sub-pathway is the most efficient LP-BER pathway when the downstream 5’-dRP is
modified, and the pathway requires good coordination between pol β and FEN1.
However, pol β is not essential for the strand-displacement-mediated LP-BER, the
polymerases involved in the repair can be DNA polymerase δ (pol δ) or DNA polymerase
ε (pol ε) [8, 27, 28]. Each of the polymerases synthesize continuously, displacing the
downstream strand and facilitating the formation of a long flap [8, 27, 28]. The long flap
is then captured and removed by FEN1, and the removal results in a nick that
subsequently sealed by LIG I, which finishes the repair [8, 27, 28]. The stranddisplacement-mediated LP-BER is the least efficient BER sub-pathway, and it usually
involves 3-10 nt replacement [8, 52].

7

Figure I.4 Base excision repair pathway [8]
The figure inllustrates the 1-nucleotide-patch BER on the left, the “Hit
and Run” BER in the middle, and the long-patch BER subpathways on
the right.

Base excision repair is a sophisticated and complex pathway. Proper functioning
and coordination of BER enzymes guarantee a precise and efficient repair of DNA base
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lesions. The DNA glycosylases and APE1 play vital roles in initiation steps of BER, and
the proper functioning of pol β and FEN1 guarantee the efficiency of BER. For example,
APE1 is essential for cell survival and its knockout is embryonic lethal [53]. Although
OGG1 is not necessary for survival, it plays a vital role in maintaining genomic stability:
the OGG1 knockout mice presented an increased risk for cancer development [54]. On
the other hand, pol β also plays a critical role in survival and growth. Disruption of the
pol β gene causes massive apoptotic events among the postmitotic neuron cells, resulting
in death of neonatal mice [55]. This indicates that pol β is essential for cell survival.
Moreover, although the embryonic mouse fibroblasts lack of pol β are viable, they are
hypersensitive to base damaging DNA agents, which cause accumulative repair
intermediates [56]. In addition, the knock-out of FEN1 also causes early embryonic
lethality of mice [57], suggesting an essential role of FEN1 for cell survival.
On the one hand, population-based studies showed that germline polymorphisms
of some BER enzymes are associated with elevated risks of cancers [58-60]. For instance,
the APE1 Asp148Glu genetic carriers has been reported to have an increased risk of
colorectal cancer [58]. Meanwhile, the OGG1 Ser326Cys genetic carriers show an
increased risk of developing breast cancer [59]. In addition, the heterozygous pol β
variant with deletion of exon 4-6 and 11-13 is associated with an increased risk of ovarian
carcinoma [60]. In addition, some functional studies of polymorphic variants of BER
enzymes also revealed a linkage between variants of BER enzymes and cancers [61, 62].
Studies of pol β Arg137Gln indicate the impaired DNA synthesis activity, which results
in accumulative DNA repair intermediates, contributes to the higher risk in cancer
development compared to the wild-type pol β carriers [61, 62]. In fact, many non-
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germline mutants of BER enzymes have also been identified in a variety of cancers: more
than 140 pol β mutants with multiple or single amino acids alternation have been
identified in different cancers including gastric, colorectal, prostate, lung, breast, bladder,
and esophageal cancers [63]. Some mutations also cause an altered enzymatic activity of
pol β. The pol β Leu22Pro mutant with the mutation at the dRP lyase domain, which was
identified in a gastric carcinoma, exhibits impaired dRP lyase activity [64]. Another pol β
mutant, pol β Glu295Lys, has a reduced DNA synthesis fidelity, which can cause high
mutation frequency during DNA synthesis, resulting in cellular transformation [65, 66].
On the other hand, the colorectal cancer-related FEN1 mutant (FEN1 Leu209Pro) was
identified to have an impaired endonucleolytic activity, and the reduced endonucleolytic
activity induces cellular transformation [67]. Therefore, the integrity of BER enzymes is
essential for genomic stability.
The interaction between BER enzymes and cofactors guarantees the efficiency of
BER enzymes. The BER cofactors modulate enzymatic activity and regulate the
coordination between the BER enzymes. For instance, one BER cofactor (XRCC1) that
functions as a scaffold protein, which does not possess any catalytic activities, can
enhance the enzymatic activity of APE1 and several DNA glycosylases including OGG1,
UNG2, NEIL1, and NEIL2 [68-72]. The functional stimulation of APE1 and DNA
glycosylases by XRCC1 indicate an important role of XRCC1 in regulating the
enzymatic coordination during the initiation of BER. In addition, the XRCC1 interacts
with pol β via its N-terminal domain, while the C-terminal BRCT domain of XRCC1
forms a strong complex with LIG IIIα [68]. Disruption of the interaction between pol β
and XRCC1 leads to a reduced efficiency of ligation by LIG IIIα [73], which
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compromises the efficiency of BER. Meanwhile, an alternation in the BRCT domain of
XRCC1 that interact with LIG IIIα directly affects expression of LIG IIIα [74], causing
reduced ligation, which further allows pol β strand displacement synthesis, thus resulting
in the least-efficient strand-displacement LP-BER [75]. The impaired BER in the
presence of XRCC1 mutants indicates a critical role of XRCC1 in ensuring the efficiency
of SP-BER by regulating the coordination between pol β and LIG IIIα.
Another important BER cofactor, the proliferating cell nuclear antigen (PCNA),
also plays an important role during BER [76]. Proliferating cell nuclear antigen, a central
scaffold protein, acts as the central regulator that coordinates not only BER but also other
metabolic pathways including DNA replication through protein-protein interactions [77].
At least 200 proteins contain the PCNA-interacting protein (PIP) box, a conserved 8amino-acid motif that allows the proteins to physically interact with PCNA [78]. During
BER, several DNA glycosylases, such as UNG2 and MPG, interact with PCNA [69, 79].
In addition, PCNA can stimulate replicative DNA polymerase pol δ, FEN1, and LIG I via
the interaction with their PIP box during LP-BER [80-82]. Although PCNA regulates its
binding partners through interaction with PIP boxes, the binding affinities of different PIP
boxes and the availability of these PIP boxes to the hydrophobic surface of PCNA also
affect PCNA interactions [78]. The diffitiatial binding affinity to PIP boxes of PCNA
allows PCNA to regulate BER enzymes (pol δ, FEN1, and LIG I) through a sequential
switching (from pol δ to FEN1 and then to LIG I), thereby ensuring an efficient LP-BER
[83]. Disruption of the interaction between FEN1 and PCNA or between LIG I and
PCNA results in a defective LP-BER [84, 85]. Therefore, BER cofactors, such as XRCC1
and PCNA, not only affect the enzymatic activity of the BER core enzymes, but also
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regulate the coordination between the enzymes, which ensure a precise and efficient
BER.
Efficient BER is critical in safeguarding the integrity and stability of the genome.
However, inefficient BER leads to the accumulation of DNA repair intermediates and
causes mutation and genomic instability, thereby inducing the development of cancers
and lupus [86, 87]. Also, inefficient BER can induce trinucleotide repeat (TNR)
instability [14], a typical form of genomic instability that is mainly associated with
neurodegenerative diseases and several cancers [88-90].

C. Trinucleotide Repeat Instability and Human Disease
Trinucleotide repeats (TNRs) are a subset of microsatellite DNA that consist of 3
nucleotides in each repeat unit [91]. Trinucleotide repeats are highly polymorphic and are
prone to a gain or loss of repeats resulting in repeat expansions and deletions [91, 92].
Both repeat expansions and deletions are associated with human diseases [88-90, 93].
The repeat deletions are associated with human cancers; e.g., the CAG repeat deletion in
androgen receptor (AR) gene is associated with prostate cancer [93]. Studies of the
association between TNR expansions and human diseases is more established. Currently,
more than 40 neurodegenerative diseases, such as Huntington’s disease (HD),
Friedreich’s ataxia (FRDA), fragile X syndrome (FXS), and myotonic dystrophy (DM),
are identified as the results of progressive TNR expansions, which can cause cellular
toxicity through protein aggregations, induce functional impairment of respective
proteins, suppress essential mRNA production, and generate RNA toxicity via production
of immature RNA transcripts [88-90]. All such abnormal cellular events can result in

12

death

of

neuronal

cells,

leading

to

the

onset

of

TNR-expansion-mediated

neurodegnerative diseases.
The likelihood of the repeat expansions tremendously increases if the repeat
length exceeds a crucial threshold length [92]. Normal individuals carry the same repeats
below the threshold length in the respective regions; however, some individuals carry
more repeats than the threshold length, the pre-mutation length [92]. The repeats below
the threshold are relatively stable. Whereas, the repeats within the pre-mutation range are
unstable and tend to result in repeat expansions: typically the longer the repeat tract is,
and the earlier the onset of the diseases occurs [92, 94]. The TNR expansions can occur at
both the encoding region and the noncoding region (Figure I.5): generally, small repeat
expansions as short as 10 repeats occur at the encoding region, and more substantial
repeat expansions of 100-10,000 occur at the noncoding region [92]. The difference in the
scales of repeat expansions between the encoding and noncoding region indicates that the
small repeat expansions occurred in the encoding region can directly cause protein
aggregation and cell death, while the large repeat expansions occurred in the noncoding
can result in the deregulation of gene expression and indirect cytotoxicity.

Figure I.5 Trinucleotide repeat expansions in encoding and
noncoding regions [7]
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The functional loss of certain proteins can be very destructive. For examples, the
expansions of the GNC repeats can result in partial functional loss of zinc-finger protein
of the cerebellum 2 (Zic2), which causes abnormality during early development and
differentiation [95, 96], leading to holoprosencephaly [97, 98]. On the other hand, the
protein aggregates resulted from misfolded protein can be equally deleterious [97, 99].
The repeat expansions occurring at the encoding regions are either (CAG)n or (GNC)n,
which encodes polyglutamine (polyQ) or polyalanine (polyA), respectively, and
expansions of such repeats can induce deleterious cellular events [97, 99]. Both the
polyQ and polyA have an increasing tendency to aggregate when the number of the CAG
or GNC repeats increases [97, 99-101]. The protein aggregates (Figure I.6), which are
refractory to protein degradations, are toxic to the cells and can induce cell death [102,
103], thereby leading to development of disease. The exact mechanisms of how the
protein aggregates formed by polyQ or polyA tracts and how they induce neuronal
degradations remain to be elucidated. However, it has been proposed that proteins with
the expanded polyQs tend to form amyloid-like fibrils abundant in β sheets, leading to
dysregulation of transcription, impairment of the ubiquitin-proteasome system,
mitochondrial dysfunction, and autophagy defects and thus induce cellular toxicity [100].
There are nine polyglutamine disorders, including spinal and bulbar muscular atrophy,
Huntington’s disease, and six types of spinocerebellar ataxias [99]. On the other hand,
polyA has been suggested to form similar protein aggregates with polyQ [97]. However, a
more plausible theory has been proposed that polyA tend to form α-helical clusters [101],
given the fact that the difference in the hydrophobicity between alanine and glutamine
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may induce aggregations with a distinct mechanism [104]. There are at least nine
polyalanine disorders caused by the expansion of GNC repeats, including synpolydactyly
type II (SPD) and oculopharyngeal muscular dystrophy (OPMD) [105].

Figure I.6 Protein aggregation and cellular toxicity [11]
In contrast, repeat expansions occurring in the noncoding regions (5’-UTR,
introns or 3’-UTR) of certain genes are more dramatic and can indirectly cause cellular
toxicity by suppressing gene transcription of essential proteins or by generating immature
RNA transcripts, resulting in progressive functional loss of essential proteins or
accumulation of RNA toxicity [106-112]. For example, CGG repeat expansion in the 5’UTR usually cause hypermethylation of CpG of the promoter region of the fragile X
mental retardation 1 (FMR1), leading to a reduction in mRNA of FMR1 that is
responsible for normal cognitive development and female reproductive function [111].
The loss or reduction of the protein leads to progressive cognitive declination and
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learning disabilities [111]. Similarly, expansion of GAA repeats in the first intron of the
frataxin gene (FXN) can reach to 1700 repeats [110]. The mega repeat expansions lead to
suppression of FXN transcription and reduction of frataxin (Figure I.7). The functional
loss of frataxin consequently results in the mitochondrial iron overload and extensive
oxidative stress [109], causing neuronal death and the development of Friedreich ataxia
[108]. Meanwhile, the CTG repeat expansions in 3’-UTR of myotonic dystrophy type 1
(DM1) can reach to 1000 repeats, causing defective mRNA splicing and the accumulative
RNA toxicity [106, 107]. The accumulative RNA toxicity leads to neuronal death and
neurodegenerative symptoms such as progressive muscle wasting and feebleness [107].

Figure I.7 GAA repeats expansions suppress frataxin expression [6]
The upper panel illustrates the normal unaffected allele. The lower
panel illustrates the affected FRDA allele.
The expansions of TNRs in both encoding and noncoding regions interfere with
vital cellular metabolism in a variety of ways. The outcomes of TNR expansions usually
result in neurodegenerative disorders. Without available cures, such neurological
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disorders cause huge financial and health burdens to the patients’ family and the society.
Therefore, it is essential to understand the mechanisms of the TNR-related diseases. Such
knowledge can assist in identification of potential targets for treatment and prevention of
TNR-related diseases.

D. Trinucleotide Repeat Instability and DNA Replication
The TNR instability occurring in the cells is a consequence of imbalanced DNA
transactions from the DNA metabolism that involved in addition of new nucleotides into
the DNA or removal of existing nucleotides from the DNA. Imbalanced addition and
removal of TNRs lead to gain or loss of repeats during DNA metabolism, thereby causing
TNR instability. One reason that the TNRs are prone to repeat expansions or deletions is
because TNRs have high tendency to form non-B DNA structures/secondary structures
[7, 113]. Formation of secondary structures modulates DNA metabolic enzymatic
activities, facilitating additions or removal of TNRs and promoting repeat instability. In
normal condition, DNA adopts right-handed B-form double helix structure via WatsonCrick base-pairing (A-T and G-C base-pairing) [114]. Whereas, during DNA replication,
DNA repairs, DNA transcription, and DNA recombination in TNR tracts, the two strands
(sense strand and anti-sense strand) that are separated can form secondary structures such
as loops and hairpins, G4 DNA structures, H-DNA, and sticky DNA (Figure I.8) by selfbasepairing [7, 92]. The non-B DNA structures can disrupt the coordination among DNA
metabolic enzymes, causing repeat instability. For example, when the newly synthesized
strand loops out forming a hairpin structure, the polymerases continuously synthesize
from the 3’-end of the upstream primer, thereby introducing more repeats during the
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synthesis and causing TNR expansions (Figure I.9). When the secondary structures
formed on the template strand, the polymerase directly bypasses the hairpin, which
results in fewer repeats synthesized on the template, leading to repeat deletions (Figure
I.9). Moreover, formation of the secondary structures is sequence dependent. Both
(CAG)n/(CTG)n and (CGG)n/(GCC)n can form hairpin structures [7]. In addition,
(CGG)n/(GCC)n can also form G4 DNA structures with four G’s base-pairing with each
other via Hoogsteen base-pairing [7, 115]. The (GAA)n/(CTT)n, on the other hand, can
loop out forming a loop, or H-DNA, or sticky DNA [7]. The stability of the secondary
structures also correlates with the length of the repeats with a high stability of the
secondary structures formed in the long repeat tracts [116, 117].

Figure I.8 Formation of secondary structures on TNRs [7]
a. Hairpin structure, b. G-quadruplex, c. Hairpin structures on both
CAG and CTG repeats, d. H-DNA, and e. Sticky DNA.
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Figure I.9 Secondary structures disrupt DNA synthesis of DNA
polymerases [7]
Although several DNA metabolic pathways including DNA replication, NER,
BER, and DNA recombination may induce the formation of secondary structures, many
in vivo and in vitro studies support the DNA replication [118-121] and the BER [1, 2, 14,
122, 123] are two primary mechanisms that cause repeat expansions since TNR
expansions occur in diving cells where both the DNA replication and the BER may be
involved and TNR expansions occur in non-diving cells where only the BER is involved
[92]. Because secondary structure can easily form during DNA replication and the
replicative DNA polymerases, pol ε and pol δ, exhibit rapid DNA synthesis, the DNA
replication has been proposed to be responsible for substantial repeat expansions in
diving cells. Several studies of TNR instability from bacteria, yeast, and mammalian cells
have shown that TNR expansions can occur during DNA replication, and repeat
expansions occur only at the leading strand [118, 120, 121], exhibiting repeat-sequence
orientation dependency. Moreover, it has been shown that the replication fork stalling
during DNA replication is responsible for TNR expansions [124]. In vivo studies show
that the replication fork stalls in expanded TNR tracts during the lagging strand synthesis
[125, 126], which has been directly visualized by using electron microscopy during the
DNA replication of CTG/CAG repeats [127], suggesting that secondary structures formed
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in the repeat tracts trigger the replication fork regression during the lagging strand DNA
synthesis. Such studies led to a proposed the replication restart model [7, 120]. In the
replication restart model (Figure I.10), secondary structures formed on the lagging strand
can induce both repeat expansions and repeat deletions. When the pol δ skips the
secondary structure, it results in repeat deletions. On the other hand, the secondary
structures formed on the lagging strand cause the replication fork stalling, and the
subsequent replication restart leads to resolution of the secondary structure on the lagging
strand, forcing formation of a secondary structure on the leading strand through the realignment of the nascent synthesized leading strand to its template strand. Consequently,
pol ε synthesized from the 3’-end of the newly formed secondary structure on the leading
strand, which results in repeat expansions (Figure I.10).

Figure I.10 Replication restart leads to TNR instability [7]
The upper panel illustrates that the secondary structure induce repeat
contraction during lagging strand synthesis. The lower panel illustrates that the
secondary structure formed on the lagging strand triggers the replication
collapse and restart, resulting in repeat expansion.
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The DNA replication fork stall model has successfully explained TNR expansions
in dividing cells. However, it cannot explain why substantial repeat expansions occur in
the post-mitotic cells [92] where DNA replication is absent. Given the fact that the
neuron cells are post-mitotic cells where the DNA replication is absence, and the fact that
many disease patients have their first symptoms of the diseases appeared at the age of 50s
or 60s [128-130], other mechanisms, such as oxidative DNA damage and its repair by the
BER pathway, have been proposed to be responsible for TNR expansions in somatic
cells.

E. Trinucleotide Repeat Instability and Base Excision Repair
Base excision repair is one of the most abundant and efficient DNA repair
pathways that exist in both dividing and non-dividing cells [45]. It repairs many oxidative
DNA damage including the most commonly generated base lesions, 8-oxoG, abasic
lesions, and ssDNA breaks, which can also occur in TNR tracts [27, 28]. In fact,
oxidative DNA lesions frequently accumulates in TNR tracts since the abundance of
guanines with a low-reduction-potential, which increases the frequency of oxidative DNA
damage on TNRs [131]. To repair DNA base lesions on the TNR tracts, DNA
glycosylases, such as OGG1, initiate BER by removing the damaged bases, and APE1
incises the DNA backbone at the 5’-side of an abasic site, generating a single strand DNA
break that in turn result in DNA strand separation [14]. The single strand break then
promotes the formation of secondary structures. The secondary structures may further
affect the activities of DNA metabolic proteins, leading to TNR expansions or deletions.
Thus, oxidative stress has been reported to be closely associated with TNR expansions in

21

both stem cells and somatic cells [14, 123]. However, oxidative damage alone are not
sufficient for TNR instability [14, 122], and the co-existence of OGG1 and other BER
enzymes along with the oxidative lesions has been reported to be crucial for TNR
instability [14, 122], suggesting BER is a mediator for TNR expansions.

Figure I.11 BER-mediated TNR expansions [1]
Subpathway 1 and 2 illustrate that no repeat instability induced by FEN1
efficient 5’-flap cleavage during “Hit and Run” BER and long-patch BER.
Subpathway 3 illustrates that repeat expansion induced by hairpin structure
formed on the downstream damage strand, which inhibits FEN1 cleavage.
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In the BER-mediated TNR instability, only the strand-displacement LP-BER has
been reported to promote repeat instability [1]. In SP-BER and the hit-and-run pathways,
the number of TNRs synthesized by pol β equals the one removed, and therefore no
repeat instability occur in such situations [8]. However, in the LP-BER sub-pathway, the
repeat instability occurs because the secondary structures disrupt the coordination among
BER enzymes, particularly the coordination between pol β and FEN1 [1]. In a model
proposed for TNR expansion (Figure I.11) [1]. A hairpin structure is formed on the
downstream substrate, which leaves a multi-nucleotide gap for pol β to fill in [1]. The pol
β generates multi-nucleotide gap filling synthesis, which results in addition of extra
repeats [1]. Meanwhile, the hairpin cannot be removed by FEN1 since FEN1 requires
specific 5’-flaps as its substrates [1]. The inability to remove the hairpin by FEN1
consequently leads to alternate cleavage by FEN1 in removing a short 5’-flap, leading to
ligation of the hairpin [1]. During the repair, pol β synthesizes more repeats than FEN1
removes, leading to repeat expansion [1]. However, the analysis of TNR expansion
profiles in non-dividing cells shows that a single TNR expansion mediated by BER of a
single DNA base lesion cannot explain substantial repeat expansion of 3000 GAA repeats
in the FXN gene and 100-1000 CTG repeats in the DM1 gene [92]. Given the fact that the
onsets of TNR-mediated neurodegenerative disorders require progressive development of
the diseases for 10 years or longer in some cases [132, 133], it is possible that multiple
rounds of BER-mediated TNR expansions must occur to substantially expand large TNR
tracts. The hypothesis of multiple BER leads to large repeat expansion is supported by
the fact that large TNR expansions can be induced through BER in a Huntington’s
transgenic mouse model through aging, which presumably result in accumulation of
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oxidative DNA damage in expanded CAG repeats [14]. This has been further supported
by the fact that the CAG repeat expansions in mouse neuron cells occur in an agedependent manner [14]. It is conceivable that during each round of BER, CAG repeats
are expanded by a small number, which make the repeats more unstable [14]. With the
increasing repeat expansion of the repeat tract and accumulative oxidative damage,
multiple rounds of BER in CAG repeats lead to a “toxic oxidation cycle” in a lesionBER-expansion manner (Figure I.12), which ultimately promote the repeat length to be
expanded over the threshold, leading to onset of the diseases.

Figure I.12 BER-mediated toxic oxidation cycle [14]
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Moreover, the mismatch repair protein complex, the MSH2-MSH3 complex, also
contributes to repeat expansion in a BER-dependent manner (Figure I.13). Under a
normal condition, MSH2-MSH3 serves as a structure recognition protein that specifically
binds to small insertion/deletion loops; MSH2-MSH3 undergoes a conformational change
and carries out its normal function, which coordinates the removal of the structures by
adenosine triphosphate (ATP) hydrolysis [134]. However, binding to the relatively large
loop and hairpin structures formed on expanded CAG repeats tracts can abolish the
ability of MSH2-MSH3 for conformational change and ATP hydrolysis. The binding on
the hairpin then traps MSH2-MSH3 on these secondary structures [135]. During BER on
TNRs, the entrapment of MSH2-MSH3 on the secondary structures stabilizes the
secondary structures, which subsequently prevents FEN1 cleavage [2]. Meanwhile,
MSH2-MSH3 physically interacts with pol β at the lesion sites [2]. The interaction
stimulates pol β synthesis of TNRs, which further prevents pol β hairpin-bypass and
removal of TNRs by FEN1, leading to repeat expansions [2].
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Figure I.13 MSH2-MSH3 coordinates BER enzymes to promote TNR
expansions [2]
Subpathway on the left illustrates that repeat deletion occurs during BER in the
absence of MSH2-MSH3. Subpathway on the right illustrates that MSH2-MSH3
facilitates repeat expansion by inhibiting 5’-flap cleavage activity of FEN1 and
stimulating DNA synthesis activity of pol β.

On the other hand, BER can also induce TNR deletions. It has been reported that
some chemotherapeutical reagents such as temozolomide, ironizing radiation, UV
radiation, hydrogen peroxide, and environmental pollutants such as chromate, bromate
can induce TNR deletions in bacteria, mouse stem and kidney cells, and human kidney
cells and lymphoblasts [5, 136-141]. The discrepancy of the outcomes of TNR instability
(repeat expansions and repeat deletions) from different cell types and different
endogenous and exogenous DNA damaging agents indicate that TNR instability induced
by DNA base lesion through BER is a complex process that involves many factors. Both
in vivo and in vitro studies have suggested that several factors contribute to the
discrepancy TNR instability mediated by BER. These factors include the locations/sites
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and the sizes of the secondary structures, the types of lesions on the TNRs, the
coordination among BER enzymes, and the involvement of other nucleases and cofactors
[1, 5, 9, 14, 122, 142-149].
In vitro studies have demonstrated that the locations of the secondary structure are
important in governing TNRs instability [1, 142]. When a secondary structure forms on
the downstream damage strand, it inhibits FEN1 cleavage [1, 5]. The inhibition forces
FEN1 to perform an alternate flap cleavage activity to remove a shorter flap instead of
removing the hairpin, which results in more repeats synthesized by pol β than removed
by FEN1, leading to ligation of a hairpin and TNR expansions (Figure I.11 3rd pathway).
However, when the secondary formed on the template strand, pol β can skip over the
secondary structures on the template strand [5, 142]. The pol β only synthesizes a small
portion of repeats within a TNR [142]. The inability of pol β to synthesize within the
hairpin results in direct bypass of the big hairpin, leading to FEN1 removal of more
repeats and repeat deletions as a consequence [142]. The bulky oxidized DNA base
lesions such as the 5’,8-cyclo-2’-deoxypurines (cdPus) [150] can distort the DNA
backbone because it contains the covalently linkage between the C5 of the 2’deoxyribose and the C8 of the purine [150]. The distortion on the DNA backbone
facilitates formation of a small loop structure with the cdPu lesions [143]. During BER,
pol β bypasses the loop, allowing FEN1 to remove more repeats than those synthesized
by pol β, leading to TNR deletions [143].
In addition, sites of the base lesions may contribute to the formation of secondary
structures with varying sizes located at different DNA strands, which disrupts BER
enzymatic coordination [5]. The sites of base lesions are associated with the formation of
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different secondary structures on both damage and template strands, contributing to
varying outcomes of repeat instability (Figure I.14). When an AP lesion located at the 5’side of a TNR repeat tract from the random sequence flanking region, it promotes a larger
hairpin to form on the downstream damage strand [5]. The secondary structures facilitate
pol β multi-nucleotide gap-filling synthesis, FEN1 alternate flap cleavage, and ligation of
a hairpin, causing repeat expansion [5]. However, if a base lesion occurs in the middle,
multiple small hairpins can occur in the upstream and downstream strand of the damaged
strand and template strand [5]. In this scenario, pol β performs weak synthesis of TNRs
and bypasses a small hairpin on the template strand while FEN1 removes the unstable
downstream hairpins, leading to removal of more repeats than those synthesized and
resulting in repeat deletion [5]. In a scenario where multiple abase lesion occurs in the
middle of the repeat tract, a large hairpin along with a small hairpin forms on the template
strand, which results in pol β skip over the hairpins, leading to large repeat deletion [5].
In contrast, when the lesion occurs at the 3’-side of a TNR tract from the random
sequence flanking region, no repeat instability occurs since the sizes of secondary
structures on both the damage strand and the template strand are equal [5].
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Figure I.14 Locations of base lesions govern BER-mediated TNR
instability [5]
Subpathway 1 illustrates that base lesion located on the 5’-end of repeat tract
induces small repeat expansion. Subpathway 2 illustrates that base lesion
located in the middle of repeat tract induces small repeat deletion. Subpathway
3 illustrates that base lesion located at the 3’-end of repeat tract does not
induce repeat instability. Subpathway 4 illustrates that several base lesions
located in the middle of repeat tract induce large repeat deletion.
Trinucleotide repeat expansions usually occur in an age- and tissue-dependent
manner [14, 122]. It has been shown that CAG repeat expansion preferentially occurs in
striatum with a high level of pol β, a low level of FEN1, and a low level of high mobility
box 1 (HMGB1), a cofactor in LP-BER that can stimulate FEN1 flap cleavage [122,
144]. In contrast, neither TNR expansions nor high level of pol β expression have been
observed in cerebellum [122, 144]. The study suggests that a high level of pol β and a
low level of FEN1 is critical in repeat expansions. Therefore, a reduction in DNA
synthesis activity of pol β or an enhancement of FEN1 cleavage may contribute to TNR
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deletions. In fact, pol βY265C with impaired DNA synthesis activity has been reported to
reduce repeat expansion frequency in both sperm and brain cells of the heterozygous pol
βY265C fragile X-related disorder mice [146, 151], demonstrating that DNA synthesis
activity of pol β is critical in modulating TNR instability. On the other hand, other DNA
repair nucleases can also contribute to TNR deletions by coordinating with FEN1 during
BER. It has been shown that both APE1 and Mus81/Eme1 can be involved in removing a
CAG repeat hairpin embedded in the expanded TNRs [9, 145]. The guanines embedding
in the single strand regions of secondary structures, such as the loop regions of hairpins,
are susceptible to oxidative DNA damage compared to that are in duplex DNA where
they base-pairs with cytosines [152, 153]. The DNA base lesions in the loop regions of a
CAG repeat hairpin can be removed by DNA glycosylases, OGG1, NEIL1, and NEIL2
[145, 152-154], leaving an abasic site in the loop region of the hairpin. The APE1
cleavage then results in the formation of a double flap intermediate that contains a 3’-flap
and a 5’-flap, which can then be removed by the coordinated flap cleavage activity
between Mus81/Eme1 [145] or the APE1 3’-5’ exonucleolytic activity and FEN1 (Figure
I.16).
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Figure I.15 APE1 suppresses TNR expansions by facilitating removal of
upstream repeats [9]
Subpathway 1 illustrates that APE1 3’-5’ exonuclease activity facilitates
removal of upstream repeats and prevents repeat expansion. Subpathway 2
illustrates that upstream hairpin structure inhibits APE1 3’-5’ exonuclease
activity and cause repeat expansion. Subpathway 3 illustrates that
coordination between 5’-flap cleavage activity of FEN1 and 3’-5’
exonuclease activity of APE1 prevents repeat expansion.
The coordination among BER enzymes and cofactors can also contribute to the
outcomes of TNR instability. The X-ray repair cross-complementing protein 1 (XRCC1)
and proliferating cell nuclear antigen (PCNA) are two crucial cofactors in SP-BER and
LP-BER, respectively. Although there is no direct evidence between XRCC1 and TNR
instability, it is likely XRCC1 may promote repeat deletions by interacting with APE1 in
resolving a hairpin structure since XRCC1 can stimulate APE1 3’-5 exonucleolytic
activity [155]. Moreover, XRCC1 is important for maintaining the efficiency of SP-BER,
disruption of the interaction between pol β and XRCC1 can lead to inefficient ligation by
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LIG IIIα [75], which subsequently promotes pol β strand-displacement DNA synthesis
leading to LP-BER increasing the probability of TNR instability. The PCNA, on the other
hand, has been supported to be crucial in TNR instability by several studies [147-149]. A
polymorphic PCNA variant, PCNA Ser228Ile variant with impaired interaction with
FEN1 and LIG I, has been reported to be responsible for deficiency in DNA repair, which
contributes to a high susceptibility to neurodegeneration [144, 156, 157]. Because PCNA
stimulates the activities of both FEN1 and LIG I by interacting with both enzymes via
PIP box, the coordination between PCNA and these enzymes are crucial in modulating
TNR instability [147-149]. Disruption of the interaction between human PCNA and LIG I
leads to an increased TNR instability [147]. Disruption of the interaction between PCNA
and LIG I or FEN1 also increases TNR instability frequency in budding yeast [148].
Moreover, PCNA assists the resolution of a CAG repeat hairpin by stimulating FEN1 flap
cleavage activity and LIG I activity, facilitating repeat deletion and removal a CAG
repeat hairpin and preventing TNR expansion [149]. Furthermore, PCNA interacts with
MSH3, and the interaction is important for MSH2-MSH3 mediated lesion recognition
[158], suggesting a role of PCNA in modulating TNR instability by interacting with
MSH2-MSH3.
Proliferating cell nuclear antigen can also modulate TNR instability through its
posttranslational modification. For example, mono-ubiquitination of PCNA can regulate
the coordination between BER enzymes and enzymes from other DNA repair pathways,
e.g., translesion (TL) DNA synthesis [159-161]. Although there is no direct evidence of
mono-ubiquitinated PCNA (ub-PCNA) induces TNR instability, the importance of ubPCNA in regulating different DNA polymerases and nucleases implicates it may play a
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critical role in modulating TNR instability through BER. PCNA can be ubiquitinated at
Lsy164 by RAD18-RAD6 ubiquitin ligase complex mediated mono-ubiquitination [162,
163]. The RAD18-RAD6 ligase can be recruited to the lesion site by replication protein A
(RPA) [164, 165], a single strand DNA binding protein that is involved in the DNA
replication and DNA repair, including BER [166]. Mono-ubiquitination of PCNA can
also be induced by the DNA base damage agents, methyl methanesulfonate (MMS) and
UV irradiation [167]. Since MMS-induced alkylating DNA damage is subject to BER
[168], this indicates that PCNA can be mono-ubiquitinated during BER. Monoubiquitination of PCNA provides additional protein binding surfaces (Figure I. 19) to
interact with other DNA repair proteins with a high binding affinity via either an
ubiquitin-binding module (UBM) or an ubiquitin-binding zinc domain (UBZ). All the TL
polymerases, including REV1, pol η, pol κ, and pol ι, have UBM or UBZ [161]. It has
been shown that interaction between ub-PCNA with pol η, pol κ, and pol ι enhances their
DNA synthesis activity. It has also been suggested that TL polymerases are involved in
DNA replication-mediated repeat instability where pol δ was mutated in budding yeast
[169]. Unlike the replication polymerases (pol ε and pol δ) and other DNA repair
polymerases, such as pol β, TL polymerases have an enlarged active site. The enlarged
active site may allow the polymerases to interact with the secondary structures formed on
TNR tracts with more flexibility that further increases the likelihood of repeat instability.
Additionally, since ub-PCNA does not physically interact with pol β, the binding between
the TL polymerases and ub-PCNA may enhance the DNA synthesis activity of the TL
polymerases, leading to TNR instability with a mechanism that is different from the one
employed by pol β.
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Figure I.16 Mono-ubiquitinated PCNA (the ubiquitin depicted as cyan
and the PIP binding box depicted as magenta) [4]
On the other hands, ub-PCNA can also regulate the activity of nucleases during
the repair. The ub-PCNA can compromise the interaction between PCNA and FEN1.
Structural alignment between ub-PCNA and PCNA-FEN1 complex reveals an overlap
between ubiquitin and the active site of FEN1 (Figure I.20), suggesting ub-PCNA may
not be able to interact with FEN1 and stimulate its activity. The ub-PCNA can also
physically interact with the Fanconi anemia-associated nuclease 1 (FAN1) via UBZ and
the non-canonical PIP box located at N-terminal domain of FAN1 [159, 160]. The FAN1
was initially identified as nuclease with the ability to unlock the interstrand crosslink
(ICL) [170, 171] in Fanconi anemia (FA) DNA repair pathway, and its deficiency results
in a rare genetic kidney disorder [172]. It has been shown that single nucleotide
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polymorphisms of FAN1 are associated with the modulation of onset age of Huntington’s
disease [173, 174], suggesting a critical role of FAN1 in modulating CAG repeat
instability. The FAN1 may facilitate in suppressing CAG repeat expansion through its 5’3’ exonucleolytic and 5’-flapendonucleolytic activity. The 5’-flap exonucleolytic activity
of FAN1 requires dimerization of two FAN1 monomers in a head-to-tail fashion [171,
175]. However, the 5’-3’ exonucleolytic activity only requires its monomer [171, 175]
and may be particularly important in resolving the hairpin structures formed on the
downstream strand of a TNR tract. Thus, although ub-PCNA may suppress the interaction
with FEN1, it may stimulate FAN1 activity to resolve a downstream TNR hairpin
modulating TNR instability during BER.

Figure I.17 Ubiquitin may prevent interaction between FEN1
and PCNA via PIP box [4]
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In summary, BER plays an active role in modulating somatic TNR instability
induced by DNA base lesions and ssDNA breaks. The BER-mediated TNR instability is
complex and involves many different factors. Some factors have been identified to
promote TNR expansions, the others have been shown to induce TNR deletions.
Exploration of the molecular mechanisms underlying BER-mediated TNR instability is
particularly important as it can help to identify potential therapeutic targets for
attenuation of the expanded TNRs, thereby facilitating the development of the treatment
and prevention for TNR expansion diseases. In my Ph.D. dissertation research, I explored
the underlying molecular mechanisms of BER-mediated somatic TNR instability from
three different areas. The results have been summarized in the three chapters in the
dissertation. Chapter 1 evaluates the effects of the polymorphic variants of DNA
polymerase β (pol β) on TNR instability during BER. Chapter 2 explores the mechanisms
how the DNA synthesis activity of pol β modulates the outcomes of TNR instability, and
how the inhibition of pol β activity can preferentially contribute to CAG repeat deletion,
and the implications of inhibition of pol β DNA synthesis in the treatment of neurological
disorders mediated by TNR expansions. Chapter 3 of my dissertation investigates how
the coordination between ub-PCNA and nucleases, FAN1, and FEN1, can modulate TNR
instability through BER, and the implications of the coordination as a new target for the
treatment TNR expansion diseases.
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OVERVIEW
Trinucleotide repeat (TNR) expansions are associated with more than 40 human
neurological disorders including Huntington’s disease, Friedreich’s ataxia, and fragile X
syndrome. The repeat expansions can occur through maternal transmission and continue
to progress after post-mitotic differentiation. The DNA replication, DNA repairs, DNA
recombination, and gene transcription have been proposed to be associated with inherited
and somatic TNR expansions and deletions. Recent studies show that BER is one of the
major pathways that is responsible for TNR expansion in post-mitotic neuronal cells. The
BER-mediated TNR instability is the result of inability of the BER enzymes in resolving
the secondary structures, and consequently resulting in an imbalance between addition of
TNRs by DNA polymerases or removal by nucleases during BER. Other factors
including the sites of DNA base lesions, locations and sizes of the secondary structures,
the lesion types, the coordination among BER enzymes and cofactors, and involvement
of nucleases and cofactors from other DNA repair pathways all contribute to modulating
of TNR instability mediated by BER. Yet the mechanisms as to how the enzymes and
cofactor and their posttranslational modifications can modulate TNR instability through
regulating the balance between the addition and removal of TNRs during BER remain to
be elucidated. Since there are no effective treatment for TNR-mediated neurological
disorders, exploration of the molecular mechanisms is essentially important as it provides
new insights into development and prevention of TNR expansion diseases, which will
further aid in identification of new therapeutic targets and biomarkers for early diagnosis
of TNR-related diseases.
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In Chapter 1, we evaluate the effects of a germline polymorphic pol β R137Q
variant on CAG repeat instability during BER. The results indicate that pol βR137Q does
not significantly affect CAG repeat instability during BER suggesting that the
polymorphic variant R137Q carriers may not have a higher risk in developing TNR
expansion mediated neurological disorders than the normal population (published). In
Chapter 2, we explore the mechanisms as to how the DNA synthesis activity of pol β can
modulate the outcomes of TNR instability, how the inhibition of pol β activity can
preferentially lead to CAG repeat deletion, and the implications of inhibition of pol β
DNA synthesis in the treatment of TNR-expansion neurological disorders. We find that
weak DNA synthesis activity promotes BER-mediated TNR deletions. Inhibition of pol β
DNA synthesis activity may be utilized as a potential therapeutic strategy to shorten the
expanded TNR. In Chapter 3, we explore the effect of the ub-PCNA on TNR instability
by modulating activities of the nucleases, FEN1 and FAN1. We find that ub-PCNA
stimulates FAN1 5’-3’ exonucleolytic activity in resolving the downstream hairpins,
thereby suppressing TNR expansions.
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CHAPTER 1: MODULATION OF TRINUCLEOTIDE REPEAT INSTABILITY
BY DNA POLYMERASE β POLYMORPHIC VARIANT R137Q

ABSTRACT
Trinucleotide

repeat

(TNR)

instability

is

associated

with

human

neurodegenerative diseases and cancer. Recent studies have pointed out that DNA base
excision repair (BER) mediated by DNA polymerase β (pol β) plays a crucial role in
governing somatic TNR instability in a damage-location dependent manner. It has been
shown that the activities and function of BER enzymes and cofactors can be modulated
by their polymorphic variations. This could alter the function of BER in regulating TNR
instability. However, the roles of BER polymorphism in modulating TNR instability
remain to be elucidated. A previous study has shown that a pol β polymorphic variant,
polβR137Q is associated with cancer due to its impaired polymerase activity and its
deficiency in interacting with a BER cofactor, proliferating cell nuclear antigen (PCNA).
In this study, we have studied the effect of the pol βR137Q variant on TNR instability.
We showed that pol βR137Q exhibited weak DNA synthesis activity to cause TNR
deletion during BER. We demonstrated that similar to wild-type pol β, the weak DNA
synthesis activity of pol βR137Q allowed it to skip over a small loop formed on the
template strand, thereby facilitating TNR deletion during BER. Our results further
suggests that carriers with pol βR137Q polymorphic variant may not exhibit an elevated
risk of developing human diseases that are associated with TNR instability.
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INTRODUCTION
Human genome is susceptible to a variety of types of DNA damage that can
modify DNA bases, deoxyribose sugar phosphate (dRP) groups as well as directly break
DNA backbone [176]. It has been estimated that more than 10,000 base lesions are
generated per cell per day [177], and these lesions are efficiently repaired by DNA base
excision repair (BER) [49, 177] through the single-nucleotide or long-patch BER subpathway [8, 27, 73, 178, 179].
Genome instability, typically microsatellite instability is responsible for many
human diseases [180-183] including GT repeat instability that is associated with colon
cancer [184] as well as trinucleotide repeat (TNR) expansion diseases [89, 92, 185, 186].
TNR expansion has been identified as the cause of more than 40 neurodegenerative
diseases [7, 92] including Huntington’s disease (HD), spinocerebellar ataxia (SCA) type
1, 2, 3, 6, 17 and spinal bulbar muscular atrophy (SBMA) (Kennedy's disease) (CAG
repeat expansion) [89, 187, 188], myotonic dystrophy type 1 (DM1) (CTG repeat
expansion), Friedreich’s ataxia (GAA repeat expansion) and fragile X syndrome (CGG
repeat expansion) [189-191]. TNR expansions can occur in both the coding or non-coding
regions of the genes associated with disease development, leading to aberrant protein
aggregation or deficiency of gene expression [7, 192, 193]. On the other hand, CAG
repeat deletion is associated with cancer [194]. CAG repeat deletion in the androgen
receptor (AR) gene can result in a high transcriptional activity of the AR protein [194196], which may potentially lead to progression of prostate cancer [197, 198].
TNR instability is mediated by the formation of secondary structures, including
hairpins, loops and G4-quadruplex [7, 92], during DNA replication [199], repair [14,
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200]and recombination [201] as well as gene transcription [202]. Furthermore, it has been
shown that DNA repair [92] and gene transcription [202] play crucial roles in modulating
somatic TNR instability [203] especially in postmitotic neurons. Since TNR tracts
contain a long stretch of guanines that are susceptible to DNA base damage [177, 204],
they form hotspots of base lesions and are constantly subject to multiple cycles of BER,
which leads to a “toxic oxidation cycle" resulting in TNR expansion [14, 92]. This is
supported by the fact that TNR expansion is promoted by increased amount of 8oxoguanine (8-oxoG) in the neurons of HD transgenic mice [14] and germ cells of fragile
X syndrome mice treated with an oxidative DNA damaging agent, potassium bromate
[205]. Moreover, TNR deletion can also be induced by an alkylating DNA damaging
agent, temozolomide [206] in the lymphoblasts of Friedreich’s ataxia patients through
BER [207]. As a core enzyme of BER, pol β plays a critical role in maintaining genome
stability [49, 208] as well as modulating TNR instability [1, 14, 209-211]. It has been
found that pol β promotes TNR expansion by performing multi-nucleotide gap-filling
synthesis on a TNR repeat tract [14] and facilitating FEN1 alternate flap cleavage of a
short repeat flap. This subsequently leads to ligation of a hairpin during long-patch BER
[1]. It has been suggested that during DNA replication, pol β can also promote repeat
expansion by extending the 3'-terminus of a hairpin to produce extra repeats [209]. A
recent study has also shown that pol β can interact with mismatch repair proteins MSH2MSH3 to promote TNR expansion [2]. On the other hand, pol β facilitates TNR deletion
by skipping over a TNR hairpin on the template strand [210, 211] or bypass a 5’, 8-cyclo2’-deoxyadenosine (cdA), a bulky base lesion located in a loop on the template of a CTG
repeat tract [212]. Our previous studies have shown that pol β coordinates with FEN1 to
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govern the balance between the addition and removal of nucleotides during the repair on
TNRs, thereby leading to TNR expansion or deletion in a damage-location dependent
manner [210]. All these indicate that in coordination with FEN1, pol β modulates TNR
expansion or deletion during long-patch BER via its multi-nucleotide gap-filling
synthesis, strand displacement DNA synthesis, hairpin-bypass synthesis. Since the longpatch BER in the context of a TNR tract is much less efficient than the single-nucleotide
BER, this allows the formation of secondary structures, such as hairpins and loops. Thus,
efficient BER prevents TNR instability by inhibiting DNA slippage and the formation of
hairpin and loop structures in a TNR tract, whereas inefficient BER can promote the
processes and TNR instability [1, 8].
Genetic variations, i.e. polymorphism of DNA repair enzymes and cofactors, 8oxoguanine DNA glycosylase (OGG1) [59, 213], APE1 [214], X-ray repair crosscomplementing protein 1 (XRCC1) [215-217], XPC [218, 219], MSH3 [220-223], RPACDK7 [224] among others have been reported to be associated with cancer and
neurodegenerative diseases. However, some studies do not support the notion [225-227].
The controversy is due to lack of knowledge of the effects of these BER polymorphic
variants on genome stability and integrity. Thus far, three germline polymorphic variants
of pol β with single amino acid substitution have been identified in human population.
They are pol βR137Q, pol βP242R, and pol βQ8R variant that are associated with cancer
[61, 228-232]. Among them, pol βR137Q variant is particularly of interest. It contains the
substitution of arginine 137 with glutamine, which occurs in the polymerase domain of
pol β and is involved in mediating the interaction between pol β and proliferating cell
nuclear antigen (PCNA) [233]. The pol β variant exhibits impaired DNA synthesis
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activity and deficiency in interacting with PCNA. This results in cellular hypersensitivity
to an alkylating DNA damaging agent, methyl methanesulfonate (MMS) [61]. Thus, it is
conceivable that the impaired DNA synthesis activity of pol βR137Q may disrupt the
coordination between pol β and other BER proteins, promoting genome instability such
as TNR instability during BER. To test this possibility, we initially characterized DNA
synthesis activity of the polymorphic pol βR137Q variant and its effects on CAG and
CTG repeat instability during BER. We found that pol βR137Q variant showed weaker
DNA synthesis activity than wild-type pol β during BER in the context of CAG and CTG
repeats. Yet it exhibited similar ability as wild-type pol β to cause deletion of CAG and
CTG repeats during BER of an abasic lesion at various locations. We provide the first
evidence that pol βR137Q variant modulates TNR instability in a similar manner as wildtype pol β. Our results further suggest that the individuals who carry pol βR137Q
polymorphic variant, do not exhibit a higher risk of development of TNR instability and
its associated diseases than individuals who have wild-type pol β.

MATERIALS AND METHODS
Materials
DNA oligonucleotide substrates were synthesized by Integrated DNA
Technologies (Coralville, IA, USA). The radionucleotides γ-32P ATP (6000 mCi/mmol)
and Cordycepin 5’-triphosphate 3’-α-32P (5000 mCi/mmol) were purchased from
PerkinElmer Inc. (Boston, MA). T4 polynucleotide kinase, terminal deoxynucleotidyl
transferase and deoxynucleoside 5’-triphosphates (dNTPs) were purchased from Thermo
Fisher Scientific (Waltham, MA). Micro Bio-Spin 6 Columns were purchased from Bio-
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Rad Laboratories (Hercules, CA). Pierce Avidin Agarose resin was from Thermo Fisher
Scientific (Waltham, MA). QuikChange II XL Site-Directed Mutagenesis kit was
purchased from Agilent Technologies (Santa Clara, CA). All other standard chemical
reagents were from Thermo Fisher Scientific (Waltham, MA) and Sigma-Aldrich (St.
Louis, MO). Purified enzymes including APE1, pol β, FEN1 and LIG I were made
according to the procedures described previously [51, 145].

Oligonucleotide substrates
The 100 nt oligonucleotide substrates contain (CAG)20 repeats or (CTG)20 repeats
with a tetrahydrofuran (THF), an analog of a modified abasic site. The THF residue
substituted the first or tenth repeat unit of the (CAG)20 or (CTG)20 containing substrates.
This mimics the scenario that the damage occurred at the 5’- end or in the middle of the
repeat tract. Substrates were constructed by annealing the damaged strand with the
template strand at a molecular ratio of 1:2. A strand of DNA fragment containing
(CAG)20 or (CTG)20 repeats without damage was used as a size marker. The sequences of
substrates are listed in Table 1.

Table 1. Oligonucleotide Sequences [13]
Oligonucleotide
nt
Sequence (5’-3’)
Undamaged strand
CAG-0 (undamaged)
100 CGA GTC ATC TAG CAT CCG TA CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG TA CGT
AGA CTT ACT CAT TGC
CTG-0 (undamaged)
100 GCA ATG AGT AAG TCT ACG TA CTG
CTG CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG CTG CTG
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CTG CTG CTG TA CGG ATG CTA GAT
GAC TCG
THF containing substrate
CAG-1 (THF 5’-end)

99

CAG-10 (THF middle)

99

CTG-1 (THF 5’-end)

99

CTG-10 (THF middle)

99

CGA GTC ATC TAG CAT CCG TA
CATHF CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG TA CGT
AGA CTT ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CATHF CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG TA CGT AGA
CTT ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA
CTTHF CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG TA CGT AGA
CTT ACT CAT TGC
GCA ATG AGT AAG TCT ACG TA CTG
CTG CTG CTG CTG CTG CTG CTG CTG
CTTHFCTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG TA CGG ATG CTA
GAT GAC TCG

Template strand
CAG-T (CAG-1 and CAG-10 100 GCA ATG AGT AAG TCT ACG TA CTG
CTG CTG CTG CTG CTG CTG CTG CTG
template)
CTG CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG TA CGG ATG CTA GAT
GAC TCG
CTG-1-T (CTG-1 template)
100 GCA ATG AGT AAG TCT ACG TAC AG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG TA CGG ATG
CTA GAT GAC TCG
CTG-10-T (CTG-10 template) 100 CGA GTC ATC TAG CAT CCG TA CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG TA CGT
AGA CTT ACT CAT TGC
1-nt gap substrate
CAG-gap-upstream
50 CGA GTC ATC TAG CAT CCG TA CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG
CAG-gap-downstream
49 AG CAG CAG CAG CAG CAG CAG
CAG CAG CAG TA CGT AGA CTT ACT
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CAG-gap-template

Random-gap-upstream
Random-gap-downstream
Random-gap-template

Nick substrate
Nick-CAG-1-up
Nick-CAG-1-down

Nick-CAG-1-Template

Nick-CAG-10-up
Nick-CAG-10-down
Nick-CAG-10-Template

CAT TGC
100 GCA ATG AGT AAG TCT ACG TA CTG
CTG CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG TA CGG ATG CTA GAT
GAC TCG
50 CGA GTC ATC TAG CAT CCG TA TCG
CAC TGT TAT CAT TTC GTG TAC TTC
ATG
49 GT ATG TGT CAT ATA TTC ATT TGC
GCT AAC TA CGT AGA CTT ACT CAT
TGC
100 5'- GCA ATG AGT AAG TCT ACG TAG
TTA GCG CAA ATG AAT ATA TGA CAC
ATA CAC ATG AAG TAC ACG AAA TGA
TAA CAG TGC GAT ACG GAT GCT AGA
TGA CTC G
23
77

CGA GTC ATC TAG CAT CCG TA CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG TA CGT AGA
CTT ACT CAT TGC
100 GCA ATG AGT AAG TCT ACG TA CTG
CTG CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG TA CGG ATG CTA GAT
GAC TCG
50 CGA GTC ATC TAG CAT CCG TA CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG
50 CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG TA CGT AGA CTT ACT
CAT TGC
100 GCA ATG AGT AAG TCT ACG TA CTG
CTG CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG TA CGG ATG CTA GAT
GAC TCG

Primers for DNA fragment
analysis
CAG reverse primer
23
CAG forward primer
CTG-1 reverse primer

21
23

6-FAM -CAA TGA GTA AGT CTA CGT
ACT GC
CGA GTC ATC TAG CAT CCG TAC
6-FAM -CAA TGA GTA AGT CTA CGT
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CTG-1 forward primer
CTG-10 reverser primer

20
19

CTG-10 forward primer
21
Primers for site directed
mutagenesis
Pol beta R137Q fwd
44
Pol beta R137Q rev
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ACA GC
CGA GTC ATC TAG CAT CCG TAC
6-FAM- CGA GTC ATC TAG CAT CCG
TAC
GCA ATG AGT AAG TCT ACG TA
AAT TGA ACC ATC ATC AGC AGA TTG
GG CTG A AAT ATT TTG GGG AC
GTC CCC AAA ATA TTT CAG CCC AAT
CTG CTG ATG ATG GTT CAA TT

Construction of pol βR137Q variant expression vector and expression and
purification of pol βR137Q variant protein
The expression vector of pol βR137Q variant was constructed by site-directed
mutagenesis using the encoding region of wild-type pol β-(His)6 cloned in pET15b vector
as the template. Site-directed mutagenesis was conducted with the QuickChange II XL
Site-Directed Mutagenesis Kit. A forward PCR primer and a reverse primer (Table S1)
were used for PCR reactions under the conditions as follows: 1 cycle of 95°C for 30 s;
then 16 cycles of 95°C for 30 s, 52°C for 1 min, 68°C for 7 min. The expression vector
with pol βR137Q variant with a (His)6 tag was then transformed into E. coli BL21DE3
(Aligent Techologies, Santa Clara, CA) for their expression according to the procedures
described previously [51, 145]. Briefly, cell pellets were resuspended in the lysis buffer
that contains 50 mM NaH2PO4, 30 mM NaCl, 10 mM imidazole, 10 mM
ethylenediaminetetraacetic acid (EDTA), 10 mM dithiothreitol (DTT), 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1 mM benzamidin, 1 µg/ml leupeptin and 1
µg/ml pepstatin A. Soluble proteins and cell debris were then separated by centrifugation
at 12,000 rpm, 4°C for 30 min. The supernatant was subjected to Ni-NTA agarose column
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from Qiagen (Hilden, Germany) for purification. Proteins were eluted by elution buffer
containing 30 mM 4-(2-hydroxyethyl)-1-piperazineethane-sulfonic acid (HEPES), pH7.5,
300 mM NaCl, 500 mM imidazole, 10 mM EDTA and 10 mM DTT. Peak fractions were
collected and dialyzed into buffer that contains 30 mM HEPES, pH 7.5, 0.5% inositol,
1.7M (NH4)2SO4 and 1 mM PMSF. Proteins were separated by phenyl sepharose 6 fast
flow column (GE Healthcare Bio-Science, Uppsala, Sweden). Eluted peak fractions were
combined and dialyzed into 30 mM HEPES, pH 7.5, 0.5% inositol, 30 mM KCl, 1 mM
EDTA and 1 mM PMSF. Proteins were then subjected to purification with the Q
sepharose (GE Healthcare Bio-Science, Uppsala, Sweden). Peak fractions were combined
and dialyzed into storage buffer that contains 30 mM HEPES, 100 mM KCl. 20%
glycerol and 1mM PMSF, aliquoted and frozen at -80°C for storage.

In vitro reconstituted BER
Reconstituted BER was performed by incubating purified APE1, wild-type pol β
or pol βR137Q variant, along with FEN1, LIG I and (CAG)20 or (CTG)20 substrates (25
nM) containing a THF residue in a reaction mixture (20 µl) that contained 5 mM MgCl2,
50 µM dNTPs, 2 mM ATP, 50 mM Tris-HCl (pH 7.5), 50 mM KCl, 0.1 mg/ml BSA, 0.1
mM EDTA and 0.01% NP-40. Reaction mixtures were assembled on ice and incubated at
37°C for 15 min. Reactions were terminated with 2X stopping buffer (95% formamide
and 10 mM EDTA) and incubation at 95°C for 10 min. Substrates and products were then
separated in 15% urea-denaturing polyacrylamide gel (PAGE) and detected by a Pharos
FX Plus PhosphorImager (Bio-Rad Laboratory, CA).
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Probing of secondary structures formed in a TNR tract by S1 nuclease
The formation of hairpin structures on the damaged and template strands of the
(CAG)20 or (CTG)20 substrate was probed with the S1 nuclease that makes cleavage
specifically on a single-strand DNA (Promega Life Science, Madison, WI). 100 nM
substrates containing a THF residue that substitutes the G at the first or tenth repeat were
initially incubated with 10 nM APE1 in the absence or presence of 5 nM wild-type pol β
or pol βR137Q for 30 min in the BER buffer as described previously. Subsequently, the
10 µl reaction mixtures were subjected to S1 nuclease digestion at 37°C for 1, 3, 5, 10, 15
min, respectively with 5 µl S1 nuclease reaction mixtures that contained optimized
concentrations of S1 nuclease in the buffer containing 30 mM sodium acetate (pH 4.6),
50 mM NaCl, 1 mM ZnCl2, 0.5 mg/ml denatured calf thymus DNA and 5% glycerol. The
S1 nuclease digestion was optimized by employing 25 U and 2 U of S1 nuclease for the
digestion of the the damaged strand and template strand of the (CAG)20 containing
substrate that contains a THF located at the first repeat, respectively; and by employing 3
U, 25 U and 5 U of S1 nuclease for the digestion of the upstream damaged strand,
downstream damaged strand and the template strand of the (CAG)20 containing substrate
that contains a THF located at the tenth repeat, respectively. Reactions were then
quenched with addition of 2 µg proteinase K and incubation at 55°C for 30 min. Reaction
mixtures were then mixed with the same volume of 2X stopping buffer and denatured at
95°C for 10 min. Substrates and products were separated in an 18% urea-denaturing
PAGE and detected by a PhosphorImager.
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Enzymatic activity assay
Pol β DNA synthesis activity were determined by incubating wild-type pol β or
pol βR137Q variant in the absence or presence of PCNA with 25 nM (CAG)20 or (CTG)20
substrate with a THF residue in reaction buffer containing 50 mM Tris-HCl, pH 7.5, 50
mM KCl, 0.1 mM EDTA, 0.1 mg/ml bovine serum albumin and 0.01% Nonidet P-40
along with 50 µM dNTPs and 5 mM Mg2+ at 37°C for 15 min. FEN1 cleavage activity on
the substrates was measured in the absence and presence of wild-type pol β or pol
βR137Q variant at 37°C for 15 min in reaction buffer under the conditions described
previously. The 20 µl of reaction mixture was assembled on ice, and reaction was
quenched by addition of 20 µl stopping buffer and incubation at 95°C for 10 min.
Substrates and products were separated by a 15% urea denaturing gel and detected by a
PhosphoImager.

Sizing analysis of BER products by DNA fragment analysis
To isolate a repaired strand specifically, the template strand of all substrates was
tagged by a biotin residue at the 5’-end. BER reactions were terminated with 1 µl of 100
mM EDTA, and reaction mixtures were incubated with 50 µl avidin agarose beads
(Pierce-Thermo Scientific, Rockford, IL) for 2 hrs, allowing the binding of avidin beads
to the biotin on the template strand. Reaction mixtures were then subjected to incubation
with 0.15 M NaOH at room temperature for 15 min with rotation allowing separation of
repaired strands from the template strands. This was followed by 2 min centrifugation at
5000 rpm pelleting the template strands bound by avidin beads. The repaired strands in
the supernatant were precipitated with ethanol and subsequently dissolved in TE buffer
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for PCR amplification and size analysis. Repaired products were amplified through PCR
with the AmpliTaq Gold 360 DNA polymerase Kit (Applied Biosystems, Foster City,
CA) at the conditions: denaturation at 95°C for 30 s, annealing at 50°C for 30 s,
extension at 72°C for 90 s for 35 cycles with a final extension at 72°C for 1 hr. CAG
forward primer and 6-carboxyfluorescein (6-FAM) tagged CAG reverse primer, were
used for PCR amplification of the repaired products from the (CAG)20 substrate with a
THF at 5’-end or in the middle of the repeat tract. CTG-1 forward primer and 6-FAM
tagged reverse primer were used for PCR amplification of the repaired products from the
(CTG)20 substrate with a THF at 5’-end of the repeat tract; while CTG-10 forward primer
and 6-FAM tagged reverse primer were used to amplify the repaired products of (CTG)20
substrate with a THF in the middle of the repeat tract. The sequences of the primers are
indicated in Table1. PCR products along with the size marker MapMarker 1000
(Bioventures, Murfreesboro, TN) were then subject to capillary electrophoresis via an
ABI 3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA) at Florida
International University DNA sequencing core facility. The sizes of PCR products were
determined by DNA fragment analysis with the Peak Scanner version 1.0 software
(Applied Biosystems, Foster City, CA).

RESULTS
Pol βR137Q polymorphic variant exhibits weaker DNA synthesis activity than wildtype pol β in the context of CAG and CTG repeats
Since pol β DNA synthesis plays a crucial role in mediating TNR expansion [1]
and deletion during BER [211] in a damage location dependent manner [210], we initially
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examined the DNA synthesis activity of pol βR137Q with the (CAG)20 or (CTG)20 repeat
substrate containing an abasic site (THF) located at the 5'-end or in the middle of the
repeat tract. We found that with the damage located at the 5’-end of the (CAG)20 repeat
tract, pol βR137Q and wild-type pol β at 1 nM, mainly inserted 1 and 3 nucleotides
(Figure 1.1A, compare lane 5 with 3). However, 5 nM pol βR137Q variant inserted up to
4 repeats (Figure 1.1A, lane 6), whereas the same concentration of wild-type pol β
inserted up to 6 repeats (Figure 1.1A, lane 4). With the damage located in the middle of
the repeat tract, pol βR137Q inserted up to 3 nucleotides and wild-type pol β inserted up
to 5 nucleotides (Figure 1.1B, compare lane 11 with lane 9). However, 5 nM pol βR137Q
variant inserted up to 4 repeats, whereas the same concentration of wild-type pol β
inserted up to 5 repeats (Figure 1.1B, compare lane 12 with lane 10). Similarly, for the
(CTG)20 substrate with the damage at the 5'-end, 1 nM pol βR137Q mainly inserted 1
nucleotide, while the same concentration of wild-type pol β mainly inserted 3 nucleotide
on the substrate (Figure 1.1C, compare lane 6 and lane 3). 2.5 nM and 5 nM pol βR137Q
inserted up to 2 and 3 repeats with the same substrate while wild-type pol β inserted up to
3 or 5 repeats (Figure 1.1C, compare lanes 7 and 8 with lanes 4 and 5). With the damage
located in the middle of the (CTG)20 substrate, 1 nM and 2.5 nM pol βR137Q variant
inserted 2 nucleotides and 1 repeat, respectively (Figure 1.1D, lanes 14-15), whereas the
wild-type pol β at the same concentrations inserted 1 nucleotide and up to 2 repeats,
respectively (Figure 1.1D, lanes 11-12). At the concentration of 5 nM, pol βR137Q
variant inserted up to 3 repeats, while wild-type pol β inserted up to 5 repeats (Figure
1.1D, compare lane 16 with lane 13). The results indicated that pol βR137Q exhibited
weaker DNA synthesis activity than wild-type pol β in the context of TNRs.
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Figure 1.1 Pol βR137Q variant exhibits weak DNA synthesis activity during
BER of a base lesion in context with (CAG)20 and (CTG)20 repeats [13].
DNA synthesis activity of wild-type pol β (pol β WT) or pol βR137Q variant at
various concentrations, was measured with 25 nM substrates containing (CAG)20
and (CTG)20 with a THF residue. DNA synthesis activity of pol β on the (CAG)20
and (CTG)20 repeat substrates was measured at the concentrations of 1 nM, 2.5 nM
and 5nM. Substrates were 32P-labeled at the 5’-end of the damaged strand. (A) and
(B) Measurement of DNA synthesis activity with (CAG)20 substrate containing a
THF at the first and tenth repeat, respectively. Lanes 1 and 11 represent substrate
only. Lane 2 and 12 represent APE1 cleavage products. Lanes 3-4 and 13-14
represent pol β WT synthesized products. Lanes 5-6 and 15-16 represent pol β
R137Q variant synthesized products. (C) and (D) Measurement of DNA synthesis
activity assay in the context with (CTG)20 substrate with a THF at the first and tenth
repeat, respectively. Lanes 1 and 15 represent substrate only. Lane 2 and 16
represent the reaction with APE1 along. Lanes 3-5 and 17-19 illustrate the reactions
with pol β WT. Lanes 6-8 and 20-22 represent reactions with pol βR137Q. The red
circles superimposed in the gels indicate the locations of the synthesized products of
pol β WT or pol βR137Q.

To compare the gap-filling synthesisactivity of pol βR137Q variant and wild-type
pol β at low concentrations, the gap-filling synthesis of pol βR137Q variant and wildtype pol β at the concentrations of 0.1 nM, 0.2 nM and 0.5 nM was measured with the
substrates containing the (CAG)20 and (CTG)20 with a THF at the 5’-end or in the middle
of the repeat tract. For the (CAG)20 and (CTG)20 substrates with a THF at the 5’-end, both
wild-type pol β and pol βR137Q incorporated 1 nucleotide at the concentrations of 0.1
nM and 0.2 nM (Figures 1.2A and 1.2C, lanes 3-4 and 6-7). Moreover, wild-type pol β
and pol βR137Q variant at 0.5 nM incorporated up to 3 nucleotides (Figures 1.2A and
1.2C, lanes 5 and 8). Similarly, for the (CAG)20 and (CTG)20 substrates with a THF in the
middle, wild-type pol β and pol βR137Q variant at the concentrations of 0.1 nM, 0.2 nM
and 0.5 nM mainly inserted one nucleotide (Figures 1.2B and 1.2D, lanes 11-16). The
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results indicated that pol βR137Q variant exhibited similar gap-filling synthesis activity
as wild-type pol β at low concentrations. We also examined the gap-filling synthesis
activity of wild-type pol β and pol βR137Q variant at low concentrations of 0.1 nM, 0.2
nM and 0.5 nM on the 1 nt-gap substrates with (CAG)20 repeats or a random DNA
sequence. For the 1-nt gap substrate with (CAG)20 repeats, both wild-type pol β and pol
βR137Q variant mainly inserted one nucleotide to fill in the gap at all tested
concentrations (Figure 1.2E, lanes 2-7). For the substrate containing a random DNA
sequence, both wild-type pol β and pol βR137Q inserted one nucleotide to fill in the gap
at concentrations of 0.1 nM and 0.2 nM (Figure 1.2F, lanes 9-10 and 12-13).
Furthermore, both wild-type pol β and pol βR137Q at 0.5 nM inserted additional 2
nucleotides to displace the downstream flap (Figure 1.2F, lanes 11 and 14). The results
indicated that pol βR137Q variant at low concentrations exhibited slightly weaker onenucleotide gap-filling synthesis compared to that of wild-type pol β on the 1-nt gap
substrate with (CAG)20 repeats (Figure 1.2E) and similar gap filling synthesis and strand
displacement synthesis activity with the wild-type polymerase on the 1-nt gap substrates
with a random DNA sequence (Figure 1.2F).
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Figure 1.2. Pol β R137Q variant exhibits similar gap-filling synthesis activity
compared to that of wild-type pol β [13].
Pol β gap-filling synthesis was conducted by incubating 0.1 nM, 0.2 nM and 0.5 nM
of wild-type pol β or R137Q variant with 25nM 32P-labeled substrates (5’-end
labeled). The experimental conditions are described in the Materials and Methods.
(A) and (B) The gap-filling synthesis of pol β WT or pol βR137Q variant on the
(CAG)20 substrates that contains a THF at the 5’-end or in the middle of the repeat
tract. (C) and (D) The gap-filling synthesis of pol β WT or pol βR137Q variant on
the (CTG)20 substrates that contains a THF at the 5’-end or in the middle of the
repeat tract. Lanes 1 and 9 represent substrate only. Lanes 2 and 10 represent APE1
cleavage products. Lanes 3-5 and 11-13 represent pol β WT synthesized products.
Lanes 6-8 and 14-16 represent pol β R137Q variant synthesized products. (E) The
gap-filling synthesis of pol β WT or pol βR137Q variant on 1-nt gap substrate
containing (CAG)20. (F) The gap-filling synthesis of pol β WT or pol βR137Q
variant on the 1-nt gap substrate containing a random sequence. Lanes 1 and 8
represent substrate only. Lanes 2-4 and 9-11 represent pol β WT synthesized
products. Lanes 5-7 and 12-14 represent pol β R137Q variant synthesized products.
The red circles superimposed in the gels indicate the synthesized products of pol β
WT or pol βR137Q.
PCNA does not affect DNA synthesis activity of pol βR137Q variant
As a BER cofactor, PCNA can stimulate the activities of both FEN1 and LIG I
during long patch BER [234, 235]. However, it remains unknown whether PCNA may
affect pol β DNA synthesis activity although it has been found that PCNA can physically
interact with pol β [236]. Since pol βR137Q variant has weak interaction with PCNA
[61], it is possible that this can affect pol βR137Q DNA synthesis activity, promoting
TNR instability. To test this, high concentrations of PCNA (50 nM and 100 nM) were
employed to determine if PCNA could stimulate pol β DNA synthesis activity in the
context of TNRs at a low concentration (0.2 nM) of wild-type pol β or pol βR137Q
variant. We found that in the absence of PCNA or presence of 50 nM and 100 nM PCNA,
at 0.2 nM, both pol βR137Q and wild-type pol β generated a similar amount of one
nucleotide insertion product during BER of an abasic lesion (THF) located at either the
5’-end (Figure 1.3A, compare lanes 4-5 with lane 3 and lanes 7-8 with lane 6) or in the
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middle of the (CAG)20 repeat substrates (Figure 1.3B, compare lanes12-13 with lane 11
and lanes 15-16 with lane 14). The results showed that at the high concentration of
PCNA, no stimulatory effect was detected for the gap-filling synthesis activity of wildtype pol β and pol βR137Q variant (Figure 1.3), indicating that PCNA did not affect the
processivity of pol β WT and pol βR137Q variant either. This further demonstrates that
the impaired interaction between PCNA and pol βR137Q variant did not affect the
polymerase gap-filling synthesis activity of the pol β variant.
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Figure 1.3. PCNA does not affect DNA synthesis activity of pol β WT and pol
βR137Q during BER of a base lesion on (CAG)20 repeats [13].
The effects of PCNA on pol β was examined by determining pol β DNA synthesis in
the presence of 0.2 nM of pol β WT or pol βR137Q along with 50 nM and 100 nM
PCNA. 25 nM substrates were 32P-labeled at the 5’-end of the damaged strand of
the substrates. (A) and (B) Pol β DNA synthesis in the presence of PCNA with the
(CAG)20 substrate containing a THF located at the first repeat and tenth repeat,
respectively. Lanes 1 and 9 represent substrate only. Lanes 2 and 10 represent
reaction with APE1. Lanes 3 and 11 illustrate reactions with pol β WT. Lanes 6 and
14 represent reactions with pol βR137Q. Lanes 4-5 and 12-13 represent reactions
with pol β WT in the presence of increasing concentrations of PCNA. Lanes 7-8 and
15-16 represent reaction mixtures with pol βR137Q in the presence of increasing
concentrations of PCNA.

The weak DNA synthesis of pol βR137Q variant leads to weak FEN1 cleavage
during BER in a TNR tract
Since pol β DNA synthesis in the context of TNR tracts facilitates FEN1 cleavage
by creating a TNR flap during BER [207, 210, 211], we then examined the effect of pol
βR137Q on FEN1 cleavage activity by measuring FEN1 activity in the presence of 1 nM
or 5 nM polβR137Q variant during repair of an abasic site located at the 5’-end and in the
middle of the (CAG)20 repeat substrates (Figure 1.4). We found that in the absence of pol
βR137Q variant or wild-type pol β, FEN1 cleaved up to 3 nucleotides at 5 nM and up to 5
nucleotides at 10 nM on the substrate with the lesion at the 5’-end (Figure 1.4A, lanes 34). However, FEN1 still removed up to 3 nucleotides at 5 nM and up to 5 nucleotides at
10 nM in the presence of 1 nM pol βR137Q variant or wild-type pol β (Figure 1.4A,
compare lanes 5-8 with lanes 3-4). In the presence of 5 nM pol βR137Q, the same
concentrations of FEN1 (5 nM and 10 nM) removed up to 2 and 3 CAG repeats from the
CAG repeat substrate (Figure 1.4A, lanes 11-12), whereas in the presence of 5 nM wild-
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type pol β, FEN1 at 5 nM and 10 nM of removed up to 3 and 4 repeats, respectively
(Figure 1.4A, lanes 9-10). Similarly, FEN1 cleavage activity on the substrate with the
lesion in the middle of the repeat tract, was not altered significantly in the presence of 1
nM pol βR137Q and wild-type pol β by comparing to in the absence of pol βR137Q and
wild-type pol β, FEN 1 cleaved up to 3 and 5 nucleotides at 5 nM and 10 nM in the
absence of pol β, respectively (Figure 1.4B, lanes 14-15); with additional 1 nucleotide
cleaved by FEN1 in the presence of 1 nM pol βR137Q variant and wild-type pol β at the
concentration of 10 nM of FEN1 (Figure 1.4B, compare lane 18 and lane 20 with lane
16). However, in the presence of 5 nM pol βR137Q, FEN1 (5 nM and 10 nM) mainly
cleaved 2 and 3 CAG repeats, respectively, compared to 3 and 4 CAG repeats,
respectively, removed by FEN1 (5 nM and 10 nM) in the presence of 5 nM wild-type pol
β (Figure 1.4B, compare lanes 23-24 with lanes 21-22). The results indicate that the weak
DNA synthesis of pol βR137Q resulted in weaker FEN1 cleavage of TNRs than that from
wild-type pol β by creating a shorter repeat flap.
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Figure 1.4. Pol βR137Q leads to weak FEN1 cleavage during BER in the
contextof (CAG)20 repeats [13].
FEN1 flap cleavage activity at 5 nM and 10 nM on the (CAG)20 substrate with a THF
located at the first repeat (A) or tenth repeat (B) was measured in the presence of 1
nM and 5 nM pol β. Lanes 1 and 13 represent the substrate only. Lanes 2 and 14
represent reactions with APE1 alone. Lanes 3-4 and lanes 15-16 represent reactions
with FEN1 alone. Lanes 5-6 and 17-18 represent reactions with FEN1 in the presence
of 1 nM pol β WT. Lanes 7-8 and 19-20 illustrate reactions with FEN1 in the
presence of 1 nM pol βR137Q. Lanes 9-10 and 21-22 represent reactions with FEN1
in the presence of 5 nM pol β WT. Lanes 11-12 and 23-24 illustrate reactions with
FEN1 in the presence of 5 nM of pol βR137Q variant. Substrates were 32P-labeled at
the 3’-end of the damaged strand. The red circles superimposed in the gels indicate
the locations of FEN1 cleavage products.

Pol βR137Q variant leads to small TNR deletions during BER of an abasic site in a
TNR tract.
To further determine whether the weak DNA synthesis of pol βR137Q variant
may affect trinucleotide repeat instability, we reconstituted BER of an abasic lesion in the
context of a TNR tract with the pol β variant and the (CAG)20 or (CTG)20 substrates
containing the lesion at the 5'-end or in the middle of the repeat tract and measured the
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length change of the repeats (Figure 1.5). We found that 1 nM and 5 nM wild-type pol β
and pol βR137Q led to repaired products during BER of an abasic lesion in the context of
a (CAG)20 (Figure 1.5A, lanes 3-4 and lanes 9-10 for wild-type pol β; Figure 1.5A lanes
5-6 and lanes 11-12 for pol βR137Q) or (CTG)20 repeat tract (Figure 1.5B, lanes3, 5,11
and 13 for wild-type pol β; Figure 1.5B lanes 6, 8, 14 and 16 for pol βR137Q). Further
analysis on the repeat size of the repaired products showed that BER reconstituted with 1
nM pol βR137Q or wild-type pol β resulted in a product with one repeat deletion with the
CAG and CTG substrates containing the base lesion at the 5’-end (Figure 1.5C and 1.5D,
left panel, panel b and c), whereas 5 nM pol βR137Q or wild-type pol β led to full length
repaired products (Figure 1.5C and 1.5D, left panel, panel d and e). BER reconstituted
with 1 nM pol βR137Q or wild-type pol β and the substrates with the lesion in the
middle, resulted in the repaired products with one or two repeat deletion (Figure 1.5C and
1.5D, right panel, panel b and c). 5 nM pol βR137Q and wild-type enzyme decreased the
amount of the deletion product (Figure 1.5C and 1.5D, right panel, panel d and e). The
results indicate that pol βR137Q exhibited the same ability as wild-type pol β enzyme to
modulate TNR instability by causing one or two repeat deletions.
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Figure 1.5. Effects of pol βR137Q on the instability of (CAG)20 and (CTG)20
repeats [13].
BER was reconstituted with 10 nM of APE1, 10 nM FEN1, 5 nM LIG I and
increasing concentrations of pol β WT or pol βR137Q (1 nM and 5 nM on (CAG)20
substrate and 1 nM, 2.5 nM and 5 nM on (CTG)20 substrate) along with 25 nM
substrates. (A) BER reconstituted with the (CAG)20 substrate with a THF located at
the first repeat (left panel) or the tenth repeat (right panel). Lane 1 and lane 7
represent substrates only. Lane 2 and 8 represent reactions with APE1 only. Lanes 34 and 9-10 represent reactions with pol β WT. Lanes 5-6 and 11-12 represent
reactions in the presence of pol βR137Q. (B) BER reconstituted with the (CTG)20
substrate with a THF located at the first repeat (left panel) and the tenth repeat (right
panel). Lane 1 and lane 9 represent substrates only. Lane 2 and 10 represent reactions
with APE1 only. Lanes 3-5 and 11-13 present reactions with pol β WT. Lanes 6-8 and
14-16 illustrate reactions with pol βR137Q. Repaired products were subjected to
PCR and capillary electrophoresis and analyzed by DNA fragment analysis to
determine the length. (C) DNA fragment analysis of the repaired products of from
the substrate with a lesion located at the first (left panel) and the tenth of the (CAG)20
substrate. (D) DNA fragment analysis of the repaired products of from the substrate
with a lesion located at the first (left panel) and the tenth of the (CTG)20 substrate.
Panel a represent a (CAG)20 or (CTG)20 marker without damage. Panel b and c
indicate the sizes of the repaired products in the presence of 1 nM pol β WT or 1 nM
R137Q, respectively. Panel d and e represent the sizes of the repaired products in the
presence of 5 nM pol β WT or 5 nM pol βR137Q, respectively.

Pol βR137Q variant skips over a small loop on the template strand of a TNR repeat
tract
Our previous studies have shown that secondary structures such as hairpins and
loops can form readily during BER in a TNR tract [1, 7, 210, 211], and pol β can readily
skip over the structures on the template strand [211]. The “skip over” refers to a scenario
where the polymerase encountered the secondary structures such as a hairpin or loop
structure formed on the template strand, it performed DNA synthesis to bypass the
secondary structures other than copying through the inside of the secondary structures.
We have further demonstrated that pol β DNA synthesis modulates TNR expansion and
deletion by altering the balance between the synthesis of TNRs and removal of the
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repeats by FEN1 flap cleavage [210, 211]. Since the weak DNA synthesis activity of pol
βR137Q resulted in weak FEN1 cleavage activity, it is possible that the pol β
polymorphic variant can alter TNR instability. To test this possibility, a single-stranded
DNA specific endonuclease Aspergillus S1 nuclease [237] was used to probe the
secondary structures that formed on the template strand of the (CAG)20 repeat substrate in
the absence or presence of DNA synthesis of pol β at the time intervals of 1 min-15 min.
We found that in the absence of pol β, S1 cleavage on the template strand of the (CAG)20
substrate with a THF located at the 5’-end, resulted in the products of 18 nt, 19 nt, 20nt,
21 nt, 22 nt and 23 nt (Figure 1.6A, left panel, lanes 3-7). This indicated the formation of
a small loop containing one CTG repeat adjacent to the 3’-end of the flanking region of
the repeat tract (Figure 1.6A, the scheme below the gel). In the presence of DNA
synthesis of wild-type pol β and pol βR137Q variant, S1 nuclease cleavage led to the
products of 21 nt, 23 nt, 24 nt, 26 nt and 27 nt indicating the formation of a loop
containing two CTG repeats (Figure 1.6A, the panels in the middle and on the right, lanes
3-7). The results indicated that in both the absence and presence of DNA synthesis of
both pol βR137Q variant and wild-type pol β, a small (CTG)2 loop formed on the
template strand. This further indicated that the DNA synthesis of pol βR137Q variant and
wild-type pol β only altered the position of the loop by shifting the loop toward the 5’end of the template. We also observed that in the presence of DNA synthesis of wild-type
pol β and pol βR137Q variant, the S1 nuclease cleavage products were much weaker than
those generated in the absence of pol β DNA synthesis. This was because pol β DNA
synthesis copied through the template strand, which converted the S1 nuclease-sensitive
ssDNA loop region on the template strand to a S1 nuclease-resistance dsDNA region.
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Furthermore, the pol β DNA synthesis displaced the downstream damaged strand,
exposing the annealed template strand as a ssDNA region. This then allowed the ssDNA
region on the template strand approximately 1 repeat to shift towards the 5’-end. This is
consistent with the 1 repeat insertion observed in DNA synthesis (Figure 1.1A). Further
analysis of S1 nuclease cleavage on the downstream strand of the damaged strand of the
substrate showed that S1 nuclease resulted in the products of 64 nt, 67 nt, 70 nt, 73 nt and
76 nt in the absence and presence of both pol βR137Q and wild-type pol β indicating that
the downstream strand formed a single-stranded (CAG)5 flap (Figure 1.6B, lanes 3-7, and
schemes below the gels), and DNA synthesis pol βR137Q variant and wild-type pol β did
not alter the formation of the downstream flap.
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Figure 1.6. S1 nuclease probing of loops formed in (CAG)20 repeats with a THF
located at the first CAG of the (CAG)20 repeat substrate in the absence and
presence of pol β WT or pol βR137Q DNA synthesis [13].
The S1 nuclease probing of a loop located at the template strand (A) and the
downstream damage strand of the (CAG)20 substrate. (B) Both the template strand
and damage strand were labeled at the 3’-end. Substrates were incubated with 2 U or
25 U S1 nuclease. Panels on the left, in the middle and on the right, correspond to S1
nuclease cleavage results in the presence of APE1 alone, pol β WT and pol βR137Q,
respectively. Lane 1 represents the substrate only. Lane 2 represents the reaction with
APE1 alone. Lanes 3-7 represent reaction mixtures with S1 nuclease in the absence
or the presence of pol β DNA synthesis at different time intervals. Lane 8 represents
a synthesized marker with different sizes of DNA fragments. The schemes below the
gels illustrate S1 nuclease cleavage patterns in the absence and presence of pol β WT
and pol βR137Q. The red circles superimposed in the gels indicate the locations of
the S1 nuclease digestion products.
For the (CAG)20 substrate with a THF in the middle of the repeat tract, S1
cleavage on the template resulted in the products of 45 nt, 48 nt and 49 nt at the time
interval of 1-15 min in the absence of pol β (Figure 1.7A, left panel, lanes 3-7) indicating
the formation of a (CTG)2 loop (Figure 1.7A, left panel, the scheme below the gel). In the
presence of DNA synthesis of wild-type pol β or pol βR137Q variant, S1 nuclease
cleavage on the template strand resulted in the products of 48 nt, 49 nt, 50 nt and 51 nt.
This also indicated the formation of a (CTG)2 loop that was shifted toward the 5'-end of
the template strand (Figure 1.7A, the panels in the middle and on the right, lanes 3-7).
The size of the loop is consistent with deletion of one or two repeats resulting from BER
reconstituted by wild-type pol β and pol βR137Q with the substrate (Figure 1.5C and
1.5D, the left panel). This further suggested that pol β skipped over the loop structure and
performed DNA synthesis to displace the downstream strand generating a flap. To test
this, we then examined S1 nuclease cleavage on the upstream strand of the damage strand
of the (CAG)20 substrate (Figure 1.7B). We found that in the absence of pol β, S1
nuclease cleavage resulted in the products of 47 nt, 46 nt and 45 nt that are shorter than
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the APE1 cleavage product of 50 nt (Figure 1.7B, left panel, lanes 3-7), indicating the
formation of an upstream flap containing two CAG repeats (Figure 1.7B, the scheme
below the left panel). In the presence of S1 nuclease and DNA synthesis of wild-type pol
β or pol βR137Q, a product of 53 nt, which is longer than the APE1 cleavage product of
50 nt, was detected (Figure 1.7B, the panels in the middle and on the right, lanes 3-7),
indicating that both wild-type pol β and pol βR137Q efficiently pushed the upstream flap
to re-anneal to the template strand and extended the upstream strand (Figure 1.7B, the
schemes below the panels in the middle and on the right). This further indicated that pol β
DNA synthesis displaced the downstream strand and created a flap. This can be
confirmed by the FEN1 cleavage results showing that FEN1 cleaved more nucleotides in
the presence of wild-type pol β or pol βR137Q variant than the ones in the absence of pol
β (Figure 1.4B, compare lanes 18, 20, 22 and 24 to lane 16). The cleavage of the
downstream strand of the substrate in the absence and presence of wild-type pol β or pol
βR137Q variant resulted in the product of 39 nt, 42 nt, 45 nt and 48 nt (Figure 1.7C, left,
middle and right panels, lanes 3-7). However, S1 nuclease cleaved more on the substrate
in the absence of pol β and fewer on the substrate in the presence of pol β (Figure 1.7C,
compare lanes 3-7 from the panels in the middle and on the right with lanes 3-7 in the
panel on the left). This suggests that pol β bound to the strand break intermediate
generated by APE1 5'-incision of the THF, which protected the 5’-flap downstream
ssDNA from S1 nuclease cleavage. The results indicate that the weak DNA synthesis
activity of pol βR137Q still exhibited the similar ability as wild-type pol β in skippingover of a small loop as well as in performing strand-displacement synthesis to create a
downstream flap during BER in the context of CAG repeats.
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Figure 1.7. S1 nuclease probing of loops formed in (CAG)20 repeats with a THF
located at the tenth CAG of the (CAG)20 repeat substrate in the absence and
presence of pol β WT or pol βR137Q DNA synthesis [13].
S1 nuclease probing of a loop on the template strand (A), the upstream damaged
strand (B) and the downstream damaged strand (C) of the (CAG)20 substrate with a
THF at the tenth repeat were conducted. The template strand and downstream strand
of the damaged strand were labeled at the 3’-end, and the upstream damaged strand
was labeled at the 5’-end. Substrates were incubated with 5 U, 3 U and 25 U S1
nuclease in the absence and presence of pol β WT and pol βR137Q. Panels on the
left, in the middle and on the right, correspond to reactions with S1 nuclease and
APE1 alone, in the presence of pol β WT and in the presence of pol βR137Q,
respectively. Lane 1 represents the substrate only. Lane 2 represents the reaction
with APE1 alone. Lanes 3-7 represent reaction mixtures with S1 nuclease and APE1
at different time intervals. Lane 8 represents synthesized markers. The schemes
below the gels illustrate S1 nuclease cleavage pattern on the different strands of the
substrate. The red circles superimposed in the gels indicate the S1 nuclease
digestion products.

In order to exclude the possibility that the digestion bands may be the result of the
“breathing effect”, we performed the control experiments with the nick substrates
digested by S1 nuclease, where the nicks were located after the first CAG or after the
tenth CAG of the (CAG)20 substrates. Under the same experimental condition with Figure
1.6A and Figure 1.7A, no S1 digestion products that indicate the S1 cleavage at the site
opposite the nick on the template strand detected (Figure 1.8A and 1.8B, lanes 2-7). This
indicates that S1 cleavage did not result from the “breathing effect”. This further suggests
that S1 nuclease cleavage products were the result of the skipping over of the template
loop by the polymerases (Figures 1.6A and 1.7A, the panels in the middle and on the
right, lanes 3-7).
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Figure 1.8. S1 nuclease digestion of the (CAG)20 substrates with a nick located
after first CAG or after the tenth CAG [13].
Both substrates were labeled at the 5’-end.of the template strand. (A) S1 nuclease
digestion of the (CAG)20 substrate with a nick located after first CAG. Substrates
were incubated with 2 U S1 nuclease. (B) S1 nuclease digestion of (CAG)20
substrate with a nick located after tenth repeat. Substrates were incubated with 5 U
S1 nuclease. Lane 1 represents the substrate only. Lane 2 represents the reaction
with APE1 alone. Lanes 3-7 represent reaction mixtures with S1 nuclease and APE1
at different time intervals. Lane 8 represents synthesized markers.

DISCUSSION
Recent studies have shown that the polymorphism of several DNA repair proteins
is associated with TNR diseases and the age of disease onset. This includes the
polymorphisms in OGG1 (Rs1052133) (Ser326Cys) [238, 239], MSH3 (Rs26279) [220,
239], XPC [239] and ERCC6 (rs2228528)[224]. This suggests that the polymorphisms of
proteins of BER, mismatch repair (MMR) and nucleotide excision repair (NER)
pathways can modulate TNR instability. In this study, for the first time, we showed that
pol βR137Q exhibited weaker DNA synthesis activity than wild-type pol β in the context
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of TNRs (Figure 1.1). However, the DNA synthesis activity of pol βR137Q was not
affected by PCNA during BER (Figure 1.3) although it is reported that this pol β variant
has lost the interaction with PCNA [61]. The weak DNA synthesis of the pol β
polymorphic variant further led to weak FEN1 cleavage of TNR flaps (Figure 1.4). Yet
we found that pol βR137Q exhibited the similar ability to that of wild-type pol β in
mediating deletion of one or two TNRs during BER (Figure 1.5). We demonstrated that
this was because the polymorphic variant exhibited similar capability to that of wild-type
pol β of skipping over a small template loop structure during BER (Figure 1.6 and Figure
1.7).
A previous study has shown that pol βR137Q exhibits 30% of wild-type
enzymatic activity in the context of random sequence, which in turn reduces BER
capacity and increases cellular sensitivity to alkylating DNA damaging agents as well as
promotes apoptosis [61]. This effect has been further confirmed in a pol βR137Q
transgenic mouse model in vivo in a recent study [62]. The results of the studies suggest
that the pol β polymorphic variant exhibits significantly reduced DNA synthesis activity
in random DNA sequence compared with wild-type pol β, and this may result in genome
instability. However, our results showed that pol βR137Q polymorphic variant exhibited
similar one-nucleotide gap-filling synthesis and strand displacement synthesis (Figure
1.2) and slightly weaker DNA synthesis compared with the wild-type enzyme in the
context of TNRs. Thus, pol βR137Q variant exhibited similar ability in skipping over a
template loop (Figure 1.7) with the wild-type enzyme, thereby resulting in the same size
of small repeat deletions as wild-type pol β. Since the dynamic TNR tracts readily form
secondary structures such as hairpins and loops on the damaged and template strand,
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which would not form on random DNA sequence during BER [145, 207, 210, 211], Our
results further indicate that secondary structures formed on the damaged and template
strands of a TNR tract facilitated pol βR137Q to skip over a secondary structure on the
template strand to readily perform DNA strand-displacement synthesis, thereby leading to
the same effect on TNR instability as the wild-type enzyme.
A previous study has shown that pol βR137Q variant exhibits the impaired
interaction with PCNA [61]. Our results showed that PCNA did not affect gap-filling
synthesis activity of both wild-type pol β and pol βR137Q variant in the context of a TNR
tract (Figure 1.3). This indicates that the impaired interaction between pol βR137Q
variant and PCNA did not affect pol β activity and its resulted TNR instability during
BER. However, our results cannot rule out a possibility that PCNA with post-translational
modifications may alter the activity of wild-type pol β and pol βR137Q variant to
modulate TNR instability during BER. Moreover, it is possible that the interaction
between PCNA and other DNA polymerases can still modulate TNR instability by
stimulating the activities of the DNA polymerases via cooperation with pol β DNA
synthesis during BER. Previous studies have shown that ubiquitinated PCNA functions as
a platform for polymerase switching between replicative DNA polymerases such as pol δ
and translesion DNA polymerases such as pol η when encountered a DNA base lesion
[240, 241]. Thus, it is conceivable that polymerase switching between replication DNA
polymerases and translesion DNA polymerases that is mediated by ubiquitinated PCNA
may occur when a hairpin or loop structure formed in the template strand during DNA
replication and repair in the context of TNRs. It is also possible that PCNA-mediated
polymerase switching between pol β and translesion DNA polymerases may occur during
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BER in a TNR tract in the postmitotic cells. It is of interest to further elucidate the roles
of the interaction between ubiquitinated PCNA and pol β and its polymorphic variants as
well as translesion polymerases in modulating TNR instability during BER.
In summary, in this study, we provided the first evidence that pol βR137Q
polymorphic variant exhibited weaker DNA synthesis than wild-type pol β in the context
of a TNR tract. We showed that the pol β polymorphic variant led to a weak FEN1
cleavage of TNR flaps compared with wild-type pol β during BER, and PCNA did not
affect pol β DNA synthesis. Pol βR137Q polymorphic variant exhibited the same ability
to skip over a template loop structure, thereby leading to the same TNR deletion as wildtype pol βduring BER. Since pol βR137Q variant exhibited the similar activity to that of
wild-type pol β in the context of TNRs, our results suggest that human carriers of the pol
β polymorphic variant may not exhibit a higher risk than the individuals bearing wildtype pol β in developing TNR expansion diseases.
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CHAPTER 2: WEAK DNA SYNTHESIS BY DNA REPAIR POLYMERASES
PROMOTES

TRINUCLEOTIDE

REPEAT

DELETIONS

DURING

BASE

EXCISION REPAIR
ABSTRACT
Trinucleotide repeat (TNR) expansion is associated with more than 40
neurodegenerative diseases including Huntington’s disease, for which no effective
treatment is available. New treatments need to be developed to attenuate the progression
of TNR expansion diseases. Previous studies have shown that DNA polymerase β and
base excision repair (BER) pathway play a critical role in modulating somatic TNR
instability, suggesting that BER may be developed as a new therapeutic target for TNR
expansion diseases. A recent study has shown that a pol β variant, pol βY265C, with
impaired DNA synthesis activity can suppress CGG repeats expansion in the fragile X
syndrome mice, suggesting that weak DNA synthesis of pol β promotes TNR deletions
through BER. However, it remains enigmatic if the DNA synthesis activity of repair DNA
polymerases could be utilized as a potential therapeutic target that shortens expanded
TNRs. In the present study, we show that the both pol βY265C and a translesion DNA
polymerase (pol ν) with weak DNA synthesis predominantly promoted TNR deletions
through BER. The inefficient DNA synthesis of pol βY265C and pol ν leads to efficient
removal of TNRs by FEN1, resulting in TNR deletion. We further demonstrate that TNR
deletions can be induced by intentionally inhibiting DNA synthesis activity of wild-type
pol β with a pol β inhibitor during BER. Our results indicate that weak DNA synthesis
activity of repair DNA polymerases may be developed as a potential therapeutic target for
TNR expansion-mediated neurodegenerative disorders.
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INTRODUCTION
Huntington’s disease (HD), one of the most devastating fatal inherited
neurological disorders [242, 243], occurs in human population at a prevalence of 1 in
10,000 [242, 243]. It manifests as gradually losing control of movement and cognition
resulted from progressively neuronal breakdowns [244-246]. The average age of the
onset is 30-50 years old, yet the symptoms can also occur in patients with age below 20
years old [244-246]. The disease patients have a mean life expectancy of 20 years, and no
effective treatment has been developed to cure the disease except for the symptomatic
management of the disease for improvement of the quality life of the patients [244-246].
The neuronal death and the limited methods in managing the disease symptoms lead to
high mortalities [244-246]. Therefore, it is urgent to develop new treatment that can
attenuate and cure the disease.
Huntington’s disease is caused by the expansion of CAG repeats (more than 36
CAG repeats) in Huntingtin gene that is located in the Chromosome 4p16.3 [243]. The
expanded CAG repeats encode a long stretches of glutamines in the Huntingtin protein,
which can aggregate as amyloid-like fibril abundant in β-sheet in the neuron cells,
leading to neuronal toxicity, protein degradation, and neuronal cell death [247, 248]. In
addition to HD, other TNR expansion neurological disorders, such as Friedreich’s ataxia
(GAA/TTC), myotonic dystrophy (CTG/GAC), fragile X syndrome (CGG/GCC), etc.,
are all caused by TNR expansions [88, 89, 92]. Trinucleotide repeat expansions can be
induced by the formation of secondary structures including hairpins, loops, and G4
structures during DNA replication, repair, recombination, and gene transcription [7, 14,
92, 199-202]. However, the fact that substantial TNR expansions occur in somatic cells
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indicates that DNA repair is actively involved in TNR expansions in somatic cells [92].
Among the different DNA repair pathways, the base excision repair (BER) pathway has
been shown to play a critical role in regulating TNR expansions and deletions in somatic
cells since TNR tracts contain a long stretch of guanines that form hotspots to oxidative
DNA damage. Base excision repair mediates TNR expansions is further supported by the
findings showing that oxidative stress and increasing amounts of 8-oxoguanine (8-oxoG)
are associated with TNR expansions in the neuronal cells of Huntington’s transgenic mice
[14, 123, 131], and core BER enzymes, OGG1, APE1, pol β, and FEN1 play critical roles
in mediating TNR expansions [14].
During BER in context of TNRs, pol β performs multiple nucleotides gap-filling
synthesis, whereas FEN1 removes a short flap, which allows addition of more repeats
than those removed by FEN1, causing ligation of a hairpin on the damaged strand and
TNR expansions [1, 5, 14]. Furthermore, analysis on the correlations between the levels
of BER enzymes and TNR expansions in neuron cells isolated from both striatum and
cerebellum of HD mice showed that TNR expansions preferentially occur in striatum,
where the neuronal death occurs, and a high ratio of pol β to FEN1 was identified in
striatum compared to the ratio in cerebellum [122, 249]. The studies suggest that pol β
plays a critical role in BER-mediated TNR expansions. The repeat expansion may be
further mediated by the crosstalk between pol β and the mismatch repair protein complex,
MSH2-MSH3, which stimulates pol β DNA synthesis and inhibits FEN1 cleavage of
TNRs [2]. Thus, pol β and its DNA synthesis activity play a central role in mediating
TNR expansions during BER.
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On the other hand, pol β is also actively involved in BER-mediated TNR deletions
during the repair of DNA base lesions induced by environmental oxidative DNA damage
agents, bromate and chromate, and alkylating DNA agent, temozolomide [5, 141]. During
BER, pol β can promote TNR deletions by directly bypassing TNR hairpins or loops on
the template strand, resulting in fewer TNRs synthesized by pol β than removed by FEN1
[5, 142, 143]. Also, weak DNA synthesis by pol β can prevents repeat expansion, which
is supported by the fact that a pol β mutant, pol βY265C variant, with impaired DNA
synthesis activity has been reported to reduce the repeat expansion frequency in both
sperm and brain cells from heterozygous pol βY265C fragile X-syndrome mice [146,
151]. This further suggests that TNR deletions can be induced by weakening or inhibiting
DNA synthesis activity of pol β. However, the mechanisms of how the reduced DNA
synthesis activity of pol β promotes TNR deletions remains to be elucidated, and whether
a weak DNA synthesis activity of pol β can be employed as a potential therapeutic target
for TNR expansion diseases needs to be explored. In the current study, we demonstrate
that DNA synthesis activity plays a vital role in regulating TNR instability during BER.
We find that the weak DNA synthesis of pol βY265C and a translesion polymerase (pol
ν) promote TNR deletions. We also discover that the sequence of TNR modulates the
DNA synthesis activities of pol θ, thereby leading to a different outcome of TNR
instability. We further demonstrate that by internationally inhibiting DNA synthesis
activity of wild-type pol β with a pol β inhibitor, NSC666719, TNR deletions are
preferentially induced. We show that the weak DNA synthesis activity of pol β does not
significantly affect the instability of GT dinucleotides and telomere repeats that are
associated with cancers and aging-related diseases, suggesting that inhibition of repair
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DNA polymerase activity does not confer a significant adverse effect on normal cellular
function. Thus, here we provide the first evidence that DNA synthesis activity of
polymerases may be utilized as a potential therapeutic target for TNR expansion
neurodegenerative diseases through shortening of expanded TNRs.

MATERIALS AND METHODS
Materials and oligonucleotide substrates
DNA oligonucleotide substrates were synthesized by Integrated DNA
Technologies (Coralville, IA, USA). Terminal deoxynucleotidyl transferase, T4
polynucleotide kinase, and deoxynucleoside 5’-triphosphates (dNTPs) were purchased
from Thermo Fisher Scientific (Waltham, MA). The radionucleotides γ-32P ATP (6000
mCi/mmol) and Cordycepin 5’-triphosphate 3’-α-32P (5000 mCi/mmol) were purchased
from PerkinElmer (Boston, MA). Micro Bio-Spin 6 Columns were purchased from BioRad Laboratories (Hercules, CA). Pierce Avidin Agarose resin was purchased from
Thermo Fisher Scientific (Waltham, MA). All other standard chemical reagents were
from Sigma-Aldrich (St. Louis, MO) and Thermo Fisher Scientific (Waltham, MA).
Purified enzymes including wild-type (WT) pol β, APE1, FEN1, and LIG I were made
according to the procedures of protein purification described previously [51, 145]. Pol
βY265C mutant protein was provided by Dr. Joann Sweasy from Yale University.
Translesion polymerases (pol ν and pol θ) were provided by Dr. Yang Wei from National
Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Heath. The
pol β inhibitor NSC666719 was provided by Dr. Satya Narayan from University of
Florida.

80

Oligonucleotide substrates
The 100 nt oligonucleotide substrates contain (CAG)20, (CTG)20, (GAA)20, and (CGG)20
repeats with a tetrahydrofuran (THF), an analog of a modified abasic site. The THF
residue substituted the first G either at the first, fifth, tenth, or fifteenth repeat unit of the
(CAG)20, (CTG)20, (GAA)20, (CGG)20, (GT)30, and (TTAGGG)10 containing substrates,
which mimics the scenario that the damage occurs either at the 5’- end or in the middle of
the repeat tracts. Substrates were constructed by annealing the damaged strand with the
template strand at a molecular ratio of 1:2. A strand of DNA fragment containing
(CAG)20, (CTG)20, (GAA)20, (CGG)20, (GT)30, and (TTAGGG)10 without damage was
used as the size marker. The sequences of substrates are listed in Table 2.
Table 2. Oligonucleotide Sequences
Oligonucleotide
nt
(CAG)20 substrate
CAG-0 (Undamaged strand)
100

CAG-1 (THF 1st repeat)

99

CAG-10 (THF 10th repeat)

99

CAG-T (Template strand)

100

Sequence (5’-3’)
CGA GTC ATC TAG CAT CCG TA CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG TA CGT
AGA CTT ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA
CATHF CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG TA CGT
AGA CTT ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CATHF CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG TA CGT AGA
CTT ACT CAT TGC
GCA ATG AGT AAG TCT ACG TA CTG
CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG TA CGG ATG
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CTA GAT GAC TCG
(CTG)20 substrate
CTG-0 (Undamaged strand)

100

CTG-1 (THF 1st repeat)

99

CTG-10 (THF 10th repeat)

99

CTG-T (Template strand)

100

CGA GTC ATC TAG CAT CCG TA CTG
CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG TA CGT AGA
CTT ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA
CTTHF CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG TA CGT
AGA CTT ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA CTG
CTG CTG CTG CTG CTG CTG CTG
CTG CTTHF CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG TA CGT AGA
CTT ACT CAT TGC
GCA ATG AGT AAG TCT ACG TAC AG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG TA CGG ATG
CTA GAT GAC TCG

(CGG)20 substrate
CGG-0 (Undamaged strand)

100

CGG-10 (THF 10th repeat)

99

CGG-T (Template strand)

100

CGA GTC ATC TAG CAT CCG TA CGG
CGG CGG CGG CGG CGG CGG CGG
CGG CGG CGG CGG CGG CGG CGG
CGG CGG CGG CGG CGG TA CGT AGA
CTT ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA CGG
CGG CGG CGG CGG CGG CGG CGG
CGG CGTHF CGG CGG CGG CGG CGG
CGG CGG CGG CGG CGG TA CGT AGA
CTT ACT CAT TGC
GCA ATG AGT AAG TCT ACG TA CCG
CCG CCG CCG CCG CCG CCG CCG
CCG CCG CCG CCG CCG CCG CCG
CCG CCG CCG CCG CCG TA CGG ATG
CTA GAT GAC TCG

(GAA)20 substrate
GAA-0 (Undamaged strand)

100

CGA GTC ATC TAG CAT CCG TA GAA
GAA GAA GAA GAA GAA GAA GAA
GAA GAA GAA GAA GAA GAA GAA
GAA GAA GAA GAA GAA TA CGT AGA
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th

GAA-10 (THF 10 repeat)

99

GAA-T (Template strand)

100

CTT ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA GAA
GAA GAA GAA GAA GAA GAA GAA
GAA THFAA GAA GAA GAA GAA GAA
GAA GAA GAA GAA GAA TA CGT AGA
CTT ACT CAT TGC
GCA ATG AGT AAG TCT ACG TA TTC
TTC TTC TTC TTC TTC TTC TTC TTC
TTC TTC TTC TTC TTC TTC TTC TTC
TTC TTC TTC TA CGG ATG CTA GAT
GAC TCG

(GT)30 substrate
GT-0 (Undamaged strand)

100

GT-15 (THF 15th repeat)

99

GT-T (Template strand)

100

CGA GTC ATC TAG CAT CCG TA GT GT
GT GT GT GT GT GT GT GT GT GT GT
GT GT GT GT GT GT GT GT GT GT GT
GT GT GT GT GT GT TA CGT AGA CTT
ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA GT GT
GT GT GT GT GT GT GT GT GT GT GT
GT THFT GT GT GT GT GT GT GT GT
GT GT GT GT GT GT GT TA CGT AGA
CTT ACT CAT TGC
GCA ATG AGT AAG TCT ACG TA AC
AC AC AC AC AC AC AC AC AC AC AC
AC AC AC AC AC AC AC AC AC AC AC
AC AC AC AC AC AC AC TA CGG ATG
CTA GAT GAC TCG

(TTAGGG)10 substrate
TTAGGG-0
strand)

(Undamaged 100

TTAGGG-5 (THF 5th repeat)

99

TTAGGG-T (Template strand)

100

CGA GTC ATC TAG CAT CCG TA
TTAGGG TTAGGG TTAGGG TTAGGG
TTAGGG TTAGGG TTAGGG TTAGGG
TTAGGG TTAGGG TA CGT AGA CTT
ACT CAT TGC
CGA GTC ATC TAG CAT CCG TA
TTAGGG TTAGGG TTAGGG TTAGGG
TTAGGTHF
TTAGGG
TTAGGG
TTAGGG TTAGGG TTAGGG TA CGT
AGA CTT ACT CAT TGC
GCA ATG AGT AAG TCT ACG TA
CCCTAA CCCTAA CCCTAA CCCTAA
CCCTAA CCCTAA CCCTAA CCCTAA
CCCTAA CCCTAA TA CGG ATG CTA
GAT GAC TCG
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Universal PCR primers for
DNA fragment analysis
Forward primer
20
Reverse
primer
(6’-FAM 19
labeled)

CGA GTC ATC TAG CAT CCG TA
6-FAM-CA ATG AGT AAG TCT ACG TA

In vitro polymerase DNA synthesis assay and FEN1 cleavage assay
The DNA synthesis activity was determined by incubating various concentrations
of WT pol β, pol βY265C, pol ν, and pol θ separately in the presence of APE1 with 25
nM (CAG)20, (CTG)20, (GAA)20, (CGG)20, (GT)30, or (TTAGGG)10 substrates that
contain a THF residue in reaction buffer containing 50 mM Tris-HCl, pH 7.5, 50 mM
KCl, 0.1 mM EDTA, 0.1 mg/ml bovine serum albumin (BSA), and 0.01% Nonidet P-40
(NP-40) along with 50 µM dNTPs and 5 mM Mg2+ at 37°C for 15 min. FEN1 cleavage
activity on the substrates was measured in the absence and presence of wild-type pol β,
pol βY265C variant, pol ν, or pol θ in the reaction buffer containing 50 mM Tris-HCl, pH
7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mg/ml BSA, NP-40, and 5 mM Mg2+ at 37°C for 15
min. The 20 µl-reaction mixture was assembled on ice, and reactions were quenched by
addition of 20 µl 2X stopping buffer containing 95% formamide and 10 mM EDTA and
incubation at 95°C for 10 min. Substrates and products were separated in a 15% ureadenaturing polyacrylamide gel (PAGE) and detected by a Pharos FX Plus
PhosphorImager (Bio-Rad Laboratory, CA).

Reconstitution of BER
Reconstituted BER was performed by incubating purified APE1, one of the DNA
polymerases (WT pol β, pol βR137Q variant, pol ν, or pol θ), FEN1, and LIG I along
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with (CAG)20, (CTG)20, (GAA)20, or (CGG)20 substrates (25 nM) with a THF residue in a
reaction mixture (20 µl) that contained 5 mM MgCl2, 50 µM dNTPs, 2 mM ATP, 50 mM
Tris-HCl (pH 7.5), 50 mM KCl, 0.1 mg/ml BSA, 0.1 mM EDTA, and 0.01% NP-40.
Reaction mixtures were assembled on ice and incubated at 37°C for 15 min. Reactions
were terminated by addition of 20-µl 2X stopping buffer with incubation at 95°C for 10
min. Substrates and products were then separated in 15% urea-denaturing PAGE and
were detected by the PhosphorImager.

Polymerase inhibition assay
The WT pol β was pre-incubated with pol β inhibitor NSC666719 in the buffer
condition of 50 mM Tris-HCl (pH 7.5), 50 mM KCl, 0.1 mg/ml BSA, 0.1 mM EDTA,
and 0.01% NP-40 at 37°C for 30 min with rotation. The (CAG)20-containing substrate (25
nM) with an abasic lesion in the middle of the repeat tract was pre-incubated with APE1
at 37°C for 15 min. The pre-cut substrate was then added to the reaction mixture for
additional 15 min at 37°C with the presence of 5 mM MgCl2 and 50 µM dNTPs.

Determination of repeat lengths of BER products by DNA fragment analysis
To isolate a repaired strand, the template strands of all TNR-containing substrates
were tagged by a biotin residue at the 5’-end. Reconstituted BER reactions were
terminated with 1 µl of 100 mM EDTA, and reaction mixtures were incubated with 50-µl
avidin agarose beads (Pierce-Thermo Scientific, Rockford, IL) for 2 hrs with rotation,
allowing the binding of avidin beads to the biotin on the template strand. Separation of
repaired strands from the template strands was then performed by incubating the reaction
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mixtures with 0.15 M NaOH at room temperature for 15 min with rotation. This was
followed by 2-min centrifugation at 5000 rpm pelleting the template strands bound by
avidin beads. After clearing the template strands, the separated repaired strands in the
supernatant were precipitated with ethanol, and subsequently dissolved in TE buffer for
PCR amplification and size analysis. Repaired products were amplified through PCR
with the AmpliTaq Gold 360 DNA polymerase Kit (Applied Biosystems, Foster City,
CA) at the following condition: denaturation at 95°C for 30s, annealing at 52°C for 30s,
extension at 72°C for 90s for 35 cycles, and a final extension at 72°C for 1 hr. Both a
forward primer and a reverse primer were used for amplification of the repaired strands.
All the reverse primers were tagged with 6-carboxyfluorescein (6-FAM). The primer
sequences of different repeat substrates are listed in Table 2. PCR products mixed with
the size marker MapMarker 500 (Bioventures, Murfreesboro, TN) were then subject to
capillary electrophoresis via an ABI 3130XL Genetic Analyzer (Applied Biosystems,
Foster City, CA) at Florida International University DNA sequencing core facility. The
sizes of PCR products were determined by DNA fragment analysis with the Peak Scanner
version 1.0 software (Applied Biosystems, Foster City, CA).

RESULTS
The weak DNA synthesis of pol βY265C promotes CAG repeat deletions
independent of damage location
A polymorphic pol βR137Q variant with slightly weaker DNA synthesis activity
than WT pol β does not significantly promote repeat deletions compared to the wild-type
pol β [13]. However, pol βY265C, which has much weaker DNA synthesis activity than
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WT pol β, significantly reduces TNR expansion frequency in fragile X syndrome mice
[146, 151]. In addition, since the locations of DNA damage also plays a role in governing
pol β-mediated TNR expansions or deletions [5], we initially compared the DNA
synthesis activity of pol βY265C with that of WT pol β with (CAG)20-containing
substrates with a THF located at the 5’-side or in the middle of the repeat tract. We found
that WT pol β incorporated up to 2 repeats, 3 repeats, and 6 repeats at the concentrations
of 1 nM, 2 nM, and 5 nM when the damage located at the 5’-side (Figure 2.1A, lanes 35). While at the same concentrations, pol βY265C incorporated up to 1 nt, 1 repeat, and 2
repeats, respectively (Figure 2.1A, lanes 4-6). Similarly, when the damage located in the
middle of the repeat tract, WT pol β inserted up to 1 repeat, 2 repeats, and 5 repeats
(Figure 2.1B, lanes 3-5) compared to 1 nt, 2 nt, and 4 nt synthesized by pol βY265C at
the concentrations of 1 nM, 2 nM, and 5 nM, respectively (Figure 2.1B, lanes 4-6). The
difference in the sizes of the synthesized products by WT pol β and pol βY265C indicates
that pol βY265C synthesized fewer TNRs than WT pol β during BER.
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Figure 2.1. Pol βY265C exhibits weak DNA synthesis activity during BER of a
base lesion in the context of (CAG)20 repeats.
DNA synthesis activity of WT pol β or pol βY265C at concentrations of 1 nM, 2
nM, and 5 nM was measured with (CAG)20 containing substrates with a THF
residue located at the first repeat (A). Lanes 1 represents substrate only. Lane 2
represents APE1 cleavage products. Lanes 3-5 represent WT pol β synthesized
products. Lanes 6-8 represent pol βY265C synthesized products. Lanes 9-14
represent BER reconstitution with additional 5 nM FEN1 and 10 nM LIG I. Lanes
9-11 represent BER reconstitution in the presence of WT pol β. Lanes 12-14
represent BER reconstitution in the presence of pol βY265C. Substrates were 32Plabeled at the 5’-end of the damaged strand.
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Figure 2.1. Pol βY265C exhibits weak DNA synthesis activity during BER of a
base lesion in the context of (CAG)20 repeats.
DNA synthesis activity of WT pol β or pol βY265C at concentrations of 1 nM, 2
nM, and 5 nM was measured with (CAG)20 containing substrates with a THF
residue located at the tenth repeat (B). Lanes 1 represents substrate only. Lane 2
represents APE1 cleavage products. Lanes 3-5 represent WT pol β synthesized
products. Lanes 6-8 represent pol βY265C synthesized products. Lanes 9-14
represent BER reconstitution with additional 5 nM FEN1 and 10 nM LIG I. Lanes
9-11 represent BER reconstitution in the presence of WT pol β. Lanes 12-14
represent BER reconstitution in the presence of pol βY265C. Substrates were 32Plabeled at the 5’-end of the damaged strand.

To further test whether the weak DNA synthesis activity of pol β could promote
repeat deletions during BER, we reconstituted the BER in the presence of pol βY265C
with the (CAG)20-containing substrates with a THF located at the 5’-end or in the middle
of the repeat tract. We observed the repaired products in the presence of both WT pol β
and pol βY265C when the lesion located either at the 5’-side or in the middle of the
repeat tract (Figure 2.1A and 2.1B, lanes 9-14). We also observed the repeat deletion
products in the presence of all concentrations of pol βY265C (Figure 2.1A and 2.1B,
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lanes 12-14). Size analysis of the repaired products showed that pol βY265C induced 1
repeat deletion products at the concentration of 1 nM and 2 nM, and it did not induce
repeat deletions at 5 nM with the damage located at 5’-side of the repeat tract (Figure
2.2A, panels d, f, and h). Whereas, WT pol β at the same concentrations failed to induce
repeat deletions (Figure 2.2A, panels c, e, and g). For the substrate with an abasic lesion
in the middle of the repeat tract, pol βY265C induced 1 repeat deletion products through
BER at all three concentrations (1 nM, 2 nM, and 5 nM) compared to no repeat deletion
products induced by WT pol β at the same concentrations (Figure 2.2B, compare panels
d, f, and h to panels c, e, and g). The results indicated that the weak DNA synthesis
activity of pol βY265C predominantly promoted CAG repeat deletions independent of
the locations of an abasic lesion. In addition, for both the damage located at the 5’-side or
in the middle of the repeat tract, the amount of the repeat deletion products was decreased
with increasing the concentration of pol βY265C mutant protein, indicating that the DNA
synthesis activity of pol βY265C was increased at the a high concentration of the mutant
protein.
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Figure 2.2. Pol βY265 promotes (CAG)20 repeat deletions.
BER was reconstituted with 5 nM APE1, 10 nM FEN1, 5 nM LIG I, and increasing
concentrations (1 nM, 2 nM, and 5 nM) of WT pol β or pol βY265C along with
(CAG)20 substrates. The repaired products were subjected to PCR amplification and
capillary electrophoresis and the repeat lengths were analyzed by DNA fragment
analysis. (A) Length analysis of the repaired products from the substrate with a
lesion located at the first repeat of the (CAG)20 substrate. Panels a and b represent a
(CTG)20 marker without damage. Panels c, e, and g indicate the sizes of the repaired
products in the presence of 1 nM, 2 nM, and 5 nM WT pol β. Panels b, f, and h
represent the sizes of the repaired products in the presence of 1 nM, 2 nM, and 5 nM
pol βY265C. Note: Panels a and b used the same data since in the experiment, all
samples were run along with the same markers for comparison.
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Figure 2.2. Pol βY265 promotes (CAG)20 repeat deletions during BER.
BER was reconstituted with 5 nM APE1, 10 nM FEN1, 5 nM LIG I, and increasing
concentrations (1 nM, 2 nM, and 5 nM) of WT pol β or pol βY265C along with
(CAG)20 substrates. The repaired products were subjected to PCR and capillary
electrophoresis and the repeat lengths were analyzed by DNA fragment analysis. (B)
Size analysis of the repaired products of from the substrate with a lesion located at
the tenth repeat of the (CAG)20 substrate. Panels a and b represent a (CTG)20 marker
without damage. Panels c, e, and g indicate the sizes of the repaired products in the
presence of 1 nM, 2 nM, and 5 nM WT pol β. Panels b, f, and h represent the sizes
of the repaired products in the presence of 1 nM, 2 nM, and 5 nM pol βY265C.
Note: Panels a and b used the same data since in the experiment, all samples were
run along with the same markers for comparison.
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To further explore the mechanisms by which the weak DNA synthesis activity had
induced repeat deletions, we then determined the FEN1 cleavage activity in the presence
of pol βY265C. When the damage located at the 5’-side, FEN1 alone removed up to 1
repeat (Figure 2.3A, lane 3). Flap endonuclease 1 removed mainly 4 nt in the presence of
1 nM pol βY265C (Figure 2.3A, lane 7), and it removed up to 2 repeats when the pol
βY265C increased to 2 nM and 5 nM (Figure 2.3A, lanes 8-9). In the presence of WT pol
β, FEN1 exhibited efficient cleavage of repeats, it removes up to 2 repeats, 3 repeats, and
4 repeats in corresponding to 1 nM, 2 nM, and 5 nM of WT pol β, respectively (Figure
2.3A, lanes 4-6). Similarly, when the damage was located in the middle of the repeat
tract, FEN1 alone mainly removed 1 repeat (Figure 2.3B, lane 12). Flap endonuclease 1
removed up to 2 repeats in the presence of all three concentrations (1 nM, 2 nM, and 5
nM) of pol βY265C (Figure 2.3B, lanes 16-18), whereas it removed up to 2 repeats, 3
repeats, and 5 repeats with the increasing concentrations (1 nM, 2 nM, and 5 nM) of WT
pol β (Figure 2.3B, lanes 13-15). The results indicate that the presence of WT pol β
stimulated FEN1 cleavage. However, the pol βY265C did not significantly affect FEN1
cleavage activity. Comparing the major DNA synthesis products by pol βY265C with the
ones cleaved by FEN1 in the presence of the variant protein, the repeat flap removed by
FEN1 is 1-repeat longer than the repeats synthesized by pol β variant (compare Figure
2.3A, lanes 7-9 and 2.3B, lanes 16-18 to Figure 2.1A and 2.1B, lanes 6-8 respectively),
indicating that the weak DNA synthesis of pol βY265C resulted in the loss of CAG
repeats, leading to repeat deletions.
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Figure 2.3. Pol βY265C leads to weak FEN1 cleavage during BER in the
context of (CAG)20 repeats.
FEN1 flap cleavage activity at 5 nM on the (CAG)20 containing substrate with a
THF located at the first repeat (A) or tenth repeat (B) was measured in the presence
of 1 nM, 2 nM, and 5 nM of pol β. Lanes 1 and 10 represent the substrate only.
Lanes 2 and 11 represent reactions with APE1 alone. Lanes 3 and lanes 12 represent
reactions with FEN1 alone. Lanes 4-6 and 13-15 represent reactions with FEN1 in
the presence of 1 nM, 2 nM, and 5 nM of WT pol β accordingly. Lanes 7-9 and 1618 illustrate reactions with FEN1 in the presence of 1 nM, 2 nM, and 5 nM of pol
βY265C. Substrates were 32P-labeled at the 3’-end of the damaged strand.

Weak DNA synthesis activity of repair DNA polymerases promotes repeat deletions
There are 17 human DNA polymerases [161, 250, 251] with different DNA
synthesis activities that may all participate in DNA synthesis on TNR tracts. For example,
translation polymerase pol θ has deoxyribose phosphate lyase activity, indicating its role
in BER since it may be able to remove a sugar residue efficiently [252, 253]. Another
translesion polymerase, pol ν, may also be involved in modulating TNR instability during
BER. Since pol ν is specialized in bypassing the thymine glycol lesion [251], it is
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possible that it can bypass the thymine glycols formed in TNR tracts, such as
(CAG)n/(CTG)n and (GAA)n/(CTT)n, which are rich of thymine. Moreover, translesion
DNA polymerases adopt unique structures to interact with DNA, allowing them to
accommodate DNA lesions on the template strand. The interaction between the
translesion DNA polymerases and the TNR may result in different outcomes of TNR
instability. Both pol θ and pol ν can cause a primer loop-out during DNA synthesis [253,
254], which may occur in TNR tracts and forms a basis for TNR expansion. To examine
the roles of translesion DNA polymerases in modulating TNR instability during BER, we
initially compared the DNA synthesis activity of pol ν and pol θ with pol β) during BER
of an abasic lesion in the middle of a (CAG)20 repeat tract. We found that Pol ν exhibited
very weak DNA synthesis activity and mainly inserted only 1 nt, 1 nt, 1 repeat at the
concentrations of 1 nM, 2 nM, and 5 nM (Figure 2.4A, lanes 6-8), respectively, compared
to 1 repeat, 2 repeats, and 6 repeats inserted mainly by pol β at the corresponding
concentrations (Figure 2.4A, lanes 3-5). The weak DNA synthesis activity of the
translesion DNA polymerase also resulted in the products with one repeat deletion
(Figure 2.4A, lanes 12-14 and Figure 2.4B, panels b, c, and d). The repeat deletion
products decreased when the concentration of pol ν increased (Figure 2.4B, compare the
peak heights among panels b, c, and d), indicating that the increased amount of pol ν
facilitated the synthesis on repeat tract and thus prevented repeat deletion. On the other
hand, FEN1 cleaved up to 2 repeats in the presence of 1 nM, 2 nM of pol ν, and 3 repeats
in the presence of 5 nM of pol ν (Figure 2.4C, lanes 7-9), compared to 1 repeat removed
by FEN1 alone (Figure 2.4C, lane 3). The results suggest that weak DNA synthesis of pol
ν caused more repeats removed by FEN1, which led to TNR deletions.
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Figure 2.4. Weak DNA synthesis of pol ν promotes (CAG)20 repeat deletions.
(A) Measurement of DNA synthesis activity and BER reconstitution were
conducted with the (CAG)20-containing substrate with a THF residue located at
tenth repeat. Lane 1 represents substrate only. Lane 2 represents APE1 cleavage
products. Lanes 3-5 represent the DNA synthesis products by pol β at the
concentration of 1 nM, 2 nM, and 5 nM. Lanes 6-8 represent the DNA synthesis
products of pol ν at the concentration of 1 nM, 2 nM, and 5 nM. Lanes 9-14
represent BER reconstituted with additional 5 nM FEN1 and 10 nM LIG I. Lanes 911 represent BER reconstituted in the presence of pol β (1 nM, 2 nM, and 5 nM).
Lanes 12-14 represent BER reconstituted in the presence of pol βY265C (1 nM, 2
nM, and 5 nM).
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Figure 2.4. Weak DNA synthesis of pol ν promotes (CAG)20 repeat deletions. (B)
Size analysis of the repaired products in the presence of 1 nM, 2 nM, and 5 nM of pol
ν. Panel a represents the length of the (CAG)20 marker. Panels b, c, and d represent
the size change of the repaired products in the presence of 1 nM, 2 nM, and 5 nM of
pol ν, respectively. (C) FEN1 (5 nM) cleavage activities in the presence of 1 nM, 2
nM, and 5 nM of pol β or pol ν. Lane 1 represents substrate only. Lane 2 represents
APE1 cleavage products. Lane 3 represents the reaction with FEN1 only. Lanes 4-6
represent reactions with FEN1 in the presence of 1 nM, 2 nM, and 5 nM of WT pol β.
Lanes 7-9 illustrate reactions with FEN1 in the presence of 1 nM, 2 nM, and 5 nM of
pol ν. Substrates were labeled with 32P-labeled either at the 5’- end or at the 3’-end of
the damaged strand as illustrated in the figure.
The pol θ at the concentration of 2 nM, 5 nM, and 10 nM exhibited stronger DNA
synthesis activity than pol β. It inserted 4 nt, 8 repeats, and 50 nt (Figure 2.5A, lanes 6-8)
compared to 2 repeats, 5 repeats, and 10 repeats synthesized by pol β at the
corresponding concentrations (Figure 2.5A, lanes 3-5). The strong DNA synthesis
activity resulted in the maintenance of TNR stability (Figure 2.5B, compare panels b, c,
and d to panel a). The results suggest that the relatively stronger DNA synthesis of pol θ
prevented repeat deletion. Thus, it appears that only weak DNA synthesis activity of
repair DNA polymerase facilitated TNR deletions during BER.
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Figure 2.5. Pol θ does not induce (CAG)20 repeat deletions.
(A) DNA synthesis activity of pol θ at 2 nM, 5 nM, and 10 nM was measured with
the (CAG)20-containing substrate with a THF residue located at tenth repeat. Lane 1
represents substrate only. Lane 2 represents APE1 cleavage products. Lanes 3-5
represent the DNA synthesis products of pol β at 2 nM, 5 nM, and 10 nM. Lanes 6-8
represent the DNA synthesized products of pol θ at the concentration of 2 nM, 5 nM,
and 10 nM. (B) Sizing analysis of the repaired products in the presence of 2 nM, 5
nM, and 10 nM of pol θ. Panel a represents the length of the (CAG)20 marker. Panel
b, c, and d represent the sizes of the repaired products in the presence of 2 nM, 5 nM,
and 10 nM of pol θ.

DNA sequences alter TNR instability by modulating pol β DNA synthesis activity
Previous studies indicated that different repeat sequences can facilitate the
formation of different types of secondary structures [7]. For example, CAG, CTG, and
CGG repeats may facilitate the formation of hairpin structures, and the same size of
hairpin structures formed by different types of TNRs can have different thermostability
and exhibit different dynamics [7]. Hairpins with different thermostability can result in
different outcomes of repeat instability. Moreover, DNA polymerases may have different
sequence preference that may result in the different efficiency of DNA synthesis on
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different TNR tracts. To further identify whether the weak DNA synthesis activity of pol
βY265C and pol ν can also promote repeat deletions in the context of different repeated
sequences, we examined the DNA synthesis activity of pol β, pol βY265C, and pol ν in
modulating the instability of (CTG)20 and (CGG)20 tracts.
We initially tested the DNA synthesis activity of pol βY265C and its roles in
modulating CTG repeat instability during BER of an abasic lesion located at the 5’-side
or in the middle of a (CTG)20 repeat tract. Pol βY265C at 1 nM, 2 nM, 5 nM, and 10 nM
performed weak DNA synthesis on the (CTG)20 repeat tracts. For a lesion located at 5’side of the repeat tract, pol βY265C incorporated up to 1 nt, 1 repeat, 2 repeats, and 4
repeats (Figure 2.6A, lanes 7-10), whereas the same concentrations of WT pol β
incorporated 1 repeat, 2 repeats, 5 repeats, and 8 repeats (Figure 2.6A, lanes 3-6). For a
lesion located in the middle of the repeat tract, pol βY265C at the concentrations of 2 nM,
5 nM, and 10 nM inserted 1 nt, 3 nt, and 7 nt (Figure 2.6B, lanes 6-8), whereas the same
concentrations of WT pol β inserted 2 repeats, 4 repeats, and 10 repeats (Figure 2.6B,
lanes 3-5). The weak DNA synthesis of pol βY265C led to repeat deletion on the (CTG)20
repeat tract. Both WT pol β and pol βY265C at the concentration of 1 nM induced 1
repeat deletion (Figure 2.6C and 2.5D, panels c and d). However, pol βY265C-mediated
BER resulted in more repeat deletion products than WT pol β (compare panels d to panels
c in Figure 2.6C and 2.6D). At higher concentrations of 2 nM and 5 nM, only pol
βY265C promoted repeat deletions (compare panels f to e, and panels h to g in Figure
2.6C and 2.6D, respectively).
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Figure 2.6. Weak DNA synthesis of pol βY265C promotes CTG repeat deletion
during BER in the context of (CTG)20 repeats.
(A) DNA synthesis activity and BER reconstitution was measured with (CTG)20
containing substrates with a THF residue located at first repeat. Lane 1 represents
substrate only. Lane 2 represents APE1 cleavage products. Lanes 3-6 represent the
DNA synthesized products of WT pol β (1 nM, 2 nM, 5 nM, and 10 nM). Lanes 710 represent the DNA synthesized products of pol βY265C (1 nM, 2 nM, 5 nM, and
10 nM). Lanes 11-14 represent BER reconstituted in the presence of WT pol β at 1
nM, 2 nM, 5 nM, and 10 nM. Lanes 15-18 represent BER reconstituted in the
presence of pol βY265C at 1 nM, 2 nM, 5 nM, and 10 nM).
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Figure 2.6. Weak DNA synthesis of pol βY265C promotes CTG repeat
deletion during BER in the context of (CTG)20 repeats.
(B) Measurement of DNA synthesis activity and BER reconstitution was
conducted with the (CTG)20-containing substrates with a THF residue located at
the tenth repeat. Lane 1 represents substrate only. Lane 2 represents APE1
cleavage products. Lanes 3-5 represent the DNA synthesis products of WT pol β at
2 nM, 5 nM, and 10 nM. Lanes 6-8 represent the DNA synthesis products of pol
βY265C at 2 nM, 5 nM, and 10 nM. Lanes 9-11 represent BER reconstituted in the
presence of WT pol β at 2 nM, 5 nM, and 10 nM. Lanes 12-14 represent BER
reconstituted in the presence of pol βY265C at 2 nM, 5 nM, and 10 nM.
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Figure 2.6. Weak DNA synthesis of pol βY265C promotes CTG repeat
deletion during BER in the context of (CTG)20 repeats.
(C) Sizing analysis of the repaired products in the presence of 1 nM, 2 nM, and
5 nM of pol βY265C with the (CTG)20-containing substrates with a THF residue
located at the first repeat. Panels a and b represent the length of the (CTG)20
marker. Panels c, e, and g indicate the sizes of the repaired products in the
presence of 1 nM, 2 nM, and 5 nM WT pol β. Panels b, f, and h represent the
size analysis of the repaired products in the presence of 1 nM, 2 nM, and 5 nM
pol βY265C. All samples in panels a and b were run along with the same size
markers.
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Figure 2.6. Weak DNA synthesis of pol βY265C promotes CTG repeat deletion
during BER in the context of (CTG)20 repeats.
(D) Sizing analysis of the repaired products in the presence of 1 nM, 2 nM, and 5 nM
of pol βY265C with the (CTG)20 containing substrates with a THF residue located at
the tenth repeat. Panels a and b represent the length of the (CTG)20 marker. Panels c,
e, and g indicate the sizes of the repaired products in the presence of 1 nM, 2 nM, and
5 nM WT pol β. Panels b, f, and h represent the sizes of the repaired products in the
presence of 1 nM, 2 nM, and 5 nM pol βY265C. All samples in panels a and b were
run along with the same size markers.
On the other hand, pol ν performed weaker DNA synthesis activity on CGG
repeats than it did on CAG repeats. It mainly inserted 1 nt at the concentrations of 2 nM
and 5 nM. It inserted up to 1 repeat when the concentrations increased to 10 nM (Figure
2.7A, lanes 6-8), while WT pol β inserted up to 1 nt, 3 repeats, and 6 repeats at the
respective concentrations (Figure 2.7A, lanes 3-5). The weak DNA synthesis of pol ν also
resulted in the products with 1 repeat deletion (Figure 2.7B, panels d, f, h), whereas WT
pol β did not promote the formation of deletion products (Figure 2.7B, panels c, e, g).
Analysis on the FEN1 cleavage with these substrates showed that FEN1 cleaved up to 2
repeats in the presence of 2 nM, 5 nM, and 10 nM pol ν (Figure 2.7C, lanes 7-9). The
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results indicate that weak DNA synthesis of pol ν promoted repeat deletions independent
of the sequences of TNRs.

Figure 2.7. Weak DNA synthesis of pol ν promotes (CGG)20 repeat deletions.
(A) Measurements of DNA synthesis activity and BER reconstitution were conducted
with (CGG)20-containing substrates with a THF residue located at the tenth repeat.
Lane 1 represents substrate only. Lane 2 represents APE1 cleavage products. Lanes
3-5 represent the DNA synthesis products from WT pol β at 2 nM, 5 nM, and 10 nM.
Lanes 6-8 represent the DNA synthesis products from pol ν at 2 nM, 5 nM, and 10
nM. Lanes 9-11 represent BER reconstitution in the presence of WT pol β. Lanes 1214 represent BER reconstitution in the presence of pol ν. Substrates were 32P-labeled
at the 5’- end of the damaged strand.
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Figure 2.7. Weak DNA synthesis of pol ν promotes (CGG)20 repeat deletions.
(B) Sizing analysis of the repaired products from pol ν with the (CGG)20-containing
substrate with a THF residue located at the tenth repeat. Panels a and b represent the
length of the (CGG)20 marker. Panels c, e, and g indicate the sizes of the repaired
products in the presence of 2 nM, 5 nM, and 10 nM WT pol β. Panels b, f, and h
represent the sizes of the repaired products in the presence of 2 nM, 5 nM, and 10 nM
pol ν.
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Figure 2.7. Weak DNA synthesis of pol ν promotes (CGG)20 repeat deletions.
(C) FEN1 (5 nM) cleavage activities in the presence of 2 nM, 5 nM, and 10 nM of
WT pol β or pol ν. Lane 1 represents substrate only. Lane 2 represents APE1
cleavage products. Lane 3 represents reaction with FEN1 only. Lanes 4-6 represent
reactions with FEN1 in the presence of 2 nM, 5 nM, and 10 nM of WT pol β. Lanes
7-9 illustrate the reactions with FEN1 in the presence of 2 nM, 5 nM, and 10 nM pol
ν. Substrates were labeled with 32P-labeled at the 3’-end of the damaged strand.

In addition, we further compared the DNA synthesis activity of pol θ on GAA
repeats to WT pol β at 1 nM, 2 nM, and 5 nM and found that pol θ performed weaker
DNA synthesis activity than pol β on GAA repeats. Pol θ mainly inserted 1 nt at 1 nM, 2
nM, and 5 nM (Figure 2.8A, lanes 6-8), whereas the same concentrations of pol β
inserted 1 nt, 1 repeat, and 2 repeats (Figure 2.8A, lanes 3-5). Analysis on the sizes of the
repaired products showed that pol β resulted in a small amount products with 1-2 GAA
repeat deletions (Figure 2.8B, panels c, e, and g), whereas pol θ resulted in a large
amount of 1 repeat deletion products (Figure 2.8B, panels d, f, and h). The results
indicate that the DNA sequences of TNRs affected DNA synthesis activity and thus
modulated TNR instability.
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Figure 2.8. Pol θ induces (GAA)20 repeat deletions.
(A) DNA synthesis activity of 1 nM, 2 nM, and 5 nM of pol θ was measured with
the (GAA)20-containing substrate with a THF residue located at tenth repeat. Lane 1
represents substrate only. Lane 2 represents APE1 cleavage products. Lanes 3-5
represent the DNA synthesis products from pol β at 1 nM, 2 nM, and 5 nM. Lanes
6-8 represent the DNA synthesis products from pol θ at 1 nM, 2 nM, and 5 nM.

Figure 2.8. Pol θ induces (GAA)20 repeat deletions.
(B) Sizing analysis of the repaired products in the presence of 1 nM, 2 nM, and 5
nM of pol θ. Panels a and b represent the length of the (GAA)20 marker. Panels c, e,
and g indicate the sizes of the repaired products from BER in the presence of 1 nM,
2 nM, and 5 nM pol β. Panels b, f, and h represent the sizes of the repaired products
in the presence of 1 nM, 2 nM, and 5 nM pol ν. Panels a and b are the same marker
which was run along the samples.
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Inhibition of pol β significantly promotes TNR repeat deletions
To further determine whether the DNA synthesis activity of DNA polymerases
can be utilized as a potential therapeutic target that shortens the expanded TNRs, we then
used a pol β inhibitor NSC666719, which inhibits the strand displacement DNA synthesis
activity of pol β [255], to modulate TNR instability through BER. We reason that
inhibition of the strand displacement DNA synthesis of pol β during BER in TNR tracts
may reduce the formation of secondary structures such as TNR hairpins and loops on the
downstream strand. This is because pol β strand displacement DNA synthesis facilitates
separation of the downstream strand from the template strand. Formation of TNR
hairpins and loops on the downstream damage strand inhibits FEN1 5’-flap
endonucleolytic activity, resulting in FEN1 alternative cleavage of a shorter flap and
causing repeat expansion [1, 5]. Thus, reduction of DNA strand displacement synthesis of
pol β by inhibiting pol β polymerase activity may promote TNR deletions.
We found that the pol β inhibitor significantly reduced the DNA synthesis activity
of pol β on the (CAG)20 repeat tract with a lesion in the middle of the repeat tract. Pol β at
1 nM mainly inserted 1-2 repeats (Figure 2.9, lane 2). However, pol β mainly inserted 1
repeat with the presence of 1 µM, 3 µM, and 5 µM of the inhibitor (Figure 2.9, lanes 4-6).
When the concentrations of the inhibitor increased to 8 µM, 10 µM, and 25 µM, the DNA
synthesized products of pol β was reduced to 2 nt, 1 nt, and 0, respectively (Figure 2.9,
lanes 7-9). On the other hand, 10 nM pol β synthesized up to 8 repeats in the absence of
the inhibitor (Figure 2.9, lane 3). The sizes of pol β synthesis products of was reduced to
7 repeats, 6 repeats, and 4 repeats, respectively, in the presence of 1 µM, 3 µM, and 5 µM
of the inhibitor (Figure 2.9, lanes 10-12). The DNA synthesis activity of pol β on the
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repeat tract was further reduced when the concentrations of the inhibitor was increased to
8 µM, 10 µM, and 25 µM as pol β only incorporated 1 repeat, 1 repeat, and 1 nt at the
concentrations of the inhibitor (Figure 2.9, lanes 13-15).

Figure 2.9. DNA synthesis activity of pol β is inhibited by a pol β inhibitor,
NSC666719.
The inhibition of DNA synthesis activity of pol β at 1 nM and 10 nM by
NSC666719 was measured by incubating with increasing concentrations of
NSC666719 (1 µM, 3 µM, 5 µM, 8 µM, 10 µM, and 25 µM) with the (CAG)20containing substrate with a THF residue located at the tenth repeat. Lane 1
represents APE1 pre-cut substrate. Lane 2 and lane 3 represent DNA synthesis
products 1 nM and 10 nM of pol β, respectively. Lanes 4-9 represent the DNA
synthesis products from 1 nM pol β in the presence of increasing concentrations of
NSC666719. Lanes 10-15 represent the DNA synthesis products of 10 nM pol β in
the presence of increasing concentrations of NSC666719.

To determine whether the inhibition of the DNA synthesis activity of pol β
promotes TNR deletions, we measured the sizes of the repeat tracts in the repaired
products. In the absence of the inhibitor, neither 1 nM nor 10 nM WT pol β promoted
repeat deletions (Figure 2.10A, lanes 3 and 6; Figure 2.10B and 2.10C, panels b). The
inhibitor at 8 µM promoted repeat deletions in the presence of both 1 nM and 5 nM pol β
(Figure 2.10A, lanes 5 and 8; Figure 2.10B, panel d; and Figure 2.10C, panel c), and 5

109

µM inhibitor also promoted repeat deletions in the presence of 1 nM WT pol β (Figure
2.10A, lane 4; and Figure 2.10B, panel c). Interestingly, with 8 µM inhibitor, it
completely converted all full size repaired products into the products with 1 repeat
deletion (Figure 2.10B, panel d). The results suggested that inhibition of the DNA
synthesis activity of pol β significantly promoted TNR deletions through BER.

Figure 2.10. Inhibition of DNA synthesis activity of pol β promotes (CAG)20
repeat deletions
(A) BER reconstituted in the presence of NSC666719 with the (CAG)20-containing
substrates with a THF residue located at the tenth repeat. Lane 1 represents
substrate only. Lane 2 represents APE1 cleavage products. Lanes 3 and 6 represent
the repair products in the presence of 1 nM and 10 nM pol β, respectively. Lanes 45 and lanes 7-8 represent the repair products in the presence of 1 nM pol β and 10
nM pol β with 5 µM or 8 µM of NSC666719.
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Figure 2.10. Inhibition of DNA synthesis activity of WT pol β promotes
(CAG)20 repeat deletions
(B) Sizing analysis of the repaired products with the inhibition of 1 nM pol β. Panel
a illustrates the (CAG)20 size marker. Panel b illustrates the repaired products
without inhibitor. Panel c and d illustrates the sizes of the repaired products with the
inhibition of DNA synthesis activity of 1 nM pol β by NSC666719 (5 µM and 8
µM). (C) Sizing analysis of the repaired products with the inhibition of 10 nM pol
β. Panel a illustrates the (CAG)20 size marker. Panel b illustrates the repaired
products without the inhibitor. Panel c illustrates the sizes of the repaired products
with the inhibition of DNA synthesis activity of 10 nM pol β by NSC666719 (8
µM).

Weak DNA synthesis activity of pol βY265C does not significantly affect the
instability of dinucleotide GT repeats and telomere repeats
Microsatellite DNA also consists of dinucleotide repeats and hexanucleatide
repeats [91]. The repeat deletions are associated with many human cancer and agingrelated diseases [184, 256]. Deletions of GT repeats are specifically associated with
colorectal cancers [184]. Deletions of telomere repeats, TTAGGG repeats, are associated
with aging-related diseases, such as diabetes, Alzheimer’s disease, and hypertension
[256]. Although inducing repeat deletions on the expanded TNRs is beneficial for the
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individuals who are prone to TNR expansion that mediates neurodegenerative diseases,
deletions on GT repeats and telomere repeats may lead to cancer development and agingrelated diseases. Therefore, we determined whether the weak DNA synthesis activity of
pol βY265C would promote deletions of GT repeats and telomere repeats.
First, we determined the DNA synthesis and repeat instability in the presence of
pol βY265C with the substrate containing (GT)30 with a lesion located in the middle. The
results showed that both WT pol β and pol βY265C exhibited more efficient DNA
synthesis activities on GT repeats than those on CAG or CTG repeats (Compare Figure
2.11 with Figure 2.1 or Figure 2.6). Pol βY265C exhibited weaker DNA synthesis activity
than WT pol β. It incorporated 10 nt at the concentration of 2 nM (Figure 2.11A, lane 4)
compared to 14 nt incorporated by WT pol β (Figure 2.11A, lane 3). Analysis on sizes of
the repeats in the repaired products showed that both WT pol β and pol βY265C induced
1 repeat deletion products (Figure 2.11B, panels b and c). However, the weaker DNA
synthesis activity of pol βY265C on GT repeats did not significantly alter the repeat
instability during BER (compare panel c to panel b in Figure 2.11B).
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Figure 2.11. Pol βY265C does not significantly alter (GT)30 repeat instability.
(A) Measurement of DNA synthesis activity and BER reconstitution were
conducted measured with the (GT)30 containing substrate with a THF residue
located at the fifteenth repeat. Lane 1 represents substrate only. Lane 2 represents
APE1 cleavage products. Lanes 3 and 4 represent the DNA synthesis products of 2
nM WT pol β and pol βY265C, respectively. Lanes 5 and 6 represent the repaired
products in the presence of 2 nM WT pol β and pol βY265C, respectively. (B) Sizes
measurement of sizes of the repeats in the repaired products. Panel a represents the
(GT)30 marker. Panels b and c represent the lengths of the repaired products in the
presence of 2 nM WT pol β and pol βY265C, respectively.
We further evaluated the effect of weak DNA synthesis activity of pol βY265C on
telomere repeat instability through BER. With the (TTAGGG)10-containing substrate with
the lesion located at the last G of the fifth repeat, the DNA synthesis activity of WT pol β
and pol βY265C did not exhibit a significant difference. WT pol β inserted 1 repeat, 2
repeats, and 3 repeats (Figure 2.12A, lanes 3-5), whereas pol βY265C incorporated 2/3
repeat, 1.5 repeats, and 2.5 repeats at the concentrations of 2 nM, 5 nM, and 10 nM
(Figure 2.12A, lanes 6-8), respectively. However, neither WT pol β nor pol βY265C
resulted in instability of telomere repeats (compare panels b and c to panel a in Figure
2.12B). The results indicated that the weak DNA synthesis did not significantly alter
instability of GT repeats and telomere repeats. The results further suggested that
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shortening the expanded TNRs by inhibiting pol β DNA synthesis may not confer a
significantly high risk of development of cancers and aging-related diseases, which are
associated with GT repeat or telomere repeat deletions.

Figure 2.12. Pol βY265C does not significantly alter (TTAGGG)10 repeat
instability.
(A) Measurement of DNA synthesis activity and BER reconstitution were
conducted with the (TTAGGG)10-containing substrates with a THF residue located
at the fifth repeat. Lane 1 represents substrate only. Lane 2 represents APE1
cleavage products. Lanes 3-5 and lanes 6-8 represent the DNA synthesis products of
pol β and pol βY265C at the concentrations of 2 nM, 5 nM, and 10 nM,
respectively. Lanes 9-11 and lanes 12-14 represent the repaired products in the
presence of WT pol β and pol βY265C at the concentrations of 2 nM, 5 nM, and 10
nM, respectively. (B) Sizing analysis of the repaired products by DNA fragment
analysis. Panel a represents the (TTAGGG)10 marker. Panels b and c represent the
lengths of the repaired products in the presence of 2 nM WT pol β and pol βY265C.
DISCUSSION
Trinucleotide repeat expansion diseases including Huntington’s disease,
Friedreich’s ataxia, and mytonic dystrophy are fatal inherited neurological disorders [88,
89, 92]. Despite decades of studies, no cure has been developed for these diseases, and
only symptomatic managements are available for the patients [244-246]. Current studies
have mainly focused on alleviating the symptoms of patients, such as reduction of toxic
RNAs resulted from the transcription of expanded TNRs in the noncoding regions [257-
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259], decreation of the toxicity caused by aggregations of polyglutamine proteins
encoded by expanded CAG repeats [260-262], and suppression of toxic gene expression
via RNA interference [263, 264]. However, since expanded TNRs are increasingly
expanded, repeat expansions and cellular toxicity, therefore, accumulate at an accelerated
rate. These approaches do not provide a long-term solution for the patients, nor do they
provide an effective treatment targeting the root of TNR expansion diseases. Our studies
suggest that a novel strategy of shortening expanded TNR tracts can be achieved by
inhibiting the DNA synthesis activity of pol β through BER, provideing a treatment of
TNR expansion diseases by eracidating their roots. This may effectively reverse and
attenuate the courses of the diseases.
Previous studies have demonstrated that BER plays an essential role in mediating
TNR expansions in somatic cells, and pol β plays a critical role in BER-mediated TNR
expansions [1, 14, 122, 144]. In the striatum of HD mice that has high frequency of CAG
repeat expansions, a high level of pol β and a low level of FEN1 is observed [122, 249].
On the other hand, CAG repeat expansions barely occur in the cerebellum of the disease
mice, and the levels of pol β and FEN1 are balanced [122, 249]. This suggests that pol β
DNA synthesis predominantly promotes TNR expansions through BER [2]. In this study,
we demonstrated that the weak synthesis by pol βY265C and the weak synthesis by
inhibiting WT pol β DNA could both lead to TNR deletion. This indicates that TNR
expansions can be shifted to deletions by regulating the pol β DNA synthesis activity the
outcome from the to TNR deletions.
Our study further suggested a general role of DNA synthesis in regulating TNR
instability. Through characterizing the effects of the translesion polymerases, pol ν and
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pol θ on TNR instability, we discovered that pol ν, which exhibited weak DNA synthesis
activity resulted in CAG repeat deletions (Figure 2.4), whereas pol θ, which exhibited
strong DNA synthesis, did not significantly alter CAG repeat instability (Figure 2.5). The
results suggest a fundamental role of weak DNA synthesis in promoting TNR deletions
through BER. During the weak DNA synthesis-mediated TNR deletions, weak DNA
synthesis of pol βY265C and pol ν resulted in addition of fewer repeats than those
removed by FEN1 (Figure 2.3 and Figure 2.4). This further suggests that regulation of
TNR instability through BER is governed by the balance between the synthesis of TNRs
by the polymerases and the cleavage of TNRs by the nucleases such as FEN1 and
Mus81/Eme1. Our results further demonstrate that translesion DNA synthesis can
actively involved in modulating TNR instability during DNA replication and repair.
In our current study, we also demonstrated that the sequence of TNR tracts may
play a role in modulating TNR instability by altering DNA synthesis activity of repair
DNA polymerases. TNRs such as (GAA/CTT)n, (CAG/CTG)n, and (CGG/GCC)n have
increasing thermostabilities because their GC pairs in each repeat unit increases, and the
repeats with higher thermostabilities are more challenging for DNA polymerases to
separate them to perform the strand displacement synthesis. This may reduce the
efficiency of TNR synthesis by pol β and pol ν, leading to weak synthesis of TNRs
during BER. We found that pol βY265C performed similary level of DNA synthesis on
(CAG/ CTG)n and (CTG/ CAG)n tracts, resulting similar deletions of TNRs during BER.
Pol ν exhibited weak DNA synthesis activity and promoted more severe deletions of
(CGG/GCC)n than it did on (CAG/CTG)n (compare the height of the peaks in Figure 2.7B
to that in Figure 2.4B with the concentrations of 2 nM and 5 nM of pol ν). The sequence

116

differences in DNA synthesis and repeat instability may attribute to the higher
thermostability of (CGG/GCC)n than that of (CAG/CTG)n. On the other hand, pol θ
exhibited a marked difference in DNA synthesis on the (GAA/CTT)n from that on the
(CAG/ CTG)n, causing different outcomes of repeat instabities. On the (CAG/CTG)n, pol
θ exhibited similar DNA synthesis activity as pol β and did not alter the instability of
(CAG/ CTG)n (Figure 2.5). However, it performed weaker DNA synthesis activities on
(GAA/CTT)20 tract and resulted in GAA repeat deletion (Figure 2.8). The results indicate
that pol θ may not be able to efficiently bind to a more dynamic upstream 3’-OH in the
upstream strand of the GAA repeat tract during BER of a base lesion located in the
middle of the repeat tract. In addition, DNA sequences may also affect DNA synthesis
activities of polymerases on the TNRs: polymerases have stronger DNA synthesis on
their preferred template. This is supported by the fact that the translesion polymerase, pol
η, binds more tightly to the sequence that can form G-quadruplex and performe more
efficiently DNA synthesis than that of the random sequence, whereas pol ε has a reduced
binding and synthesis on the same sequence that can form G-quadruplex [265].
Moreover, pol ι has a preference to incorporate nucleotides opposite to a template A
[266], and pol ν has preferentially misincorporates dTTP to a template G [267]. The
substrate preferences and different DNA synthesis fidelity of DNA polymerases may
further explain the differences of DNA synthesis activities on different repeat sequence,
particularly with the weaker DNA synthesis of pol ν on the CGG repeats than on the
CAG repeats.
Since deletions of GT and telomere repeats are associated with cancers and agingrelated diseases [184, 256], here, we also evaluated how the weak DNA synthesis activity

117

can affect instability of GT repeats and telomere repeats (TTAGGG repeats) during BER.
Our results showed that WT pol β and pol βY265C did not exhibit significant differences
in synthesizing GT repeats and TTAGGG repeats as well as in modulating the repeat
instability (compare Figure 2.11 to Figure 2.1-2 and Figure 2.6). The similar amount of
GT repeat deletion products induced by WT pol β and pol βY265C indicates that the
slightly weaker DNA synthesis activity of pol βY265C on GT repeats than that of WT pol
βY265C does not alter the outcome of GT repeat instability. On the other hand, the
telomere sequence requires at least 6 nucleotides for misalignments, which make it
difficult for the formation of secondary structures, especially on the template strand that
can facilitate repeat instability during BER. This is supported by our results showing that
neither WT pol β nor pol βY265C failed to cause repeat instability (Figure 2.12). The
results further suggest that inhibition of DNA synthesis of pol β can be employed to
contract expanded TNRs without significantly affecting the stability of other repeats that
are associated with development of cancers and aging-related diseases.
Taken together, our study has demonstrated that weak DNA synthesis activity of
repair DNA polymerases can lead to TNR deletion through BER. We found that repeat
sequence of TNRs can modualte altering DNA synthesis activities of polymerases and
thus contributes to a different outcome of TNR instability. We demonstrate that TNR
deletions can be induced by inhibiting DNA synthesis activity of pol β during BER, and
the inhibition of DNA synthesis does not affect instability of GT repeats and telomere
repeats. Our study further suggests that transient inhibition of DNA synthesis activity can
be potentially developed as a therapeutic strategy for treating TNR expansion
neurological disorders.
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ABSTRACT
Trinucleotide repeat (TNR) instability is associated over 40 neurodegenerative
diseases including Huntington’s disease. Previous studies have indicated that PCNA
promotes FEN1 5’-flap cleavage activity to prevent TNR expansion. Yet the role of posttranslational modification of PCNA in TNR instability remains to be elucidated. Recent
studies have indicated that monoubiquitinated PCNA (ub-PCNA) can physically interact
with the Fanconi anemia-associated nuclease 1 (FAN1), which is a 5’-endo/exonuclease
and a genetic modifier of polyglutamine diseases including Huntington’s disease. This
suggests that ub-PCNA may modulate TNR instability by cooperating with FAN1. In our
current study, we discover that ub-PCNA stimulated 5’-3’ exonucleolytic activity of
FAN1 in processing a TNR hairpin, which destabilized a hairpin, converting it into a flap
that was then cleaved by FAN1 5’-endonuclease activity or FEN1. The coordination
among ub-PCNA, FAN1, and FEN1 led to removal of TNR hairpins, preventing TNR
expansion. Our study provides the first evidence that the cooperation among ub-PCNA,
FAN1, and FEN1 plays a critical role in preventing TNR expansions. Our study further
suggests that an essential role of post-translation modification of PCNA in maintaining
TNR stability by coordinating nucleases in removing secondary structures during BER on
TNRs.
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INTRODUCTION
Trinucleotide repeat instability is associated with more than 40 neurodegenerative
diseases including Huntington’s disease (CAG)n, fragile X syndrome (CGG)n,
Friedreich’s ataxia (GAA)n, and myotonic dystrophy (CTG)n [88, 89, 92]. Trinucleotide
repeat expansions can occur during maternal transmission or after cellular differentiation
[92]. However, rencent studies show that BER is responsible for TNR expansions in postmitotic neuron cells [2, 14, 122]. Base excision repair mediates TNR expansions is
supported by the fact that oxidative DNA damage facilitates TNR expansions in somatic
cells through multiple rounds of BER in TNR tracts [14, 123, 131]. Base excision repair
contributes to TNR expansions is further supported by the fact that TNR expansions
consistently occur in the neuronal cells of Huntington’s disease transgenic mice through
the repair of 8-oxoG [14]. The mechanism of BER mediated TNR instability has been
proposed that the formation of secondary structures, such as hairpins, loops, and G4quadruplex, which disrupts enzymatic coordination during BER, lead to extra repeat
synthesized by DNA polymerases or removal of extra repeats by nucleases, resulting in
repeat expansions or deletions [1, 5, 7, 142]. It has been found that inefficient cleavage
from flap endonuclease 1 (FEN1) promotes TNR expansions through BER [1, 5]. The
hairpins inhibit FEN1 5’-flap cleavage and force the enzyme to adopt an alternate flap
cleavage of a short flap, resulting in ligation of a TNR hairping and repeat expansions [1,
5]. In addition, the mismatch repair protein complex, MSH2-MSH3, inhibits FEN1
cleavage by binding and stabilizing a TNR hairpin or loop that formed on downstream
damage strand, while it stimulates the synthesis of TNRs by pol β [2]. Moreover, a low
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level of FEN1 and high level of pol β has also been observed in the neuronal cells of
striatum of Huntington’s disease (HD) mice that exhibits an abundance of CAG repeat
expansions, suggesting that FEN1 plays a critical role in preventing TNR expansion by
efficiently removing the repeats during BER [122, 144]. Facilitation of the removal of
TNRs by other nucleases can also prevent TNR expansion and promote TNR deletions
[9, 145]. The 3’-5’ exonucleolytic activity of AP endonuclease 1 (APE1) can remove
TNRs from the upstream strand exonucleolytically during BER of a TNR tract [9]. The
Mus81/Eme1 can remove upstream 3’-flap endonucleolytically [145]. In cooperating
with FEN1, APE1 and Mus81/Eme1 facilitate the removal of TNRs, thereby suppressing
TNR expansions [9, 145]. Other DNA nucleases including Exonucelase 1 (EXO1),
Xeroderma pigmentosum complementation group G endonuclease (XPG), and Fanconi
anemia-associated nuclease 1 (FAN1) [170, 268] may also facilitate the removal of TNRs
and prevent repeat expansions. In particular, FAN1 may participate in suppressing TNR
expansions since single nucleotide polymorphisms of FAN1 have been associated with
early or late onset of HD [173, 174]. Fanconi anemia-associated nuclease 1, which
possesses both 5’-3’ exonucleolytic activity [269] and 5’-flap endonucleolytic activity
[270], may cooperate with FEN1 in removing TNR hairpins and prevent repeat
expansions.
Proliferating cell nuclear antigen is a DNA replication and repair cofactor, which
acts as a central regulator to facilitate DNA replication and DNA repair through proteinprotein interactions [77]. At least 200 proteins contain the PCNA-interacting protein
(PIP) box, a conserved 8-amino-acid motif that can physically interact with PCNA [78].
During BER in TNRs, PCNA assists in resolving a hairpin structure by stimulating FEN1
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5’-flap endonucleolytic activity and LIG I catalytic activity and thus facilitates shortening
of the expanded TNR [149]. PCNA can also regulate its binding partners through the
monoubiquitination of PCNA [4]. Monoubiquitination of PCNA can be induced by DNA
damage agents such as methyl methanesulfonate (MMS) and UV irradiation [167].
Repair of MMS-induced alkylating DNA damage is subjected to the BER pathway [168],
indicating that PCNA can be monoubiquitinated during repair of base lesions. In fact, ubPCNA can physically interact with FAN1 with a high binding affinity via the ubiquitinbinding zinc domain (UBZ) and a non-canonical PIP box located at the N-terminal
domain of FAN1 [159, 160], suggesting a potential role of FAN1 in BER-mediated TNR
instability that can be regulated by ub-PCNA. To test this possibility, we chareacterize the
effects of ub-PCNA on FAN1 during BER and find that ub-PCNA stimulated the 5’-3’
exonucleolytic activity of FAN1. The stimulation allowed FAN1 to resolve a CAG repeat
hairpin structure by destabilizing the hairpin through its 5’-3’-exonuclease leading to the
removal of the hairpin through BER. Our study provides the first evidence that the
coordination between ub-PCNA and FAN1 plays a critical role in suppressing TNR
expansions during BER. Our study further suggests that an essential role of posttranslation modification of PCNA in maintaining TNR stability by coordinating DNA
nucleases in removing secondary structures during BER.

MATERIALS AND METHODS
Materials and oligonucleotide substrates
DNA oligonucleotide substrates were synthesized by Integrated DNA
Technologies (Coralville, IA, USA). The Cordycepin (3’-deoxyadenosine) 5’-
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triphosphate 3’-α-32P (5000 mCi/mmol) and γ-32P ATP (6000 mCi/mmol) were purchased
from PerkinElmer (Boston, MA). Terminal deoxynucleotidyl transferase and T4
polynucleotide kinasewere were purchased from Thermo Fisher Scientific (Waltham,
MA). Micro Bio-Spin 6 Columns were purchased from Bio-Rad Laboratories (Hercules,
CA). All other standard chemical reagents were purchased from Sigma-Aldrich (St.
Louis, MO) or Thermo Fisher Scientific (Waltham, MA). Purified human enzymes
including APE1, wild-type pol β, FEN1, and DNA LIG I were made according to the
protein purification procedures described previously [51, 145]. Human ubiquitin was
purchased from Boston Biochem (Boston, MA).

Oligonucleotide substrates
The nicked flap substrate containing a (CAG)15 was made by annealing the
upstream primer, downstream primer, and the template strand with a molar ratio of 4:1:2.
The hairpin substrate containing a (CAG)11 hairpin and a nicked (CAG)1 5’-flap was
made by annealing the upstream primer, downstream primer, and the template strand with
a molar ratio of 4:1:2. The sequences of substrates are listed in Table 3.

Table 3. Oligonucleotide Sequences
Oligonucleotide
nt
5’-flap substrate

Upstream strand-(CAG)15

65

Sequence (5’-3’)

CGA GTC ATC TAG CAT CCG TA CAG
CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
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Downstream strand-(CAG)15

65

CAG CAG CAG CAG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAG TA CGT AGA CTT ACT CAT TGC

Template strand-(CAG)20

99

GCA ATG AGT AAG TCT ACG TA CTG
CTG CTG CTG CTG CTG CTG CTG
CTG CTG CTG CTG CTG CTG CTG TA
CGG ATG CTA GAT GAC TCG

Upstream strand

38

CGA GTC ATC TAG CAT CCG TA GCA
GTC CTC TAG TCG TAG

Downstream strand

65

CAG CTC GAG TGG CAG CAG CAG
CAG CAG CAG CAG CAG CAG CAG
CAGTA CGT AGA CTT ACT CAT TGC

Template strand

100

GCA ATG AGT AAG TCT ACG TA CCA
CTC GAG CTA CGA CTA GAG GAC
TGC TAC GGA TGC TAG ATG ACT CG

Hairpin substrate

Protein purifications
The recombinant plasmids of UBE1 (Ube1/pET21d) and UbcH5c S22R (UbcH5c
S22R pET28a) were purchased from Addgene (Cambridge, MA). The expression vector
with UBE1 and UbcH5c S22R were then transformed into E. coli BL21DE3 purchased
from Thermo Fisher Scientific (Waltham, MA). The recombinant FAN1/pGEX-2T
plasmid was a gift from Dr. Josef Jiricny from the University of Zurich.
Purification of FAN1 is followed by the procedures described previously [271273].
The purification of human PCNA was followed by the procedures described
previously [274] with modifications. The PCNA/pT-7 was transformed and expressed in
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E. coli BL21DE3 (Agilent Technologies, Santa Clara, CA), which was sequentially
inoculated and expressed in 6 L LB with OD researched to 0.6 with addition of 1 mM
IPTG. Cell pellets were resuspended in the lysis buffer with the pH at 7.5 that contains
0.1 M KCl, 20 mM Tris-HCl (pH 7.5), 30 mM spermidine, 10% sucrose, 0.5 mM
ethylenediaminetetraacetic acid (EDTA), 2 mM dithiothreitol (DTT), and 0.2 M
phenylmethylsulfonyl fluoride (PMSF). The PCNA was purified followed by a 7-column
procedure. Briefly, soluble proteins and cell debris were separated by centrifugation at
12,000 rpm, 4°C for 30 min. The supernatant was subjected to 40 ml P11 column from
Sigma-Aldrich (St. Louis, MO) for purification. Proteins were eluted by elution buffer
containing 0.1 M KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10% glycerol, 2 mM
DTT, and 0.2 mM PMSF. The flowthrough was collected and applied to the 12-ml DEAE
sepharose column from Thermo Fisher Scientific (Waltham, MA). The protein was eluted
with buffer containing 0.5 M KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10%
glycerol, 2 mM DTT, and 0.2 mM PMSF. Peak fractions were collected and dialyzed into
buffer that contains 1 M ammonium sulfate, 50 mM KCl, 20 mM Tris-HCl (pH 7.5), 0.5
mM EDTA, 10% glycerol, 2 mM DTT, and 0.2 mM PMSF. The hPCNA was eluted with
buffer containing 50 mM KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10% glycerol,
2 mM DTT, and 0.2 mM PMSF. The peak fractions were then combined and dialyzed
into the buffer A containing 0.1 M KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10%
glycerol, 2 mM DTT, and 0.2 mM PMSF. Proteins were then separated by the 10-ml Q
sepharose column (GE Healthcare Bio-Sciences, Pittsburgh, PA) with the elution buffer
containing 0.8 M KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10% glycerol, 2 mM
DTT, and 0.2 mM PMSF. The peak fractions were combined and dialyzed into the buffer
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A. Proteins were then applied to Heparin-Sepharase column (GE Healthcare BioSciences, Pittsburgh, PA) and the flowthroughs were then dialyzed into the buffer
containing 0.2 M KCl, 50 mM sodium acetate (pH 5.5), 0.5 mM EDTA, 10% glycerol, 2
mM DTT, and 0.2 mM PMSF. The flowthroughs were then collected for final purification
with Mono Q (GE Healthcare Bio-Sciences, Pittsburgh, PA) with the elution buffer
containing 1 M KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10% glycerol, 2 mM
DTT, and 0.2 mM PMSF. Peak fractions were combined and dialyzed into the storage
buffer containing 150 mM KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10% glycerol,
2 mM DTT, and 0.2 mM PMSF. The hPCNA was then aliquoted and froze at -80°C for
storage.
The UBE1 was expressed in E. coli BL21DE3 AI strain (Agilent Technologies,
Santa Clara, CA). Cells transformed with UBE1/pET21 plamids were inoculated into 1 L
LB with OD researched to 0.6, UBE1 was expressed with addition of 1 mM IPTG and
0.1% arabinose. Cell pellets were resuspended in the lysis buffer that contains 50 mM
NaH2PO4 (Ph7.8), 300 mM NaCl, 30 mM imidazole, 10 mM EDTA, 10 mM DTT, 1 mM
PMSF, 1 mM benzamidin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin A. Soluble proteins
and cell debris were then separated by centrifugation at 12,000 rpm, 4°C for 30 min. The
supernatant was subjected to Ni-NTA agarose column from Qiagen (Hilden, Germany)
for purification. Proteins were eluted with elution buffer containing 50 mM NaH2PO4
(pH7.8), 300 mM NaCl, 500 mM imidazole, and 1 mM PMSF. Peak fractions were
collected and dialyzed into buffer that contains 50 mM NaCl, 20 mM Tris-HCl (pH 7.8),
and 1 mM PMSF. Proteins were separated by Mono Q column (GE Healthcare BioScience) with the elution buffer containing 400 mM NaCl, 20 mM Tris-HCl (7.8), and 1
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mM PMSF. Eluted peak fractions were combined, aliquoted, and froze at -80°C for
storage.
The UbcH5c S22R (UbcH5c S22R pET28a) plasmids were transformed in E. coli
BL21DE3 (Agilent Technologies, Santa Clara, CA). A bacterial colony was sequentially
inoculated into 1 L LB with OD researched to 0.8. The UbcH5c S22R was expressed with
addition of 1 mM IPTG. The UbcH5c S22R was initially purified with the Ni-NTA
column and then purified with SP column. Cell pellets were resuspended in the lysis
buffer that contains 50 mM NaCl, 20 mM Bis-tris (pH 6.0), 1 mM EDTA, 1 mM PMSF, 1
mM benzamidin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin A. Soluble proteins and cell
debris were then separated by centrifugation at 12,000 rpm, 4°C for 30 min. The
supernatant was subjected to SP column (GE Healthcare Bio-Science) for purification.
Proteins were eluted with elution buffer containing 1 M NaCl, 20 mM Bis-tris (pH 6.0), 1
mM EDTA, and 1 mM PMSF. Peak fractions were collected and dialyzed into buffer that
contains 50 mM NaCl, Tris-HCl (pH 7.8), and 1 mM PMSF. Proteins were separated by
Mono Q column (GE Healthcare Bio-Science, Uppsala, Sweden) with the elution buffer
containing 400 mM NaCl, 20 mM Tris-HCl (7.8), and 1 mM PMSF. Eluted peak fractions
were combined and dialyzed into the storage buffer that contains 25 sodium phosphate,
150 mM NaCl, and 20% glycerol at pH 7.0. UbcH5c S22R was then quoted and froze at 80°C for storage.

In vitro construction and purification of ub-PCNA
The in vitro ubiquitination of PCNA was performed according to the conditions
described in a previous study [275]. The reaction-condition was optimized, and the final
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reaction was assembled on ice in a 500-ul reaction mixture containing 160 nM Ube1, 32
uM UbcH5c S22R, 32 uM ubiquitin, and 16 uM PCNA with the buffer conditions of 50
mM MMT (pH 9.0), 25 mM NaCl, 3 mM MgCl2, 0.5 mM TCEP, and 3 mM ATP. The
reactions were incubated in the water bath at 37 °C for 2 h.
The reaction-mixtures were further dialyzed into the buffer A, and the ub-PCNA
was then purified by a 3-column procedure. The proteins were then subjected to the 10ml Q sepharose column (GE Healthcare Bio-Science) with the elution buffer containing
0.8 M KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10% glycerol, 2 mM DTT, and
0.2 mM PMSF. The peak fractions were combined and then dialyzed into 1 M
ammonium sulfate, 50 mM KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10%
glycerol, 2 mM DTT, and 0.2 mM PMSF. The ub-PCNA protein was eluted out with 50
mM KCl, 20 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 10% glycerol, 2 mM DTT, and 0.2
mM PMSF. The peak fractions were pooled and dialyzed into the buffer A. The proteins
were subject to the Mono Q column with the same elution buffer for the PCNA
purification. The ub-PCNA was then dialyzed into the same storage buffer as PCNA.

In vitro enzymatic assays
FEN1 and FAN1 cleavage assays were performed by incubating FEN1 and FAN1
separately with 100 nM hairpin substrate and flap substratein reaction buffer that contains
50 mM Tris-HCl, pH 7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mg/ml BSA, and 0.01%
Nonidet P-40 along with 5 mM Mg2+ at 37°C for 15 min. The PCNA and the ub-PCNA
stimulation assays were performed by incubating FEN1 or FAN1 in the presence of
PCNA or ub-PCNA in the same condition described earlier. The 10-µl reaction mixture
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was assembled on ice, and the reaction-mixtures were quenched with addition of 10 µl
stopping buffer containing 95% formamide and 10 mM EDTA with incubation at 95°C
for 10 min. Substrates and products were further separated in a 15% urea-denaturing
polyacrylamide gel (PAGE) and detected by a Pharos FX Plus PhosphorImager (Bio-Rad
Laboratory, CA).

Reconstitution of BER
Reconstituted BER was performed by incubating purified FEN1 or FAN1 along
with LIG I with the CAG repeat hairpin- or flap-containing substrates (100 nM) in the
reaction mixture (10 µl) with the same reaction condition described earlier in the
Materials and Methods. Reaction mixtures were assembled on ice and incubated at 37°C
for 15 min. Reactions were then terminated by addition of 2X stopping buffer with 10min incubation at 95°C. Substrates and products were then separated in 15% ureadenaturing PAGE and detected by a PhosphorImager.

RESULTS
PCNA purification
PCNA is a homotrimer protein with the total molecular weight (MW) of 87 kDa.
The isoelectric point (pI) of PCNA is 4.53. Our previously purified PCNA with Nterminal His-tag was not correctly assembled as homotrimer. Since the His-tag may affect
the protein folding, we used PCNA/pT 7 plasmid, which generates a non-tagged PCNA.
Since the challenge of the purification of un-tagged PCNA is to eliminate the nuclease
and Pol I contaminations, so in each step we have tested the nuclease and Pol I
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contaminations in addition to SDS-PAGE to verify the purified protein and to determine
the contamination of fractions during purification. Initially, we have verified the
expression of PCNA. Since the SDS-PAGE is a denaturing gel, the denatured PCNA
protein is shown as a monomer with the MW of 27 kDa, after verification of the
expression level, the purification was followed by a 7-column purification. Our strategy
in purifying the un-tagged PCNA focused utilization of the charge statuts and
hydrophobicity of PCNA protein.
For the first column, we used the P11 column at pH of 7.5. This column was
efficient in removing the DNA that bound to the PCNA. Since the PCNA is a DNA
binding protein, the negatively charged resins bound to PCNA, which helped to remove
DNA from cell lysates. Since PCNA was negatively charged at pH 7.5, the protein was
eluted out into the flowthrough (Figure 3.1). After verifying the size of PCNA with SDSPAGE, the peak fractions containing PCNA were then pooled and applied directly to the
10-ml DEAE column (Figure 3.2). DEAE resins were positively charged at pH 7.5, so the
negatively charged PCNA bound to the DEAE resins along with other proteins. After
elution, the fractions were tested with SDS-PAGE, and protein concentrations were
measured. Majority of the contaminants were removed during the flowthrough and the
wash steps (Figure 3.2B-D). The peak fractions (E5-E9) containing PCNA were pooled
and dialyzed into the buffer for the Phenyl Sepharose column.
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Figure
3.1.
P11
phosphocellulose
cation
exchange
chromatography of PCNA.
A. Chromatography profile of fractions after DEAE
chromatography. The X-axis represents all the flowthrough and
wash fractions. The Y-axis indicates the total amount of protein in
each fraction.

Figure 3.2. DEAE ion-exchange chromatography of PCNA.
A. Chromatography profile of fractions after DEAE chromatography. The X-axis
represents the elution fractions. The Y-axis indicates the total protein in each
fraction. B, C and D. Coomassie strained PAGE analysis of selective fractions
after DEAE chromatography of PCNA (29 kDa). Selected fractions from
flowthrough (F), wash (W) and elution (E) were analyzed in determining the
cleaner peak fractions that contains PCNA for purification with next column.
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The third column is the Phenyl Sepharose column (Figure 3.3), and the
purification was based on the hydrophobicity of of different proteins. PCNA was eluted
out with ammonium sulfate concentration between 0.2- 0.8 M. Since the PCNA was
eluted out with a very broad range of salt concentrations, we have tested every fraction
with the SDS-PAGE. Not surprisingly, the PCNA was in each fraction (Figure 3.3B-E).
We further tested the nucleases and Pol I contaminations. The fractions of E8-E17 have
the minimum amount of the nucleases contamination (Figure 3.3G, lanes 5-14). On the
other hand, the fractions of E11-E27 were highly contaminated with Pol I (Figure 3.3F,
lanes 6-16). However, based on our previous PCNA purification, nuclease contamination
was more challenging to be eliminated than that of Pol I contamination. We combined the
fraction E8-E17 for dialysis and prepared for the 4th column: Q column (5 ml) (Figure
3.4). After verified with SDS-PAGE, PCNA was eluted out between fractions of E18-E24
(Figure 3.4B and 3.4C). With further verification of Pol I and nuclease contamination, we
observed that Pol I was eliminated in the flowthrough and early wash steps (Figure 3.4D,
lanes 2-3). Since fraction E19 and later fractions have the minimal nuclease
contamination (Figure 3.4F, lanes 18-24), we combined and dialyzed those fractions for
the purification with the Heparin-Sepharose column (10 ml).
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Figure 3.3. Phenyl sepharose chromatography of PCNA.
A. Chromatography profile of fractions after phenyl sepharose chromatography. The
X-axis represents the elution fractions. The Y-axis indicates the total protein in each
fraction. B. Coomassie strained PAGE analysis of selective fractions after phenyl
sepharose chromatography of PCNA (29 kDa). OP depicts as on-put, which is the
protein before loading to phenyl sepharose chromatography. Selected fractions from
flowthrough (F), wash (W) and elution (E) were analyzed in determining the cleaner
peak fractions that contains PCNA for purification with next column.

Figure 3.3. Phenyl sepharose chromatography of PCNA.
C, D and E. Coomassie strained PAGE analysis of selective fractions after phenyl
sepharose chromatography of PCNA (29 kDa). OP depicts as on-put, which is the
protein before loading to phenyl sepharose chromatography. Selected fractions from
flowthrough (F), wash (W) and elution (E) were analyzed in determining the cleaner
peak fractions that contains PCNA for purification with next column.
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Figure 3.3. Phenyl sepharose chromatography of PCNA.
F. Pol I contamination test with selected fractions after phenyl sepharose
chromatography. G. Nuclease contamination test with selected fractions after phenyl
sepharose chromatography. Sub depicts as substrate only. OP depicts as on-put,
which is the protein before loading to phenyl sepharose chromatography. Selected
fractions from flowthrough (F), wash (W) and elution (E) were analyzed in
determining the cleaner peak fractions that contains PCNA for purification with next
column.

134

Figure 3.4. Q sepharose anion exchange chromatography of PCNA.
A. Chromatography profile of fractions after Q sepharose anion exchange
chromatography. The X-axis represents the elution fractions. The Y-axis indicates the
total protein in each fraction. B and C. Coomassie strained PAGE analysis of
selective fractions after after Q sepharose anion exchange chromatography of PCNA
(29 kDa). OP depicts as on-put, which is the protein before loading to this column.
Selected fractions from flowthrough (F), wash (W) and elution (E) were analyzed in
determining the cleaner peak fractions that contains PCNA for purification with next
column.
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Figure 3.4. Q sepharose anion exchange chromatography of PCNA.
D. Pol I contamination test with selected fractions after Q sephearose anion
chromatography. E. Nuclease contamination test with selected fractions after Q
sepharose anion exchange chromatography. Sub depicts as substrate only. OP
depicts as on-put, which is the protein before loading to this column. Selected
fractions from flowthrough (F), wash (W) and elution (E) were analyzed in
determining the cleaner peak fractions that contains PCNA for purification with
next column.

Heparin Sepharose is a resin that can be used to separate proteins relying on the
binding affinity for heparin (GE handbook) and can be used to purify coagulation factors,
DNA binding proteins, lipoproteins. Previous studies have successfully separated
prototype foamy virus integrase from bacterial nucleases by using heparin column [276],
indicating Heparin Sepharose might be a reliable method to eliminate nuclease
contamination. In our purification, the PCNA was directly eluted out from the
flowthrough step (Figure 3.5), and the fractions were then pooled and dialyzed with the
buffer at pH 5.5 for the second round of Heparin Sepharose purification (Figure 3.6).
After the second round the Heparin Sepharose column, the fractions from the
flowthrough and wash step were then combined and dialyzed for the final purification
with Mono Q column (Figure 3.7).
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Figure 3.5. The first Heparin chromatography of PCNA.
Coomassie strained PAGE analysis of selective fractions after the first heparin
affinity chromatography of PCNA (29 kDa). OP depicts as on-put, which is the
protein before loading to this column. All the fractions from flowthrough (F), wash
(W) were analyzed in determining the cleaner peak fractions that contains PCNA for
purification with next column.

Figure 3.6. The second Heparin chromatography of PCNA.
A. Chromatography profile of fractions after the second heparin affinity
chromatography. The X-axis represents the flowthrouth, wash and elution fractions.
The Y-axis indicates the total protein in each fraction. B and C. Coomassie strained
PAGE analysis of selective fractions after after the second heparin affinity
chromatography of PCNA (29 kDa). OP depicts as on-put, which is the protein
before loading to this column. All the fractions from flowthrough (F), wash (W)
were analyzed in determining the cleaner peak fractions that contains PCNA for
purification with next column.
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Mono Q resin was positive charge at pH 7.5, so it concentrated PCNA in the
column. The PCNA was eluted out during the elution step (Figure 3.7B and 3.7C). The
Pol I and nuclease contaminations were tested. No Pol I contamination was observed
(Figure 3.7D) and only very limited nuclease contamination existed in the peak fractions
of E22-E24 (Figure 3.7E, lanes 17-19). The peak fractions (E22-E32) were also tested for
the functional stimulation of FEN1 5’-flap endonuclease activity. Compared to the FEN1
alone and BSA control (Figure 3.7F, lanes 2-3), all PCNA from the peak fractions
stimulated FEN1 cleavage (Figure 3.7, lanes 6-16). Therefore, the fractions of E25-E32
were combined and dialyzed into the storage buffer for the future experiments.
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Figure 3.7. Mono Q anion exchange chromatography of PCNA.
A. Chromatography profile of fractions after Mono Q anion exchange
chromatography. The X-axis represents the elution fractions. The Y-axis indicates
the total protein in each fraction. B and C. Coomassie strained PAGE analysis of
selective fractions after Mono Q anion exchange chromatography of PCNA (29
kDa). Selected fractions from flowthrough (F), wash (W) and elution (E) were
analyzed in determining the cleaner and functional peak PCNA for storage.
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Figure 3.7. Mono Q anion exchange chromatography of PCNA.
D. Pol I contamination test with selected fractions after Mono Q anion exchange
chromatography. E. Nuclease contamination test with selected fractions after Mono
Q anion exchange chromatography. OP depicts as on-put, which is the protein before
loading to this column. F. Functional stimulation of FEN1 nuclease cleavage activity
by PCNA. Lane 1 represents substrate only. Lane 2 represents FEN1 alone. Lane 3
illustrates the negative control of BSA in stimulating FEN1 cleavage. Lane 4
illustrates the positive control of PCNA (Enzymax, Lexington, KY) in stimulating
FEN1 cleavage. Selected fractions from flowthrough (F), wash (W) and elution (E)
were analyzed in determining the cleaner and functional peak PCNA for storage.

UBE1, UbcH5c S22R purification
The UBE1 has the MW of 118 kDa with carboxyl-terminal polyhistidine-tag. The
pI of UBE1 is 4.53. The UBE1 did not express well in the BL21 DE3 strain. The
expression of UBE1 in BL21 DE3 AI strain gave a higher yield (Figure 3.8). The
purification of UBE1 has subjected to 2 columns: the Ni-NTA column and the Mono Q
column. The UBE1 bound well with the Ni-NTA resins as it was eluted during the elution
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step. The peak fractions were combined and dialyzed, which were then subjected to the
Mono Q column (Figure 3.9).

Figure 3.8. Expression of UBE1 and UbcH5c S22R.
Coomassie strained PAGE analysis of expression of UBE1 (118 kDa) and UbcH5c
S22R (17.5 kDa). The protein without and with the induction of IPTG were
depicted as –IPTG and +IPTG, respectively.

Figure 3.9. The Mono Q anion exchange chromatography of UBE.
Coomassie strained PAGE analysis of selective elution fractions after the first
heparin affinity chromatography of UBE1 (118 kDa).

On the other hand, the UbcH5c S22R has the MW of 17.5 kDa with C-terminal
His-tag. The pI of UBE1 is 7.76. The E2 was efficiently expressed by E. coli BL21 DE3
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(Figure 3.8). However, E2 protein did not bind to the Ni-NTA resin. We then optimized
the purification procedures and purified the protein with SP column (Figure 3.10). The
peak fractions of E12-E17 were pooled and dialyzed and later concentrated with Mono Q
column.

Figure 3.10. The SP sepharose cation exchange chromatography of UbcH5c
S22R.
Coomassie strained PAGE analysis of selective elution fractions after the SP
sepharose cation exchange chromatography of UBE1 (17.5 kDa).

In vitro construction of ub-PCNA and ub-PCNA purification
Ubiquitination of PCNA in vivo requires the E1 ubiquination activating enzymes,
E2 ubiquitination conjugases, and E3 ubiquitin ligases. These three enzymes coordinate
the transportation of ubiquitin to the substrate protein [277, 278]. The E1 protein initiates
the activation of ubiquitin by covalently attaching the ubiquitin to its cysteine residue
[277, 278]. The activated ubiquitin can then be conjugated to the cysteine residue of E2
[279]. The E3 determines the target specificities by transferring the ubiquitin from E2 to
the target protein [280].
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Ubiquitination of PCNA in vivo is initiated by the RAD6-RAD18 (E2/E3
complex)-mediated monoubiquitination of lsysine164 residue of PCNA during DNA
repairs [162, 163]. Rad 6 is capable of catalyzing formation of ubiquitin chains, while the
RAD18 competitively binds to the ubiquitin, which constrains only one ubiquitin
molecule covalently attached to Lsy164 of PCNA [162].
According to the conditions described previously [275], we have successfully
generated monoubiquitinated PCNA at lysine164 by using E1 (UBE1) and E2 (UbcH5c
S22R) in vitro. However, only 60% of PCNA was ubiquitinationationed (Figure 3.11A, 14). In addition, the impurities in the factions of ub-PCNA may compromise our
experiments and complicate the purification of ub-PCNA since the ub-PCNA does not
have significantly difference of pI, hydrophobicity, and molecular weight from PCNA. To
solve the problem, we systematically tested different conditions for ubiquitination of
PCNA. The optimized condition as described in the Materials and Methods led to 95%100% ubiquitination of PCNA (Figure 3.11B, 1-6).

Figure 3.11. Mono-ubiquitination of PCNA.
Coomassie strained PAGE analysis of the yield of the monoubiquited PCNA (37.5
kDa). A. Mono-ubiquitination with low yield. Lanes 1-4 depict the ubiquitination
reactions in a 10-ul reaction. PCNA, UB, UBE1 and UbcH5c illustrate the control
of each protein. B. Monoubiquitination of PCNA under an optimal monoubiquitination.
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To remove the bacterial contaminants in the ub-PCNA fractions, we performed
the purification of ub-PCNA with additional 3 columns to eliminate contaminations of
Pol I and bacterial nuclease as well as to remove the extra ubiquitin, E1, and E2, which
were introduced during the ubquitination reaction. The ub-PCNA was initially subjected
to Q column (Figure 3.12) at pH 7.5. The ubiquitin and E2 were separated with the ubPCNA during the flowthrough and wash steps (Figure 3.12B). The eluted ub-PCNA
fractions (37.5 kDa) were fairly clean (Figure 3.12C). Contaminations of bacterial Pol I
and nucleases in the ub-PCNA fractions were tested. The results showed that Pol I was
successfully removed and went into the fractions from flowthrough and wash steps
(Figure 3.12D). However, nucleases were detected in the peak fraction of E13-14 (Figure
3.12E, lanes 11-12). We further tested the stimulation of pol η DNA synthesis activity by
ub-PCNA fractions. A stimulatory effect on pol η DNA synthesis by the peak ub-PCNA
fractions (E13-E16) was observed compared to pol η alone or to the BSA control (Figure
3.12F, compare lanes 6-9 to lanes 2-3). The peak fractions of ub-PCNA were combined,
dialyzed, and subjected to the Phenyl Sepharose column (Figure 3.13). The ub-PCNA
was eluted, and the peak fractions (E12-E19) were combined and subjected to the next
column (Figure 3.13A and 3.13C).
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Figure 3.12. Q sepharose anion exchange chromatography of ub-PCNA.
A. The chromatography profile of fractions of Q sepharose anion exchange
chromatography. The X-axis represents the flowthrough, wash and elution fractions.
The Y-axis indicates the total protein in each fraction. B and C. Coomassie strained
PAGE analysis of selective fractions after after Q sepharose anion exchange
chromatography of ub-PCNA (37.5 kDa). Selected fractions from flowthrough (F)
and elution (E) were analyzed. OP depicts as on-put, which is the protein before
loading to this column.
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Figure 3.12. Q sepharose anion exchange chromatography of ub-PCNA.
D. Pol I contamination of selected fractions from Q sephearose anion
chromatography was tested. E. Nuclease contamination of selected fractions from Q
sepharose anion exchange chromatography was examined. F. Functional stimulation
of pol η (10 nM) DNA synthesis activity by ub-PCNA. Lane 1 represents substrate
only. Lane 2 represents pol η alone. Lane 3 illustrates the negative control of BSA in
stimulating pol η DNA synthesis activity. Selected fractions from flowthrough (F)
and elution (E) were analyzed. Sub depicts as substrate only. OP depicts as on-put,
which is the protein before loading to this column.
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Figure 3.13. Phenyl sepharose chromatography of ub-PCNA.
A. The profile of phenyl sepharose chromatography of ub-PCNA fractions. The Xaxis represents the flowthrough, wash and elution fractions. The Y-axis indicates
the total protein in each fraction. B and C. Coomassie strained PAGE analysis of
selective fractions from phenyl sepharose chromatography of ub-PCNA (37.5
kDa). OP depicts as on-put..Selected fractions from flowthrough (F), wash (W)
and elution (E) were analyzed in determining the peak fractions that contain ubPCNA and its purity.
The ub-PCNA fractions were finally subjected to MonoQ column (Figure 3.14),
and the fractions were tested for the contamination of bacterial Pol I and nucleases.
Neither Pol I (Figure 3.14C) nor the nucleases were detected (Figure 3.14D).

Figure 3.14. Mono Q anion exchange chromatography of ub-PCNA.
A. The chromatography profile of Mono Q column of ub-PCNA fractions. The Xaxis represents the flowthrough, wash and elution fractions. The Y-axis indicates the
total protein in each fraction. B. Coomassie strained PAGE analysis of selective ubPCNA fractions from Mono Q sepharose anion exchange chromatography of ubPCNA (37.5 kDa). OP depicts as on-put, which was loaded on the column.
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Figure 3.14. Mono Q anion exchange chromatography of ub-PCNA
C. Pol I contamination of selected fractions from Q sephearose anion
chromatography was examined. D. Nuclease contamination of selected fractions
from Q sepharose anion exchange chromatography was examined. Sub depicts as
substrate only. OP depicts as on-put, which was loaded onto the column.

FEN1 and FAN1 have different substrate specificities on TNRs
Trinucleotide repeat expansions are mediated by the formation of the secondary
structures such as hairpins and loops [14]. TNR hairpins and loops are susceptible to
oxidative DNA damage since the exposure of the guanines towards outside of DNA
backbone in the hairpin region can increase the probability of oxidation compared to the
guanines that are buried inward when they basepair with cytosine [152, 153]. After the
OGG1 removes the 8-oxoG and APE1 generates a strand break, it forms a double flap
structure with 3’-flap and 5’-flap structures, and this double flap structure is dynamic and
can anneal back with the template strand, forming a big 5’-flap or a hairpin structure
(Figure 3.15) that can be cleaved by a 5'-flap endonuclease such as FEN1 and FAN1.
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Thus, we initially compared the cleavage activity of FEN1 and FAN1 on the substrates
with a 5'-(CAG)15 flap or with a downstream 5'-(CAG)11 hairpin, which mimic the
intermediates during BER of a base lesion on TNR tracts.

Figure 3.15. The 5’-flap and hairpin structures formed during BER in the
context of TNR tracts.

With the flap substrate, FEN1 at 5 nM, 10 nM, 50 nM, 100 nM, and 200 nM
removed the 5’-(CAG)15 flap (Figure 3.16A, lanes 4-8). FEN1 also removed the shorter
5’-(CAG)1 and 5'-(CAG)2 flaps, suggesting that FEN1 performed the alternate flap
cleavage in removing shorter 5’-flaps attached to the transient hairpins. In contrast, FAN1
at the same concentrations only removed the shorter 5’-(CAG)1 flap that was attached to
the transient hairpins (Figure 3.16A, lanes 12-15). The results indicated that FEN1
cleaved both the (CAG)15 flap and short flaps attached to a CAG repeat hairpin, whereas
FAN1 only cleaved a short CAG flap attached to a CAG repeat hairpin. Both FEN1 and
FAN1 alone failed to remove the transient hairpins.
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Figure 3.16. FAN1 and FEN1 have different cleavage patterns in cleaving TNR.
A. FAN1 and FEN1 cleavage activities were examined by incubating increasing
concentrations (0.1 nM, 1 nM, 5 nM, 10 nM, 50 nM, 100 nM, and 200 nM) of
FEN1 and FAN1 along with the substrate containing a 5’-(CAG)15-flap (illustrated
above the gel). Lane 1 represents the substrate only. Lanes 2-8 illustrate the FEN1
cleavage products with increasing concentrations of FEN1. Lanes 9-15 illustrates
the FAN1 cleavage products with the increasing concentrations of FAN1.

To further characterize the cleavage of FEN1 or FAN1 on a short flap that was
attached to a CAG repeat hairpin, we created a ahripin substrate containing a (CAG)11
hairpin and a 5'-(CAG)1 flap. With this hairpin substrate, both FEN1 (0.1 nM, 1 nM, 5
nM, 10 nM, 50 nM, 100 nM, and 200 nM) and FAN1 (5 nM, 10 nM, 50 nM, 100 nM, and
200 nM) efficiently removed the 5’-(CAG)1 flap (Figure 3.16B, lanes 2-8 and lanes 1115). The results further confirmed that FEN1 and FAN1 performed the alternate flap
cleavage activity during BER.
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Figure 3.16. FAN1 and FEN1 have different patterns in cleaving TNRs.
B. FAN1 and FEN1 cleavage activities were examined by incubating increasing
concentrations (0.1 nM, 1 nM, 5 nM, 10 nM, 50 nM, 100 nM, and 200 nM) of
FEN1 and FAN1 with the hairpin-containing substrate (illustrated in the figure).
Lane 1 represents the substrate only. Lanes 2-8 illustrate the FEN1 cleavage
products. Lanes 9-15 illustrates the FAN1 cleavage products.

Ub-PCNA does not stimulate FAN1 5’-endonucleolytic activity, but significanly
enhances FAN1 5’-3’ exonucleolytic activity
Previous studies show that ub-PCNA can physically interact with FAN1 with a
high binding affinity via UBZ and a non-canonical PIP box located at N-terminal domain
of FAN1 [159, 160]. The FAN1 possesses both 5’-endo and exonucleolytic activity. Yet it
remains unknown whether interaction between FAN1 and PCNA or ub-PCNA can affect
the 5’-end and exonucleolytic activity of FAN1. To test the possibility, we initially
determined the effects of PCNA and ub-PCNA on FAN1 5'-endonucleolytic activity by
using the 5'-(CAG)15 flap substrate. PCNA or ub-PCNA at 100 nM and 500 nM did not
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affect FAN1 cleavage of the (CAG)15 flap or the short (CAG)1 flap attached to a transien
hairpin (Figure 3.17A, compare lanes 2-5 to lanes 6-7). The results indicate that PCNA
and ub-PCNA did not stimulate FAN1 5’-endonucleolytic activity.

Figure 3.17. Ub-PCNA stimulates FAN1 5’-3’ exonucleolytic activity, but not its
5’-endonucleolytic activity.
The effects of ub-PCNA on the 5’-flap endonucleolytic activity of FAN1 (A) and
5’-3’ exonucleolytic activity of FAN1 (B). FAN1 (2 nM) was incubated with PCNA
or ub-PCNA along and 100 nM 5’-(CAG)15-containing substrate and the substrate
containing a (CAG)1 flap attached to a (CAG)11 hairpin. Lanes 1 and 8 represent the
substrate only. Lanes 6 and 9 represents FAN1 only. Lanes 2 and 10 represent FAN1
cleavage products in the presence of 100 nM of PCNA. Lanes 4 and 12 represent
FAN1 cleavage products in the presence of 500 nM PCNA. Lanes 3 and 11
represent FAN1 cleavage products in the presence of 100 nM of ub-PCNA. Lanes 5
and 13 represent FAN1 cleavage products in the presence of 500 nM ub-PCNA.
Lane 7 illustrates the BSA control.
We further determined whether PCNA and ub-PCNA could stimulate FAN1 5’-3’
exonucleolytic activity by using the hairpin-containing substrate. We found that FAN1
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cleavage generated 1-9 repeat cleavage products (Figure, 3.17B, lane 9), which reached
to 5'-end of the hairpin (the intermediates were illustrated on the right of the gel). The
result suggests that FAN1 5’-3’ exonucleolytic activity removed the short (CAG)1 flap
and continued to progressively cleave the annealed region until it reached to the 5'-end of
the hairpin. Surprisingly, we found that both PCNA and ub-PCNA significantly
stimulated FAN1 5’-3’ exonucleolytic activity (Figure 3.17B, lanes 10-13). However, ubPCNA stimulated FAN1 cleavage at a lower concentraion (100 nM) than PCNA (500
nM) (Figure 3.17B, compare lane 11 to lane 10). The results indicated that both PCNA
and ub-PCNA stimulate FAN1 5’-3’ exonucleolytic activity.
We then determined the stimulatory effects of PCNA on FEN1 cleavage of the
(CAG)15 flap and found that PCNA significantly stimulated FEN1 cleavage of the
(CAG)15 flap as well as the alternate flap cleavage of the short (CAG)1 flap at all the
concentrations (10 nM, 25 nM, 50 nM, 75 nM, 100 nM, 200 nM, and 500 nM) of PCNA
(Figure 3.18, lanes 3-9). The result is consistent with our previous study that PCNA
stimulates FEN1 cleavage of TNRs during BER [149].
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Figure 3.18. PCNA stimulates FEN1 5’-flap endonucleolytic activity on TNRs.
The effects of PCNA on the 5’-flap endonucleolytic activity of FEN1 (1 nM) at the
increasing concentrations (10 nM, 25 nM, 50 nM, 75 nM, 100 nM, 200 nM, and
500 nM). Lane 1 represents the substrate only. Lane 2 illustrates FEN1 only. Lanes
3-9 represent FEN1 cleavage products in the presence of increasing concentrations
of PCNA. The red circles illustrate number of the repeats that were removed.

FEN1 and FAN1 alone do not suppress TNR expansions
To further test whether FEN1 and FAN1 could suppress TNR expansion by
removing a TNR hairpin, we reconstituted BER with FAN1 or FEN1 and LIG I (5 nM).
To determine whether the stimulation of the FEN1cleavage and the 5’-3’ exonucleolytic
activity of FAN1 by PCNA and ub-PCNA could facilitate suppression of expanded TNRs,
we also reconsituted BER in the absence and presence of PCNA or ub-PCNA.
In the presence of 0.1 nM FEN1 and various concentrations of PCNA or ubPCNA (100 nM and 500 nM), 5 nM LIG I resulted in ligation of a hairpin (Figure 3.19B,
lanes 5-8), suggesting that FEN1 alone failed to suppress the expanded TNRs. On the
other hand, in the presence of 10 nM of FAN1 and the PCNA or ub-PCNA (100 nM and
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500 nM), 5 nM LIG I also resulted in ligation of a small amount of hairpins (Figure
3.19A, lanes 1-4). However, additional experiments need to be performed to verify
whether the stimulation of FAN1 5’-3’ exonuclease activity by PCNA and ub-PCNA
facilitates repeat deletions since ligation efficiency was low in the absence of DNA
polymerases that can fill in the gaps generated by 5’-3’ exonucleolytic cleavage of FAN1
in the presence of PCNA or ub-PCNA.

Figure 3.19. Effects of FAN1 and FEN1 on TNR instability.
The effects of FAN1 (10 nM) (A) and FEN1 (0.1 nM) (B) on TNR expansions
mediated by hairpin ligation. The reactions were performed by incubating FAN1 or
FEN1 with 100 nM PCNA or ub-PCNA together with 5 nM LIG I and 100 nM
hairpin containing substrates. Lanes 1 and 3 represent the ligation products in the
presence of FAN1 and PCNA (100 nM and 500 nM). Lanes 2 and 4 represent the
ligation products in the presence of FAN1 and ub-PCNA (100 nM and 500 nM).
Lanes 5 and 7 represent the ligation products in the presence of FEN1 and PCNA
(100 nM and 500 nM). Lanes 6 and 8 represent the ligation products in the presence
of FEN1 and ub-PCNA (100 nM and 500 nM).
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Ub-PCNA regulates a switch between FEN1 and FAN1 in removing a TNR hairpin
Since FAN1 and FEN1 exhibited different substrate specificity during BER in
TNRs, i.e., FAN1 5’-3’ exonuclease activity directly removed repeats on CAG repeat
hairpin and FEN1 removed 5’-CAG repeat flap, we then tested whether FAN1 and FEN1
could cooperate in removing a CAG repeat hairpin. We sequentially incubated the hairpin
substrate with FAN1 and FEN1. Pre-incubation of 10 nM FAN1 with the substrate
resulted in removal of up to 9 repeats (Figure 3.20A, lane 1). Subsequent addition of 5
nM FEN1 resulted in removal of 14 repeats (Figure 3.20A, lane 3). The results suggested
a cooperative cleavage between FEN1 and FAN1 in removing the big hairpin, thereby
suppressing TNR expansions during BER.
Since the recuirement of FAN1 can be initiated by ub-PCNA and our results
indicate that ub-PCNA facilitated FAN1 5’-3’ exonucleolytic activity on the hairpins, we
further tested whether the stimulation of FAN1 5’-3’ exonucleolytic activity on the
hairpin would destabilize the hairpin to convert it into a flap, which could be further
removed by FEN1, leading to suppression of expanded TNRs. We found that 10 nM
FAN1 and 250 nM ub-PCNA, FAN1 removed up to 14 repeats (Figure 3.20B, lane 4).
Subsequent addition of 5 nM FEN1 also increased the amount of cleavage products with
9-14 repeats (Figure 3.20B, lane 6). This further suggested that ub-PCNA regulated
FEN1 and FAN1 activities in removing a big hairpin and suppressed the TNR
expansions.
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Figure 3.20. Ub-PCNA facilitates FAN1 and FEN1 in removing a big hairpin.
The cooperative FAN1 and FEN1 cleavage was measured by sequentially
incubating 10 nM FAN1 and 5 nM FEN1 in the absence (A) and the presence (B) of
250 nM ub-PCNA along with 100 nM hairpin substrate. Lanes 1 and 4 represent the
FAN1 alone in the absence and the presence of ub-PCNA, respectively. Lanes 2 and
5 represent the FEN1 alone in the absence and the presence of ub-PCNA,
respectively. Lanes 3 and 6 represent sequential cleavage of FAN1 and FEN1 in the
absence and the presence of ub-PCNA. The red circles illustrate number of the
repeats have been removed.

DISCUSSION
Trinucleotide repeat instability is caused by the formation of secondary structures,
such as hiarpins and loops that disrupt the coordination of BER enzymes and cofactors,
can lead to imbalanced synthesis of TNRs by DNA polymerases and cleavage of TNRs
by nucleases [1, 5, 7, 142]. The BER cofactors, including the scaffold proteins [281, 282]
such as XRCC1 and PCNA, provide a platform for protein recruitment via proteinprotein interactions, thereby facilitating the BER coordination [68, 78, 281]. As a cofactor
of DNA replication and repair, PCNA can be involved in preventing TNR expansions by
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stimulating both FEN1 cleavage of TNRs and LIG I catalytic activity to promote TNR
deletion through physically interacting with both enzymes [147-149]. The studies
demonstrate a vital role of PCNA in modulating TNR stability. Proliferating cell nuclear
antigen can also regulate the activities of its binding partners through post-translational
modifications [159-161]. However, how the post-translational modifications of PCNA
may affect the TNR instability remains unknown. Here, we provided the first evidence
that monoubiquitination of PCNA plays an important role in preventing TNR expansion
by regulating the coordination between FEN1 and FAN1 to remove a TNR hairpin during
BER.
Faconi anemia-associated nuclease 1 has been implicated to play an important
role in modulating CAG repeat instability since the single nucleotide polymorphisms of
FAN1 are associated with early or late onset of HD and other polyglutamine diseases.
Our results show that FAN1 removed a small flap of (CAG)1, and continue to perform its
5’-exonucleolytic cleavage of CAG repeats, thereby leading to the removal of a CAG
repeat hairpin. Since FEN1 cannot remove the downstream hairpin, the ability of FAN1
to destabilize the hairpin cooperated with FEN1 to remove a TNR hairpin, thus
maintaining TNR stability. Our results showed that FAN1 used its 5’-3’ exonucleolytic
activity to progressively cleave TNRs and destabilized a downstream CAG repeat
hairpin. The cleavage by FAN1 converted the hairpin to a flap, which was then efficiently
removed by FEN1.
FAN1 can be recruited to DNA damage sites through binding to ub-PCNA or ubFANCD2 via its UBZ [160, 283]. However, we found that cleavage of the (CAG)14 flap
in the presence of both FAN1 and FEN1 did not increase compared with the condition
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with FAN1 alone (compare lane 6 of Figure 3.20B to lane 3 of Figure 3.20A). Moreover,
FEN1 cleavage of the flap was also decreased. The decreased of FEN1 cleavage products
may result from the weaker binding affinity of FEN1 to ub-PCNA. Because FAN1
contains a UBZ, and the binding affinity between FAN1 and the ub-PCNA is much higher
than that between PCNA and FEN1, which depends solely on the PIP box interaction. In
addition, the structural alignment of ub-PCNA with the PCNA-FEN1 complex reveals
that ubiquitin on the ub-PCNA overlaps with the active site of FEN1 in the PCNA-FEN1
complex [4]. This suggests that ub-PCNA interfere with FEN1 flap cleavage. Therefore,
the interaction between FAN1 and ub-PCNA makes the 5’-TNR flap inaccessible to
FEN1, leading to a weaker FEN1 cleavage of the (CAG)14 flap. It is possible that ubPCNA coordinated FAN1 and FEN1 by initially stimulating FAN1 cleavage to destabilize
the hairpin, which convert the hairpin into a 5’-flap that was subsequently removed by
FEN1. On the other hand, de-ubiquitination of ub-PCNA can restore the interaction
between PCNA and FEN1, which can promote the cleavage of the 5’-CAG repeat flap.
Therefore, the mono-ubiquitination of PCNA and de-ubiquitination of ub-PCNA may act
as a switch in coordinating FAN1 and FEN1 cleavage to eliminate the challenging
secondary structures formed on TNR tracts during BER.
Our results also support a working model for the cooperation among FAN1, ubPCNA, and FEN1 in preventing CAG repeat expansion. FAN1 functions as two modes, it
forms as a monomer-DNA complex or a head-to-tail dimer-DNA complex [175, 270].
FAN1 monomer is responsible for the 5’-3’ exnonuclease activity, whereras FAN1 dimer
is responsible for cleaving a long 5’-flap (30 nt) [175, 270]. Although our results did not
provide the direct evidence showing FAN1 adopts a monomer or dimer when it interacts
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with ub-PCNA, the stimulatory effect of ub-PCNA on FAN1 exonuclease activity (Figure
3.17) suggestes that ub-PCNA interacted with a FAN1 monomer. Moreover, since the
dimer model requires both FAN1 units to contact with DNA via backbone phosphate
interaction that is often associted with a conformational change of the protein [175, 270],
it is likely that only one FAN1 monomer interacts with ub-PCNA as ub-PCNA would be
sandwiched by the two FAN1 monomers. Therefore, ub-PCNA interacted with FAN1
monomer to specifically stimulate its 5’-3’ exonuclease activity (Figure 3.17).
Taken together, our study has identified a critial role of mono-ubquitination of
PCNA in suppressing TNR expansions by regulating the nuclease switching between
FAN1 and FEN1. The regulation allows stimulation of FAN1 5’-3’ exonucleolytic
activity, which directly distabilizes a CAG repeat hairpin, converting the hairpin into a
flap that can be removed efficiently by FEN1. Therefore, through the cooperation among
ub-PCNA, FAN1, and FEN1, a challenging TNR hairpin formed during BER can be
removed.
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SUMMARY
Base excision repair (BER) is one of the essential DNA repair pathways that
safeguards genomic stability and fidelity in both dividing and non-dividing cells. It
repairs the most prevalent DNA damage, e.g., DNA base lesions including oxidized and
alkylated base lesions, AP lesions, and single strand DNA breaks. Repair of the base
lesions in the post-mitotic neuronal cells by BER can promote TNR expansions and
deletions, which are associated with more than 40 neurological disorders and cancer.
Trinucleotide repeat expansion diseases including Huntington’s disease, Friedreich’s
ataxia, and mytonic dystrophy are devastating genetic neurological disorders. However,
no effective cures have been developed as yet. Currently, only symptomatic
managements are available for alleaviating the disease symptoms of patients. Therefore,
understanding the molecular mechanisms that underlie the diseases is critically important
for the development of new therapeutic targets for prevention, diagnosis, and treatment of
such diseases. It has been shown that the formation of secondary structures, such as
hairpins, loops, and G4-quadruplex, can interfere with the coordination among BER
enzymes and cofactors, which can lead to extra repeats synthesized by polymerases or
removed by nucleases, resulting in repeat expansions or deletions. It appears that the
synthesis of TNRs and removal of TNRs, which are fulfilled by DNA polymerases and
nucleases, govern TNR stability. However, there are 17 human polymerases and a variety
of nucleases, how they mediate TNR instability remains to be explored, and whether they
can be utilized as therapeutic targets remains unknown. In addition, while many studies
confirm that disruption of the enzymatic coordination during BER is responsible for
BER-mediated TNR instability, the mechanisms of cellular regulation of the enzymatic
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coordination in maintaining TNR stability are not well understood. Therefore, this Ph.D.
dissertation research project focuses on exploring the role of DNA polymerases,
nucleases, and their coordination with BER cofactors on TNR instability in search of
potential therapeutic targets for repeat instability-mediated diseases.
Initially, we evaluated the effect of a germline polymorphic pol β R137Q variant
in leading TNR instability. We find the variant exhibits the similar level of gap-filling
synthesis as wild-type pol β. It performs less efficient strand-displacement DNA synthesis
than wild-type pol β. We find that pol βR137Q variant exhibits slightly weaker overall
DNA synthesis compared to WT pol β. However, it does not significantly affect TNR
instability during BER, which may attribute to both pol βR137Q and WT pol β skip over
a small loop on the template strand with an equal efficiency. This project provides the
direct evidence that the pol βR137Q individual carriers do not have an increased risk of
developing TNR instability-related cancers or neurodegenerative diseases.
In the second part of this research project, we determined the roles of DNA
synthesis activities in modulating TNR instability. We find that both pol βY265C mutant
and the translesion DNA polymerase, pol ν, have much weaker DNA synthesis activity
than WT pol β, whereas the translesion DNA polymerase, pol θ, exhibites similar DNA
synthesis activities with the WT pol β. Both pol βY265C and pol ν can induce large
amount of (CAG)1 repeat deletion, whereas pol θ does not alter the CAG repeat instability
compared to that of WT pol β. The weak DNA synthesis of pol β mutant and pol ν results
in the removal of more TNRs than synthesized, thus leading repeat deletion. We then
demonstrate the effects of TNR sequence on TNR instability. We find that the pol
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βY265C mutant shows similar DNA synthesis activities on CAG and CTG and induces
similar effect of repeat instability on both repeat tracts. The pol ν showes weaker DNA
synthesis activity on the CGG-repeat tract compared to that on the CAG repeat tract.
Therefore, it induces stronger CGG repeat deletion. Meanwhile, pol θ induces GAA
repeat deletion, which attributes to its weaker DNA synthesis activity on the GAA repeats
compared to that induced by WT pol β. Finally, we explored the effect of transient
inhibition of pol β with the pol β inhibitor, NSC666719, on TNR instability; we find that
the outcome of TNR instability is shifted towards to repeat deletions. We further
demonstrate the weak DNA synthesis of pol βY265C does not significantly alter the
instability of GT repeats and telomere repeats, suggesting that weak DNA synthesis by
inhibiting pol β with pol β inhibitors may not increases the risks in development of
cancers and aging-related diseases.
The first two parts focused on the effects of DNA polymerases and their DNA
synthesis activities on the TNR instability and evaluated the probability of DNA synthesis
activities of repair DNA polymerases as potential therapeutic targets for disease
treatment. While the enzymatic activities can be modulated through mutations or enzyme
inhibitors, the cellular regulation of enzymatic activities and enzymatic coordination can
be modulated by BER cofactors and by the post-translational modification of BER
enzymes and cofactors. In the last part of my dissertation research, we investigated how
the monoubiqituinated PCNA (ub-PCNA), a type of post-translational modification of
PCNA, regulates the coordination between FAN1 and FEN1 during BER in TNR to alter
TNR instability. We find that ub-PCNA greatly enhanced the 5’-3’ exonucleolytic
activity, and this lead to disabilizatiin of a CAG repeat hairpin, converting the hairpin to a
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5’-flap. We further find that the 5’-flap is efficiently removed by FEN1, leading to
resolution of the secondary structures and attenuation of the expanded CAG repeats. We
demonstrate that ub-PCNA plays a critical role in suppressing TNR expansions by
regulating the nuclease switching between FAN1 and FEN1. Our study also suggests a
new mechanism that maintains TNR stability by regulating nucleases switching through
post-translational modification of PCNA.
By exploring the roles of DNA polymerases, nucleases, and the post-translational
modification of BER cofactors in modulating TNR instability, this research can advance
our understanding of the molecular mechanisms of BER mediated TNR instability and
the cellular pathways that suppress the TNR expansions. We demonstrate that the posttranslational modifications of BER cofactors play an important role in maintaining TNR
stabilities by regulating enzymatic activities of nucleases. By studying the effect of DNA
synthesis activities of DNA polymerases, we further identify a potential therapeutic
strategy in treating or preventing TNR expansion mediated neurodegenerative diseases. It
should be noted that our studies are limited by using the synthesized oligonucleotides. In
cells, TNRs are wrapped by histones and may exhbit different epigenetic features, such as
methylation, histone modifications, and among others. All these factors may contribute to
TNR instability through BER. Therefore, by dissecting the interplay among BER
enzyems, cofactors, and repair proteins from other DNA repair pathways, it can help to
formulate a comprehensive understanding of molecular mechanisms underlying BERmediated TNR instability in vivo. With the understanding of the mechanisms, it can
further facilitate the development of new therapeutic strategies for disease treatment and
prevention.
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